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Introduction 
1. Neurodegenerative diseases 
Neurodegenerative diseases pose a major challenge on a personal level as well as for the 
society as a whole. They have a significant impact on the quality of life of affected patients 
as well as their relatives. The main feature of these maladies is the progressive loss of 
neurons. The specific region where the neuronal loss occurs first and foremost dictates 
the main symptoms of the specific diseases. For example, loss of dopaminergic neurons 
in the substantia nigra causes Parkinson’s disease, loss of neurons of the basal ganglia 
are the underlying cause of Huntington’s disease and degeneration of the second motor 
neuron is causative to some forms of amyotrophic lateral sclerosis (ALS) 
(Sveinbjornsdottir, 2016; Walker, 2007; Zarei, et al., 2015). Although these findings 
suggest a region specific pathological mechanism that is caused by individual mutations, 
almost all patients feature severe alteration of brain regions that were not primarily 
affected by the disease. Pathological hallmarks of Parkinson’s disease have not only been 
identified in the substantia nigra but also in the basal forebrain and the neocortex (Davie, 
2008). MRI evaluation of Huntington patients revealed consistent cortical and subcortical 
atrophy during early course of the disease (Dogan, et al., 2013). In ALS patients, it has 
been shown that the cingulate cortex is affected as well (Sudharshan, et al., 2011). 
Specific mechanisms for the degenerative processes remain elusive for a lot of cases. A 
common denominator of neurodegenerative diseases is DNA damage, which can be 
found in the genomic as well as the mitochondrial DNA and is also part of normal aging 
(Maynard, et al., 2015). However, whether these alterations are symptoms or the cause of 
the neurodegeneration is still subject of scientific debate (Coppede and Migliore, 2015; 
Madabhushi, et al., 2014). Often the disease is not initiated by a familial mono genetic 
cause but a combination of so called genetic risk factors that, together with environmental 
influence, result in the neurodegeneration. Therefore, it seems that the underlying 
molecular pathway of the pathology of these maladies can only be attributed to the 
dysregulation of a complex system. Using modern approaches of genetic epidemiology 
these factors can be identified (Khoury, et al., 1993). Investigation of the subpopulations 
of patients that have a verified monogenetic cause can however help to dissect the 
mechanisms and may give insight into their sporadic forms as well. 
1.1. Chorea-acanthocytosis – a clinical overview 
A distinct group of neurodegenerative diseases are the neuroacanthocytosis syndromes. 
This group is comprised of McLeod syndrome, Huntington’s disease-like 2, Pantothenate 
kinase-associated neurodegeneration and Chorea-acanthocytosis (ChAc) (Walker, et al., 
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2011). They all share a combination of a movement disorder, severe neurological 
alterations and misshapen erythrocytes called acanthocytes (See Figure 1). 
 
Figure 1: Acanthocytes are a common feature of the neuroacanthocytosis syndromes (Source: Dept. 
Neurology, UKD). 
ChAc is very rare disease and its prevalence and incidence are unknown. Some 
references indicate that 300 to 500 people are affected world-wide, while others estimate 
up to 1000 patients (Danek and Walker, 2005; Walker, et al., 2011). Notably, there are 
some geographically isolated clusters in Japan and the French-Canadian population that 
are probably related to a founder effect (Dobson-Stone, et al., 2005; Ueno, et al., 1982). 
The mean onset age of the disease is about 30 years and life expectancy is reduced with 
disease progression of 15 to 20 years (Velayos Baeza A, 2014; Walker, et al., 2011). 
Clinical features are involuntary choreatiform movements with occasional upper body 
spasms, orofacial hyperkinesia, dystonia and a gait similar to that of Huntington’s disease 
patients (Walker, et al., 2011). Very typical are head drops that develop during disease 
progression (Schneider, et al., 2010). Patients are also often diagnosed with epilepsy and 
Parkinsonism (Rampoldi, et al., 2002). The most prominent features of the disease are the 
involuntary movements of face, pharynx, larynx, mouth and tongue, resulting in difficulties 
with vocalization, swallowing and severe self-mutilation. Diagnostic imaging systems show 
an initial atrophy of the basal ganglia (See Figure 2). Even though in most post mortem 
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studies no evidence was found that ChAc is a proteinopathy, there was one case reported 
where the patient’s brain featured inclusion bodies positive for expanded polyglutamine 
repeats, ubiquitine and torsin A (Walker, et al., 2002). 
 
Figure 2: Image of the brain of a patient suffering from Chorea-Acanthocytosis taken with magnetic 
resonance tomography. Increased size of the lateral ventricles indicates a loss of neurons in the 
neighboring head of caudate nuclei and the putamen. Image taken from (Danek, 2005) 
In later stages, loss of neurons can be observed in the substantia nigra, which is 
associated with Parkinsonism and patients can develop a poly-neuropathy, which is often 
not clinical relevant (Velayos Baeza A, 2014). Diagnosis is mainly established by using 
optimized protocols for acanthocyte detection if a patient is suffering from unexplained 
movement disorders, hyperkinesia, dystonia or very prominent orofacial dyskinesia 
(Storch, et al., 2005). Western blot analysis of CHOREIN protein was successfully 
established for diagnosis (Dobson-Stone, et al., 2004). Current treatment approaches are 
mainly targeted towards the neuropsychiatric effects to increase the quality of life of 
patients as well as non-pharmaceutical assisting devices like feeding tubes, to prevent 
weight loss as a result of the dysarthria, or computer-assisted speech systems to counter 
muteness (Walker, et al., 2011). Local application of botulinum toxin can be used to treat 
the dystonic components of the movement disorder (Velayos Baeza A, 2014). These 
treatment approaches are, however, purely symptomatic. Even though some approaches 
rely on the current experience in treatment of Huntington patients, no prospective 
treatment studies could have been conducted due to the low number of ChAc patients. 
1.2. Chorea-Acanthocytosis – genetic considerations  
ChAc is an autosomal recessive inherited disease caused by mutations in the VPS13A 
gene. This gene spans 240kb and contains 74 exons. Its cytogenetic location is 9q21.2 
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and encodes two different isoforms of the protein CHOREIN. Transcript variant A contains 
exon 1-68 and 70-73 resulting in a 3174 amino-acid protein, while variant B is encoded by 
exon 1-69 and yields a 3095 amino-acid protein (Velayos Baeza A, 2014). A study in 2005 
identified 75 different mutations, which are distributed over the gene, in 58 patients. 
Mutation in different paralogs of the VPS13A gene cause different diseases. Alterations in 
VPS13B are causative for Cohen’s disease (Kolehmainen, et al., 2003). VPS13C is 
associated with juvenile type-2 Parkinson’s disease (Lesage, et al., 2016). Geographical 
isolated populations with distinct genetic alterations that are currently known are the 
Japanese Ehime deletion, a deletion of 260bp in exon 60 and 61, and the French-
Canadian subpopulation with a deletion of exon 70-73. VPS13A encodes the 360kDa 
protein CHOREIN. Even though its function is not yet completely understood it is suggest 
being involved in vacuolar sorting. The yeast analogue VPS13 is important for membrane 
morphogenesis during sporulation. Phosphatidylinositol phosphate levels that are pivotal 
for successful membrane closure are regulated by interaction of VPS13 with 
phospholipase D (Park and Neiman, 2012). This interaction was recently described in 
Homo sapiens (Park, et al., 2015). In 2012, Foller et al. described a link between 
CHOREIN and the acanthocyte phenotype of ChAc patients’ erythrocytes, which is 
mediated by the phosphoinositide 3 kinase – RAC1 – PAK1 pathway, leading to 
alterations in the cytoskeleton (Foller, et al., 2012). A disturbance in the ratio of globular 
(G) and filamentous (F) actin, which was significantly shifted towards G-Actin in ChAc 
patients, was observed in primary erythrocytes as well as the K562 erythroleukemic cell 
line. Changes in the membrane of ChAc patients erythrocytes were attributed to hyper 
active LYN-kinase (De Franceschi, et al., 2011). These features of ChAc have so far not 
been investigated in neurons. The first publication, that linked ChAc to neurons, analyzed 
subcellular localization of CHOREIN in dopaminergic neurons and found a co-localization 
with synaptotagmin I in dense-core vesicles (Hayashi, et al., 2012). Furthermore it was 
shown that CHOREIN interacts with β-adducin, β-actin as well as tubulin and HDAC6 
(Sasaki, et al., 2016; Shiokawa, et al., 2013). In Dictyostelium and HeLa cells, defects in 
autophagy were attributed to CHOREIN mutations, indicating a possible role in vacuolar 
sorting as postulated earlier (Munoz-Braceras, et al., 2015). Similar defects in autophagy 
were recently described in erythroid precursors of ChAc patients that impair erythroid 
maturation (Lupo, et al., 2016). Park et al. described recently the important function of the 
yeast orthologue VPS13 for mitochondrial functional (Park, et al., 2016). Even though 
some aspects of the molecular interaction have been discovered, the main mechanisms, 
especially in the primarily affected neurons of the basal ganglia, remain elusive. Until now 
ChAc related research focused mainly on clinical studies and the features of the blood 
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phenotypes. However, state of the art techniques of disease modelling allow the 
investigation of the disease relevant neurons.  
2. Disease modelling 
Modelling of diseases has become a very important field in recent years (See Figure 3). 
 
Figure 3: Time line of publications associated with the term "disease modelling". New techniques like 
sophisticated animal and new cell culture models lead to an increase in publications. Source: PubMed 
The basic understanding of protein kinetics and how proteins interact physiologically at a 
cellular level is not enough to characterize the more complex pathophysiological 
interaction. Systemic implications on the whole organism as well as individual symptoms 
cannot be predicted. Therefore different models have been developed throughout the 
years. Non-human animal models, like mice and rats, are widely used to investigate 
diseases. Using genetic engineering to incorporate defined mutations in a known and 
stable genetic background, enables the researcher to investigate the phenotypes and 
mechanisms associated with that specific mutation. Influences of the genetic background 
can be minimized with this approach. Furthermore, with the induction of specific lesions by 
using drugs or mechanical interference, neurological disease events can be recapitulated 
without the need of introduction of mutations. These models give researchers the 
opportunity to observe the whole organism, including behavioral and physical changes on 
a macroscopic level as well as investigation at a cellular level and the implication on a 
specific organ. The limitations of these models are the evolutionary and genetic difference 
to humans. Some of the induced phenotypes do not recapitulate the disease progression 
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in human. Furthermore, some behavioral changes might be differentially reflected in 
animal models. Another issue is the reproducibility of the evidence found in an animal 
model in human models. Therefore, the knowledge obtained always has to be carefully 
validated in human systems. For the modelling of neurodegenerative diseases one of the 
main effecters, the age, can only be poorly mimicked in animal models due to their 
significantly shorter life cycles and different senescence. Anatomical differences pose 
another issue when modelling a human disease in animals. For example, the direct 
monosynaptic connection of the pyramidal tract with the lower motor neurons is very 
pronounced in primates, while not present in rodents (Shapovalov, 1974). 
2.1. Human disease models 
Although the clinical examination of disease progression in patients and post mortem 
analysis led to invaluable achievements in understanding and development of effective 
treatments, the early stages and the molecular pathways involved in degenerative 
diseases cannot be unraveled by these study designs. For an in depth model there are 
two major approaches, the culture of primary tissue obtained from biopsies and the culture 
of immortalized cell lines. Primary cells can be directly obtained from a patient and 
therefore already feature the genotype that led to the phenotype of the patient. The 
amount of cells that can be obtained from a patient, however, is very limited and is far 
exceeded by the needs of modern scientific standards. Another problem that arises in the 
modelling of neurodegenerative diseases is that the affected tissue itself cannot be easily 
accessed. During the process of neurectomy the neuronal axon is severely damaged, 
causing the neuron to die and thus rendering it impossible to be successfully cultured. 
Furthermore, it has to be considered that different mutations can affect tissues 
differentially and a genotype that affects the brain might not be impairing for fibroblasts or 
keratinocytes. Post mortem biopsies are severely damaged from undersupply of oxygen 
and nutrients, rendering the tissue unsuitable for cell culture. Aberrations of morphology 
could be attributed to the necrosis itself and might not represent the pathological 
conditions that caused the disease. The usage of immortalized cell lines like human 
embryonic kidney (HEK), fibroblast lines, embryonic stem cell lines (ESC) or cancer cell 
lines like the HeLa cell line can be very useful to investigated molecular mechanisms 
(Masters, 2002). These cell lines can be easily manipulated and investigated with a large 
spectrum of analytical tools. A lot of these cell lines however, contain severe genomic 
alterations that accumulated over their long turn culture and exhibit aberrant transcriptome 
homeostasis that can hardly be considered as physiological (Landry, et al., 2013). Since 
some of these lines come from a malign background themselves, like the cancer stem 
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cells, it has to be very carefully evaluated how these background interacts with the 
disease phenotype of the introduced mutation. Another limitation of these cell models is 
the lack of functional readouts for disease specific cell types. This implication is very 
crucial for neurodegenerative diseases since the characterization of synaptic properties 
like neurotransmitter uptake or the propagation of an action potential is pivotal but 
unobtainable by some of these models. A third approach that has the advantage of high 
amount of obtainable tissue and accessibility to genetic engineering while maintaining the 
flexibility to generate various different cell types is the use of embryonic and fetal stem 
cells. ESC are pluripotent and therefore can be propagated by self-renewal or yield cells 
of each of the three germ layers, namely ectoderm, mesoderm and endoderm, by 
applying specific differentiation protocols (Takahashi and Yamanaka, 2006) Fetal stem 
cell also exhibit a strong self-renewal but their differentiation capacity is limited to the 
germ layer they have been derived from. Because both stem cells types are obtained by 
sacrificing in vitro fertilized oocytes and the modification of human embryonic tissue is 
highly restricted, the usage of these cell lines is under morale debate (Lako, et al., 2010). 
Therefore this approach cannot be applied broadly. 
2.2. Induced pluripotent stem cells 
In 2006, the discovery of so called induced pluripotent stem cells (iPSCs) by Shinya 
Yamanaka using mouse cells and the subsequent application of the very same protocol in 
human cells in 2007, gave researchers an invaluable novel tool for a human cell culture 
based model (Takahashi and Yamanaka, 2006; Yu, et al., 2007). Since these cells can be 
obtained by the introduction of exogenous transcription factors from almost any somatic 
cell, it is possible to generate a disease and patient specific iPSC line that has the same 
genetic background and disease causing mutations as the donor (See Figure 4). 
Furthermore these cells can be, like embryonic stem cells, propagated to vast amounts 
and differentiated into all three germ layers and therefore can give rise to mature 
functioning cells like, hepatocytes, osteoblasts, and neurons. These cells don’t require the 
sacrifice of an individual and therefore minimize the morale problems. Because of their 
great contribution to the scientific field, Shinya Yamanaka and John Gurdon received the 
Nobel Prize for medicine in 2012 (Gurdon, 1962). The standard procedure in generating 
iPSCs starts with obtaining tissue from an individual. Commonly used samples are skin 
biopsies from the thigh, yielding fibroblasts that can be isolated and cultured as cell lines 
as well as from hair follicle from which keratinocytes can be obtained. Both fibroblasts and 
keratinocytes can be easily purified and expanded by means of reproducible, inexpensive 
and simple protocols (Aasen, et al., 2008). 
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Figure 4: Schematic of application iPSC technology in translational research. Modified from (A. Storch, 
2010) 
The reversion of a somatic cell into an embryonic stem cell like stage is achieved by 
overexpression of a specific set of transcriptions factors. The first established set, the so 
called Yamanaka set, is comprised of OCT4, SOX2, KLF4 and MYCC (Takahashi and 
Yamanaka, 2006). OCT4, SOX2 and KLF4 form an active complex that acts as a master 
regulator of stemness and pluripotency  promoting transcription factors (Wei, et al., 2009). 
MYCC is enhancing their efficiency by facilitation epigenetic remodeling (Wernig, et al., 
2008). A second set was successfully established as well. The so called Thomson set 
relies on the overexpression of OCT4, SOX2, NANOG and LIN28A (Yu, et al., 2007). The 
role of OCT4 and SOX2 as the major active components remains the same, while LIN28A 
is introduced as a modulator of OCT4 post-transcriptional regulation (Qiu, et al., 2010). 
NANOG, a downstream target of the OCT4, induces a self-maintaining circuit and 
provides rapid and stable transformation into an ESC-like state (Kim, et al., 2008). The 
original publication used a monocistronic retrovirus based system for the introduction of 
these transgenes. The advantage of their system was the efficient infection and flexibility 
in the use of various transcription factors and different ratios for establishing a working 
protocol (Takahashi and Yamanaka, 2006). The disadvantages are related to high 
throughput generation of iPSC lines for disease modelling. Because of the need of 
production of several viruses, there is always an uncertain ratio of the transcriptions 
factors in the infected cells and possibly introduction of genetic mutations due to the 
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genomic integration of the virus itself. Once the desired transcription factors and their ratio 
had been identified new systems like the polycistronic lentivirus based system were 
established (Papapetrou, et al., 2009; Warlich, et al., 2011). These vectors come 
intrinsically with a working set of transcription factors at a functioning ratio and reporter 
expression for easy visual detection of genuinely infected cells. In order to circumvent 
poor reproducibility of iPSC line quality due to unpredictable phenotypes caused by 
random genomic integration of the virus, non-integrative system like transfection of 
plasmids, mRNA and use of the transcription factors as proteins itself were established 
(Warren, et al., 2010; Zhou, et al., 2009). These systems, however, suffer from even lower 
efficiency compared to the already low efficiency of iPSC clones obtained from viral 
approaches (Aasen, et al., 2008). State of the art reprogramming utilizes non integrative 
Sendai virus, an RNA virus, for efficient transfection and overexpression of transgenes 
without altering the host genome (Fusaki, et al., 2009). 
Ever since iPSC technology was used for disease modelling a debate about good practice 
and quality standards arose. For the first time in 2008, Maherali and Hochedlinger 
collected comprehensive guidelines on iPSC line quality controls to establish a higher 
quality of the iPSC disease modelling field itself (Maherali and Hochedlinger, 2008). 
These guidelines cover the investigation of residual expression of the introduced 
transgenes, the inspection of the karyotype of the fully reprogrammed iPSC line and the 
proof of genuine pluripotency, including the assessment of embryonic markers as well as 
the characterization of three germ layer differentiation capacity. It is highlighted that the 
differentiation capacity should not only be estimated by in vitro assays but for human cell 
lines by means of a teratoma formation assay and for other species by in vivo studies 
involving germline transmission, chimera generation or the tetraploid complementation 
assay. Showing the capability to generate organs or even a complete organism is the 
most stringent functional test for a bona fide pluripotent stem cell. 
iPSCs are capable to generate different kinds of somatic cells by applying specific 
differentiation protocols. These cells will be generated and used in this study to proliferate 
and derive patient specific neurons that can be analyzed under various treatment 
conditions. Stable iPSC cell lines can be shared with other labs. This is a great 
opportunity for scientists to contribute their expertise to the field that would be restricted 
by the limited amount of primary cultures. 
2.3. Multipotent neuronal progenitor cells  
Most applications, however, require only a very narrow range of cell types. In case one 
particular germ layer or highly selective cell is required, it is usually better to reduce the 
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potency of the cell line by generating precursor or progenitor cell lines. This process is 
usually initiated by withdrawal of stemness promoting conditions like growth factors and 
addition of supplements that promote differentiation into certain germ layer. At a certain 
point additional supplements are added that stabilize the cell culture in this committed 
stem cell stage. In 2013, Reinhardt et al. published a protocol that generated neuronal 
precursor cells out of iPSC. Since the process involved the application of small molecules, 
these cells were named small molecule neural precursor cell (smNPC) (Reinhardt, et al., 
2013). These cells are already committed to a neuroectodermal mid-/hind-brain fate. The 
biggest advantages of these cells are that further differentiation into mature neurons takes 
less time, since previous induction of ectodermal lineage is not required, and the resulting 
cell culture is more homogeneous with few contaminating cells from other germ layers. 
These smNPC are currently used to model diseases, which involve mid- and hind-brain 
neurons, like Parkinson’s disease or ALS. Neurons from more anterior regions of the brain 
cannot be readily obtained from these precursor cells. Modelling of diseases that affect 
the anterior cortex, like frontotemporal lobar degeneration, or the basal ganglia, like 
Huntington’s disease or ChAc, still require differentiation protocols that start from the 
pluripotent state. There is currently a hypothesis under debate that all neural 
differentiation protocols go through a transient anterior stage (Pankratz, et al., 2007). 
Sustaining these cells in this stage could allow a common anterior progenitor cell line that 
can give rise to cortical neurons. A different approach is a partial reprogramming. In order 
to avoid the problems of embryonic stem cell culture it is possible to use transcription 
factors that promote a direct conversion into NPCs (Han, et al., 2012; Ring, et al., 2012). 
Transdifferentiation of a given somatic cell into a neuron has been published as well 
(Caiazzo, et al., 2011). In this study smNPCs were used along the iPSC line to investigate 
the influence of ChAc differently regionalized neurons. While analysis of iPSC derived 
MSN of basal ganglia focuses on the somatic cause of the chorea, dopaminergic neurons 
derived from smNPCs give insight into the pathological changes that lead to Parkinsonism 
of ChAc patients. 
3. Objectives of this thesis 
The first aim of this thesis is to generate an iPSC based cell culture model of ChAc. 
Therefore, two differentiation protocols that yield medium spiny neurons and midbrain 
dopaminergic neurons should be established. Phenotypical screening for differences in 
differentiation capacity, survivability and energy homeostasis will be conducted. 
Furthermore, a robust and sensitive workflow for live cell imaging of mitochondria and 
lysosomes has to be established. 
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The second aim is to compare the two differentiation protocols in order to elucidate which 
is superior in disease modeling of ChAc. 
The third aim is to investigate whether the ChAc phenotypes and their respective 
treatments, which were previously described in patient red blood cells, are present in 
neurons. 
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Materials & Methods 
Table 1: Cell lines and organism used during this thesis 
Cell lines used Obtained from 
CF-1 MEF and Feeder mice obtained from Charles River, cell lines 
isolated  
smNPCs for mDAN differentiation cell lines were kindly provided by the group of 
Jared Sterneckert  
iPSC for MSN differentiation iPSC lines were generated during the project 
 
Table 2: Instruments 
Instrument Company 
Absorbance Plate reader - Sunrise Tecan group Ltd., Männedorf, Switzerland 
Analytical Balance - CP225D-0CE Satorius AG, Göttingen, Germany 
Balance – SBA 52 Scaltec Instruments GmbH, Heiligenstadt, 
Germany 
Cell culture Microscope - Axiovert Carl Zeiss, Jena, Germany 
Centrifuge – Centrifuge 5403 Eppendorf, Hamburg, Germany 
Centrifuge – Haraeus Biofuge Primo Thermo Fisher Scientific, Massachusetts, 
USA 
Centrifuge - MiniSpinPlus Eppendorf, Hamburg, Germany 
Fluorescence Microscope - AFLX6000 
TIRF 
Leica Camera, Wetzlar, Germany 
Fluorescence Microscope - DMIRE2 Leica Camera, Wetzlar, Germany 
Fluorescence Microscope - Observer.Z1 Carl Zeiss, Jena, Germany 
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Instrument Company 
Fluorescence Plate reader - Genios Tecan group Ltd., Männedorf, Switzerland 
Gel documentation – Dunkelhaube D4 Biostep GmbH, Burkhardtsdorf, Germany 
Gel electrophoresis – E865 Consort, Turnhout, Belgium 
Gel electrophoresis PSU – EPS 600 Pfizer, New York, USA  
Hemocytometer – Neubauer improved Paul Marienfeld GmbH Co. KG, Lauda-
Königshofen, Germany 
Hybridization oven – HB-1000  UVP, Upland, Canada 
Imager - LAS3000 Fujifilm, Tokyo, Japan 
Incubator – Heracell 150i Thermo Fisher Scientific, Massachusetts, 
USA 
Laminar Flow hood – Clean Wizard V 100 Kojair Tech Oy, Vilppula, Finland 
Laminar Flow hood – Herasafe Thermo Fisher Scientific, Massachusetts, 
USA 
Multichannel multistep pipette - 
Transferpette -8 
Brand GmbH & Co. KG, Wertheim, 
Germany 
pH meter – inoLab ph 720 Wtw GmbH, Weilheim, Germany 
Photometer - Biophotometer Eppendorf, Hamburg, Germany 
Real time PCR cycler - MX3000P  Agilent, Santa Clara, USA 
Shaker – incubating orbital shaker 3500l VWR International, Radnor Township, USA 
Shaker – RotaMax 150 Heidolph, Schwabach, Germany 
Stereo preparation microscope – Stemi 
DV4SteREO CL 1500 ECO 
Carl Zeiss, Jena, Germany 
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Instrument Company 
Thermomixer – Thermomixer Comfort Eppendorf, Hamburg, Germany 
Transiluminator – BioView UST 30M-8R Biostep GmbH, Burkhardtsdorf, Germany 
Laboratory water bath  Memmert GmbH & Co. KG, Schwabach, 
Germany 
Water purification system - GenePure Thermo Fisher Scientific, Massachusetts, 
USA 
Western Bloter - iBlot Thermo Fisher Scientific, Massachusetts, 
USA 
 
Table 3: Primary antibodies used for ICC 
Antibody Host Dilution Manufacturer (catalog number) 
α-Fetoprotein mouse 1:500 Abcam® , Cambridge, United Kingdom 
(ab3980) 
β-Catenin mouse 1:1000 BD Bioscience, Bedford, USA (#9562) 
ChAT rabbit 1:1500 Merck Millipore, Billerica, USA (AB143) 
Ctip2 rabbit 1:1000 Abcam® , Cambridge, United Kingdom 
(ab18465) 
Cytochrome C mouse 1:500 BD Bioscience, Bedford, USA (556432) 
Darpp32 (H-62) rabbit 1:200 Santa Cruz Biotechnology Inc., Santa Cruz, 
USA (sc11365) 
Fibronectin rabbit 1:500 Sigma Aldrich, St. Louis, USA (F7387) 
Flk-1 rabbit 1:500 Santa Cruz Biotechnology Inc., Santa Cruz, 
USA (sc504) 
GABA rabbit 1:1000 Sigma Aldrich, St. Louis, USA (A2052) 
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Antibody Host Dilution Manufacturer (catalog number) 
GalC mouse 1:500 Merck Millipore, Billerica, USA (MAB342) 
Gata4 goat 1:1000 R&D Systems, Minneapolis, USA (AF2606) 
Gata6 rabbit 1:500 Abcam® , Cambridge, United Kingdom 
(ab39123) 
Lin28A mouse 1:2000 Cell Signaling Technologies, Inc., 
Massachusetts, USA (#5930) 
Map2 chicken 1:500 Abcam® , Cambridge, United Kingdom 
(ab5392) 
Map2 mouse 1:500 BD Bioscience, Bedford, USA (556320) 
Nanog  rabbit 1:500 Cell Signaling Technologies, Inc., 
Massachusetts, USA (#35580) 
Nestin rabbit 1:500 Merck Millipore, Billerica, USA (ABD69) 
Oct4 rabbit 1:500 Abcam® , Cambridge, United Kingdom 
(ab19857) 
Olig2 rabbit 1:500 Merck Millipore, Billerica, USA (AB9610) 
Pecam-1  mouse 1:100 BD Bioscience, Bedford, USA (555444) 
S100β rabbit 1:2000 Swant Inc., Marly, Switzerland (37A) 
α-SMA mouse 1:100 Dako North America, Inc., Carpinteria, USA 
(M0851) 
SMI32 chicken 1:10000 Covance, New Jersey, USA (PCK-592P) 
Sox2  mouse 1:500 R&D Systems, Minneapolis, USA (MAB2018) 
SSEA3 rat 1:500 Abcam® , Cambridge, United Kingdom 
(ab16286) 
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Antibody Host Dilution Manufacturer (catalog number) 
SSEA4 mouse 1:500 Abcam® , Cambridge, United Kingdom 
(ab16287) 
TH rabbit 1:500 Pel Freez Biologicals, Arkansas, USA 
(P60101) 
Tra 1_60  mouse 1:500 Abcam® , Cambridge, United Kingdom 
(ab16288) 
Tuj1  mouse 1:2000 Covance, Princeton, USA (MMS-435P) 
Tuj1 chicken 1:500 Merck Millipore, Billerica, USA (AB9354) 
Vimentin  mouse 1:1000 Sigma Aldrich, St. Louis, USA (V2258) 
 
Table 4: Primary antibodies used for western blot 
Antibody Host Dilution Manufacturer (catalog number) 
Acetyl. Tubulin mouse 1:5000 Sigma Aldrich, St. Louis, USA (T7451) 
Actin rabbit 1:500 Cell Signaling Technologies, Inc., 
Massachusetts, USA (#4967) 
CHOREIN rabbit 1:500 Sigma Aldrich, St. Louis, USA (HPA021662) 
GAPDH mouse 1:100000 Merck Millipore, Billerica, USA (MAB374) 
α-Tubulin mouse 1:5000 Abcam® , Cambridge, United Kingdom 
(ab7291) 
 
Table 5: Secondary antibodies 
Antibody Host Dilution Manufacturer (catalog number) 
α-ms/rb/ch Alexa 
Fluor 488 IgG 
donkey 1:500 Thermo Fisher Scientific, Massachusetts, 
USA (A21202/A21206/A11039) 
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Antibody Host Dilution Manufacturer (catalog number) 
α-ms/rb/ch Alexa 
Fluor 594 IgG 
donkey 1:500 Thermo Fisher Scientific, Massachusetts, 
USA (A21203/A21207/ab9652) 
α-ms/rb Alexa 
Fluor 647 IgG 
donkey 1:500 Thermo Fisher Scientific, Massachusetts, 
USA (A31571/A3157) 
α-ms 
RhodaminRed 
IgM 
donkey 1:200 Jackson ImmunoResearch Laboratories Inc., 
Pennsylvania, USA (715-295-020) 
α-ch Alexa Fluor 
647 IgY 
donkey 1:500 Jackson ImmunoResearch Laboratories Inc., 
Pennsylvania, USA (703-605-155) 
α-ms hrp 
conjugated IgG 
donkey 1:5000 Jackson ImmunoResearch Laboratories Inc., 
Pennsylvania, USA (715-035-150 
α-rb hrp 
conjugated IgG 
donkey 1:5000 Jackson ImmunoResearch Laboratories Inc., 
Pennsylvania, USA (711-035-152) 
 
Table 6: Fluorescent reporters 
Name Dilution Manufacturer (catalog number) 
Phalloidin conjugated to 
Rhodamin Red 
1:100 Thermo Fisher Scientific, Massachusetts, USA  
(R415) 
DNAse conjugated to 
Alexa Fluor 488 
1:500 Thermo Fisher Scientific, Massachusetts, USA  
(D12371) 
LysoTracker Red 1:20000 Thermo Fisher Scientific, Massachusetts, USA  
(L7528) 
MitoTracker DeepRed 1:20000 Thermo Fisher Scientific, Massachusetts, USA 
(M22426) 
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Name Dilution Manufacturer 
JC-1 1:1000 Thermo Fisher Scientific, Massachusetts, USA 
(M34152) 
Hoechst33342 1:1333 Thermo Fisher Scientific, Massachusetts, USA 
(H3570) 
 
Table 7: Software 
Type Software Company 
Image acquisition Zen 2011 Carl Zeiss AG, 
Oberkochen, Germany 
Data mining and 
organization 
KNIME 3.1.1 KNIME.COM AG, Zurich, 
Switzerland 
Image and video 
evaluation 
FIJI 1.48a Open source GPLv2 
Western blot evaluation TotalLab Quant TotalLab Limited, 
Newcastle, UK 
Statistics SPSS 23 IBM, New York, USA 
Statistics GraphPad Prism 7 GraphPad Software Inc., 
La Jolla, USA 
Image processing Photoshop CS6 Adobe Systems, San Jose, 
USA 
 
Table 8: Chemicals 
Chemical Manufacturer 
2-Deoxy-Glucose Sigma Aldrich, St. Louis, USA 
Accutase Sigma Aldrich, St. Louis, USA 
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Chemical Manufacturer 
Agarose Biozym Biotech Trading GmbH, Oldendorf, Germany 
Ampicilin Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Ascorbic Acid Sigma Aldrich, St. Louis, USA 
B27-Supplement w/o Vitamin A Thermo Fisher Scientific, Massachusetts, USA 
BDNF Promega, Madison, USA 
b-Mercaptoethanol Thermo Fisher Scientific, Massachusetts, USA 
CHIR 99021 Cayman chemical company, Ann Arbor, USA 
Collagenase Type IV Thermo Fisher Scientific, Massachusetts, USA 
dbcAMP 
DMEM 
Sigma Aldrich, St. Louis, USA 
Thermo Fisher Scientific, Massachusetts, USA 
DMEM F12 Thermo Fisher Scientific, Massachusetts, USA 
DMSO Sigma Aldrich, St. Louis, USA 
DNA Marker Thermo Fisher Scientific, Massachusetts, USA 
Dorsomorphin Tocris Bioscience, Bristol, UK 
Dry milk powder Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
DTT Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
EDTA Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Ethanol VWR International GmbH, Dresden, Germany 
Etoposide Sigma Aldrich, St. Louis, USA 
Fetal bovine serum Sigma Aldrich, St. Louis, USA 
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Chemical Manufacturer 
Fetal calf serum Merck Group, Darmstadt, Germany 
FCCP Tocris Bioscience, Bristol, UK 
FGF2 Sigma Aldrich, St. Louis, USA 
FGF8 R&D Systems, Minneapolis, USA 
Fluoromount SouthernBiotech, Birmingham, USA 
Fugene Promega, Madison, USA 
Gelatine Sigma Aldrich, St. Louis, USA 
Glucose Sigma Aldrich, St. Louis, USA 
Glutamax Thermo Fisher Scientific, Massachusetts, USA 
Glycerol MP biomedicals, Santa Ana, USA 
Glycine Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
GNDF Sigma Aldrich, St. Louis, USA 
Heparin Sigma Aldrich, St. Louis, USA 
IWP2 Sigma Aldrich, St. Louis, USA 
Kanamycin Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
KO DMEM Thermo Fisher Scientific, Massachusetts, USA 
KO Serum Thermo Fisher Scientific, Massachusetts, USA 
Laminin Roche Holding AG, Basel, Switzerland 
LB Medium Thermo Fisher Scientific, Massachusetts, USA 
L-Canavanine Sigma Aldrich, St. Louis, USA 
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Chemical Manufacturer 
Loading Buffer anamed Elektrophorese GmbH, Groß-Bieberau, 
Germany 
Matrigel BD Bioscience, Bedford, USA (556320) 
Methanol VWR International GmbH, Dresden, Germany 
MG132 Sigma Aldrich, St. Louis, USA 
Mikrozid Schülke&Mayr, Norderstedt, Germany 
Mitomycin C Tocris Bioscience, Bristol, UK 
N2-Supplement Thermo Fisher Scientific, Massachusetts, USA 
NaCl Merck Group, Darmstadt, Germany 
Sodium deoxycholate Sigma Aldrich, St. Louis, USA 
Sodium orthovanadate Sigma Aldrich, St. Louis, USA 
NEAA Thermo Fisher Scientific, Massachusetts, USA 
Neurobasal Thermo Fisher Scientific, Massachusetts, USA 
Oligomycin Tocris Bioscience, Bristol, UK 
PBS Thermo Fisher Scientific, Massachusetts, USA 
PD0325901 Sigma Aldrich, St. Louis, USA 
PFA Electron Microscopy Sciences, Hatfield, USA 
Phallacidin Tocris Bioscience, Bristol, UK 
Phosphatase Inhibitor Cocktail Thermo Fisher Scientific, Massachusetts, USA 
Poly-L-orthnitine Sigma Aldrich, St. Louis, USA 
PP2 Tocris Bioscience, Bristol, UK 
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Chemical Manufacturer 
Protamin Sulfat Sigma Aldrich, St. Louis, USA 
Protease Inhibitor Cocktail Thermo Fisher Scientific, Massachusetts, USA 
Penicillin and streptomycin Thermo Fisher Scientific, Massachusetts, USA 
Penicillin, streptomycin and 
glutamine 
Thermo Fisher Scientific, Massachusetts, USA 
Pure water Thermo Fisher Scientific, Massachusetts, USA 
Purmorphamin Cayman chemical company, Ann Arbor, USA 
Pyruvate Thermo Fisher Scientific, Massachusetts, USA 
RedSafe Thermo Fisher Scientific, Massachusetts, USA 
Restriction enzymes New England Biolabs Inc., Ipswich, USA 
ROCK Inhibitor Y-27632 Abcam, Cambridge, United Kingdom 
Rotenone Sigma Aldrich, St. Louis, USA 
SB431542 Tocris Bioscience, Bristol, UK 
SDS Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Sucrose Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
TGF-β3 Peprotech, Rocky Hill, USA 
Tris-HCL Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
TritonX-100 Thermo Fisher Scientific, Massachusetts, USA 
Trypsin Thermo Fisher Scientific, Massachusetts, USA 
Tunicamycin Enzo life science, East Farmingdale, USA 
Tween 20 Serva Elektrophoresis GmbH, Heidelberg, Germany 
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Chemical Manufacturer 
Uridine Sigma Aldrich, St. Louis, USA 
Western blot marker Thermo Fisher Scientific, Massachusetts, USA 
 
Table 9: Consumables 
Material  Company 
96 well clear bottom white PS Thermo Fisher Scientific, Massachusetts, USA   
96well CELLSTAR flat 
bottomed dishes 
Greiner Bio-One GmbH, Kremsmünster, Austria 
Bottle-top vacuum filters Corning Inc., Corning, USA 
Cell culture Dishes 
4-,6-,12-,24-,96-well 
Thermo Fisher Scientific, Massachusetts, USA 
Sarstedt AG & Co., Nümbrecht, Germany 
TPP Techno Plastic Products AG, Trasadingen, 
Switzerland 
Cell scraper TPP Techno Plastic Products AG, Trasadingen, 
Switzerland 
Centrifuge tubes Greiner Bio-One GmbH, Kremsmünster, Austria 
Dissecting set Manufactures D’Outils Dumont SA, Montignez, 
Switzerland 
Microfluidic chambers  Xona Microfluidics LLC, Temecula, USA 
Millex HV low binding PVDV 
membrane filters 0.45 μm 
Merck Millipore, Billerica, USA 
NuPAGE Protein gels Thermo Fisher Scientific, Massachusetts, USA   
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Material  Company 
Pipette tips Biosphere Corporation, Dnipropetrovsk, Ukraine 
Pipettes Gilson Inc., Middleton, USA 
Eppendorf, Hamburg, Germany 
VWR International, Radnor Township, USA 
SafeSeal reaction tubes Sarstedt AG & Co., Nümbrecht, Germany 
Serological pipette 5, 10, 25 
and 50ml 
Thermo Fisher Scientific, Massachusetts, USA 
 
Table 10: Assays and kits 
Assay Company 
Alkaline Phosphatase Staining 
kit II 
Stemgent Inc., Cambridge, USA 
QuantiTect Reverse 
Transcription kit 
Qiagen, Hilden, Netherlands 
Cytotoxicity detection kit Roche Holding AG, Basel, Switzerland 
Nuclear Extract kit Active Motif, Carlsbad, USA 
QuantiTect SYBR Green PCR 
kit 
Qiagen, Hilden, Netherlands 
NulceoBond Xtra Maxi kit Macherey-Nagel GmbH & Co. KG, Düren, Germany 
Roti Nanoquant Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
RNEasy Plus Mini kit Qiagen, Hilden, Netherlands 
Seahorse XF Assay Agilent Technologies, Santa Clara, USA 
  
 
 
- 34 - 
 
Assay Company 
Presto Blue Cell viability 
reagent 
Thermo Fisher Scientific, Massachusetts, USA 
NuPAGE Running Buffer Thermo Fisher Scientific, Massachusetts, USA 
Amersham ECL Prime 
Western Blotting Detection 
Reagent 
GE Healthcare, Chicago, USA 
SuperSignal West Maximum 
Sensitivity 
Thermo Fisher Scientific, Massachusetts, USA 
 
Table 11: Primers designed 
Primer Forward sequence Reverse sequence Product size (bp) 
18S CGTAGTTCCGACCATA
AACGATGCC 
GTGGTGCCCTTCCGT
CAATTCC 
152 
ACTB TCAAGATCATTGCTCC
TCCTGAG 
ACATCTGCTGGAAGGT
GGACA 
87 
ADD2 TGCAGAGTCCCTCTTT
CAGG 
ATGAAGTCCGCGATCT
GTCG 
109 
ASCL1 GTCTCCCGGGGATTTT
GTAT 
TCTCCATCTTGGCAGA
GCTT 
199 
BLCAP CGGCCGGCTCGACTA
GAAGACTAA 
CCCTCCGCTTTCTTCA
ACCCTCAC 
216 
CFL1 CTCGTCTTCTGCGGCT
CTCGG 
CTTGCGCTTCTTCACC
TCCTCTGG 
147 
CFLAR AGGAGCAGGGACAAG
TTACA 
TCCTGAAGTTATTTGA
AGGATCCT 
100 
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Primer Forward sequence Reverse sequence Product size (bp) 
CHAT ACCTACCTGATGAGCA
ACCG 
TTGTAGCAGGCACCAT
ACCC 
133 
cMYC AGCAGCGACTCTGAG
GAGGAACA 
GGACCAGTGGGCTGT
GAGGAG 
145 
CTIP2 CGATGCCAGAATAGAT
GCCG 
GCTCCTCTATCTCCAG
ACCC 
146 
CTTN ACCCAGGTGTCCTCTG
CCTACC 
GCCTGTCCTCCTGCTC
TTTCTCC 
118 
DARPP32 CTTCGGGAGCTGGGT
TATCC 
CCACAGGTTGTCTTTT
GCCC 
137 
DLX2 AAGAGCAGCTATGACC
TGGG 
GGACTTTCTTTGGCTT
CCCG 
145 
EMX2 CTACCCTCCTCGCACT
CG 
GGCTAGTGTCGTTCCC
TTGG 
127 
FOXG1 CCCTCCCATTTCTGTA
CGTTT 
CTGGCGGCTCTTAGA
GAT 
204 
GAD67 GGCACGACTGTTTATG
GAGC 
GAGTTTATGGCGGTG
CTTCC 
135 
GSX2 CCGCCACCACCTACAA
CG 
CCGTCCTCATCCTCTT
GCC 
102 
HMBS TGCCAGAGAAGAGTG
TGGTGGGA 
TTCCGAAGCCGGGTG
TTGAGG 
118 
HPRT CCTCCTCCTCTGCTCC
GCCA 
GGTTCATCATCACTAA
TCACGACGCCAG 
113 
IL13RA2 TTTACTGGTATGAGGG
CTTGG 
AGGCTTGTTCTCTGAT
GATCC 
152 
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Primer Forward sequence Reverse sequence Product size (bp) 
Klf4 TCCTCCCGGCTTCCAT
CCCC 
TGTGGGTGGCGGTCC
TTTTCC 
182 
Krox20 CCCTTTGACCAGATGA
ACGG 
TTTCTAGGTGCAGAGA
CGGG 
122 
LHX3 GCGATGCTGCTGGAA
ACG 
GCTGCACTTGAGACAC
TTGC 
180 
LHX6 CAACAACCTCATCTGG
CACG 
CGAATCGGCTGAAGTA
GTCC 
128 
LHX8 GATTAGTGTGGAAGGT
GCCC 
GTGCATCTGGGTTGTT
GTCC 
140 
LIN28A GCAGCTTCTTCTCCGA
ACCAACCC 
GGCGCAGCCACCTGC
AAAC 
139 
MAP2 CTCTCCCAAGACCTTC
CTCC 
TTCCCTGCTCTGCGAA
TTGG 
142 
NANOG AGCAATGGTGTGACG
CAGAAGGC 
TGGAAGGTTCCCAGTC
GGGTTCA 
99 
NEUROD
1 
CCGTCCGCCGAGTTT
G 
GCGGTGCCTGAGAAG
ATTG 
101 
NKAIN2 CAGATTGTCCTCGCAC
TGG 
TGATAGCCATAAGAGT
CAAAGCC 
113 
NKX2.1 AACCCAGACCCGCGC
TT 
GGGCCATGTTCTTGCT
CAC 
115 
NNAT CCAGCGGATCTCGGC
AAACCC 
CCTGCGCTCCCCCAA
CACCT 
203 
NTRK1 TCTCTCCTTCAACGCT
CTGG 
CACAAGAACAGTGCA
GAGGG 
101 
 
 
- 37 - 
 
Primer Forward sequence Reverse sequence Product size (bp) 
NTRK2 TCTGAACTGATCCTGG
TGGG 
CTTGCTGCTTTCATTC
AGGC 
126 
NTRK3 CGCCAGTATCAACATC
ACGG 
TGTAGAGCTCCATGTC
CACG 
104 
OCT4A CTTCGCAAGCCCTCAT
TTCACCA 
GTCCGAGGATCAACC
CAGCCC 
154 
PAX6 AGCACCAGTGTCTACC
AACC 
CGCTGTAGGTGTTTGT
GAGG 
109 
PCDHB2 CTTTCTAAGGCGGTCG
CTCC 
CAGGACTTGCCTTTGT
TTCGG 
188 
PFN1 GTGGAACGCCTACATC
GACAACC 
TGCCAACCAGGACAC
CCACC 
152 
PLXNA2 AGTCCCATCAGCAGTA
CACC 
TTGACCTCCCGTAGAA
CTCG 
171 
REX1 GTGCTTCGCGGTAACA
GGGGT 
GCGGTGAGTGGGGTG
GGTTT 
145 
RPL39L GATTTGCGTCCTAGAG
TGGG 
GGCCAGGAATCGCTT
AATGG 
178 
RRS1 AAGCCTCAGCTGGAT
GTGACTAGGG 
CCTCCCTTTCTCTTGC
CCTTCTGG 
110 
SMOC1 CATCAGTGGCTCTTCT
GTGC 
GACCCGTCATCTTTCC
TTCC 
102 
SOX2 CAGCCCATGCACCGC
TACGA 
TCGGACTTGACCACC
GAACCC 
158 
SPON1 AATTCGACAACAGAGT
GATGAGG 
TAAGCCTACGTTCCAG
TCGG 
104 
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Primer Forward sequence Reverse sequence Product size (bp) 
SST AGTTTGACCAGCCACT
CTCC 
TTGGCCAGTTCCTGCT
TCC 
192 
TH AGCTCCTGAGCTTGTC
CTTG 
TGTCCACGCTGTACTG
GTTC 
234 
TUBB3 GGCCTCTTCTCACAAG
TACG 
CCACTCTGACCAAAGA
TGAAA 
129 
VPS13A TGGAGAGAAGCACGA
AAACTC 
TGGGCATCCTTACATC
CATGA 
109 
Viral 
SOX2-
E2A-
CMYC 
ATGAGCCAGCACTACC
AGAG 
GGTGAAGCTAACGTTG
AGGG 
165 
Viral 
OCT4-
P2A-KLF4 
GCATAGCAACTCTTCC
GGA 
GTTCCTCCCGCCATCT
GTT 
194 
 
Table 12: Media compositions 
Medium Composition 
293T media 89%   DMEM 
10%   FCS 
1%   PS 
Ectoderm differentiation media 48.6%   DMEM/F12 
48.6%   Neurobasal 
0.5%   N2-Supplement 
1%   B27 Supplement (w/o VitaminA) 
1%   PSG 
0.1%    β-Mercaptoethanol 
0.2%   BSA Fraction V 7.5% 
  
 
 
- 39 - 
 
Medium Composition 
Endo- /Mesoderm differentiation media 76.9%   DMEM (high glucose) 
20%   FCS Gold 
1%   PSG 
1%   NEAA 
0.1%   β-Mercaptoethanol  
1%   α-Thioglycerol 
Human Fibroblast media 87.6%   DMEM 
10%    FCS 
0.4%.   Uridin 
1%    Sodium pyruvate 
1%   PS 
iPSC proliferation media 77.8%   KO-DMEM 
20%   KO-Serum 
1%   NEAA 
1%   PSG 
0.2%   β-Mercaptoethanol 
MEF feeder  media 77.8%   KO-DMEM 
20%   KO-Serum 
1%   NEAA 
1%   PSG 
0.2%   β-Mercaptoethanol 
MEF feeder  media 87.9%   KO-DMEM 
10%   FCS Gold 
1%   NEAA 
1%   PSG 
0.1%   β-Mercaptoethano 
MEF Isolation/Proliferation media 85.9%   DMEM (low glucose) 
12%   FCS 
1%   NEAA 
1%   PSG 
0.1%   β-Mercaptoethanol 
N2 media 98%   DMEM/F12 
1%   N2-Supplement 
1%   PSG 
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Medium Composition 
N2B27 media 48.75%  DMEM/F12 
48.75%  Neurobasal 
0.5%   N2-Supplement 
1%   B27-Supplement (w/o Vitamin A) 
1%   PSG 
1. Cell culture procedures 
1.1. Coating 
One of the most crucial aspects of successful cell line passaging is the adhesion of living 
cells in the new cell culture dishes. Different cell types require different coatings in order to 
maximize the yield. 
1.2. Matrigel 
Matrigel coating was needed for proliferation conditions of smNPCs and during the 
induction phase of mDAN differentiations. Matrigel was thawed and prediluted with KO-
DMEM at a ratio of 1:5. This predilution was aliquoted and stored at -20°C. Once needed 
it was further diluted at 1:20 to yield a working solution with a final dilution of 1:100. 
Application of 0.1ml/cm² resulted in a loading of approximately 9ug/cm². Although different 
lots had different protein concentrations it has to be noted that this was not accounted for 
and the dilution steps were never adjusted. The coated plates were stored one to seven 
days at 4°C before usage. 
1.3. PLO/laminin 
PLO/laminin coating was used during maturation of mDAN and the adherent steps of 
MSN differentiation. It was applied for direct coating of cell culture dishes as well as 
coating of glass cover slip. These coverslips were treated with 65% HNO3 overnight, 
washed three times with ddH2O, one time with abs. ethanol, air dried and sterilized for 4h 
at 180°C before coating. The first step was conducted by incubating a 15% PLO solution 
at 0.1ml/cm² overnight at 37°C. The dishes were then washed twice with PBS and one 
time with ddH2O before letting them air dry. For the second step 50ug/ml laminin solution 
was prepared in PBS and 0.1ml/cm² were applied per dish and incubated overnight at 
37°C. The solution was then aspirated and the wells were incubated with a 1:1 mixture of 
Neurobasal and DMEM/F12. Dishes coated this way were used right away or stored for 
up to one month at -20°C. 
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1.4. Gelatin coating 
Gelatin coated dishes were used for iPSC culture. Bovine gelatin was solved in warm 
ddH2O with a final concentration of 0.1%. It was then sterile filtered using a 0.22μM bottle 
top filter and stored in a 4°C fridge. For coating 0.1ml/cm² gelatin solution was added in 
cell culture dishes. These dishes were then incubated for at least 30min at 37°C before 
MEF Feeder were thawed and seeded on them. 
1.5. Mouse embryonic fibroblast isolation 
Fibroblasts of mouse embryos were used as co-culture of iPSC during proliferation. In this 
study, fibroblasts of CF-1 were used. Breeding and keeping of animals was carried out by 
a technical assistant at the experimental facility of the MTZ. Pregnant mice were sacrificed 
at embryonic day 12. Carbon dioxide was used to euthanize the mice before they were 
killed by cervical dislocation. The abdomen of the mouse was than sprayed with Mikrozid 
and opened with a scissor. Both uterus horns were investigated for embryos and 
dissected. The horns were put in 70% ethanol for 30 seconds and then transferred into a 
PBS filled petri dish under a clean bench. The embryos were exposed by opening the 
amniotic sac and removing the placenta. The head and red organs were removed to 
decrease the potential contaminations from undesired cells. The remaining body was 
minced and the tissue collected and centrifuged at 200g for 5min at RT. The supernatant 
was discarded and the pellet was resuspended in 1.5 times volume of trypsin solution. 
The solution was incubated for 5min at 37°C. Then the same volume of DNAse I solution 
was added and incubation continued for 10 min. Cells were centrifuged at 200g for 5min 
at RT. Supernatant was discarded and the pellet resuspended with MEF isolation media. 
Cells were triturated with a 1000μl pipette and then filtered with a 100μm cell strainer. 
T150 flasks, which where pre-coated with gelatin for 30min, were used for attachment and 
proliferation of the isolated fibroblasts. The cell amount gained from 2-3 embryos was 
seeded into one flask. Media was changed after one day to clear the culture of dead and 
non-adhered cells. Cells were passaged once they reached confluency and splitted in a 
ratio of 1:3.  
1.6. Generation of feeder cells  
Fibroblasts proliferate very fast and have to be inactivated. Cells were treated with the 
DNA cross linker mitomycin C to be used as feeder cells when they reached a passage 
number of three. Fibroblast cultures that reached confluency were washed three times 
with PBS and then incubated with MEF media containing 10μg/ml MMC for 2h at 37°C. 
Cells were then washed three times with PBS and treated with trypsin until they detached. 
The reaction was stopped by adding the same volume MEF media to the flasks. Cell 
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suspension was collected, centrifuged at 200g for 5min and resuspended with DMEM. 
Cells were then counted and solved in MEF freezing media before they were aliquoted in 
batches of one or two million cells. MEF feeder cells obtained were stored in the -80°C 
and were used as co-culture layer for proliferation of iPSCs.  
1.7. Human fibroblast culture 
Fibroblast lines were obtained from patients clinically diagnosed with ChAc and sex/age- 
matched controls. The established lines were cultured in fibroblast media in T25 flasks 
and passaged once a week when confluency was reached. Splitting was done by washing 
the cells twice with warm PBS followed by incubation with 0.25% Trypsin/EDTA solution 
for 2min. The enzymatic reaction was stopped using serum-containing fibroblast media. 
The cell suspension was then collected and centrifuged 4 min at 200g. The cell pellet was 
resuspended in fibroblast media and either plated on new T25 flasks for expansion, 
prepared for cryopreservation or counted and used in reprogramming experiments. For 
long term storage cells were resuspended in freezing media containing 70% fibroblast 
media, 20% FCS and 10% DMSO, and aliquoted in cryo tubes. These tubes were then 
placed in freezing containers in a -80°C freezer overnight and then transferred to the liquid 
nitrogen storage. 
1.8. Reprogramming 
Prior to reprogramming, HEK 293T cells were thawed and cultivated on 10cm dishes 
using 293T media. Upon reaching confluency cells were washed twice with PBS and 
treated with 1ml 0.05% Trypsin/EDTA solution for 2 min at 37°C. The enzymatic reaction 
was stopped by adding 5 ml of the FBS containing 293T media and then the cell 
suspension was collected and centrifuged for 5min at 200g. The supernatant was 
aspirated and the pellet resuspended with 293T media. To keep the cells in proliferation 
the suspension was splitted at a ratio of 1:10. For the generation of virus supernatant, 
cells were counted using a Neugebauer counting chamber, and 5.106 cells were plated on 
one 10cm dish. One day after seeding the medium was changed to transfection medium 
containing 85% DMEM (high glucose) and 15% FCS without antibiotics. Two 2ml reaction 
tubes were prepared. In the first tube a total of 15μg plasmid DNAs and 45μl of 
polyethyleneimine (PEI) were mixed and incubated for 15min. The plasmid DNAs 
consisted of 3.19μg polycistronic OCT4/KLF4/SOX2/MYCC (OKSM) lentiviral vector, 
7.66μg pMDLg/pRRE (expressing HIV-1 and gag/pol), 3.19μg pRSV-Rev and 0.96μg 
pMD2.G (vesicular stomatitis virus glycoprotein VSV-G). In the second tube DMEM (high 
glucose) was added. The added volume was 1ml minus the volume of the plasmids/PEI 
mix. After the incubation time the plasmid/PEI solution was added to the DMEM and 
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mixed thoroughly and incubated for 30min at RT. The final solution was pipetted to the 
293T cells. To minimize the toxic effect of transfection agents the medium of the 293T 
cells was replaced with human fibroblast media 8h after transfection. The next day the 
virus containing supernatant of the 293T cells was collected and filtered using a 0.45μm 
PVDF. The virus solution was used right away or frozen in a -80°C freezer for short term 
storage. One day prior to infection, human fibroblasts were trypsinized, counted and 
seeded at specific cell density. In three wells of a 6 well plate 50000 cell/well were seeded 
and in two wells, 25000 fibroblasts were seeded. For infection all wells were treated at 
least two times with supernatant containing virus particles and one well of the 25000 and 
one well of the 50000 seeded cells was infected a third time. This procedure was chosen 
to have a broad range of virus particle to fibroblast ratio. The lowest ratio was therefore 
achieved in the two treatments/50000 cells condition and the highest ratio in the three 
treatments/25000 cells combination. This procedure ensured that within this range the 
optimal virus particle to cell ratio was present and iPSC were reproducibly obtained. On 
the day of the first infection, for each fibroblast line two 10cm dishes were coated with 
gelatin and 106 MEF Feeders were freshly thawed and plated on these dishes. The next 
day the infected fibroblast were washed twice with PBS (Ca-/Mg-) and treated with 0.05% 
Trypsin/EDTA solution for 2 min. The reaction was stopped using fibroblast media and the 
suspensions from all wells were pooled and centrifuged for 4 min at 200g. The infected 
cells were then counted and seeded at a density of 25000 and 50000 cells per 10cm dish 
in fresh fibroblast medium containing 5ng/ml FGF2 and 1mM valporic acid. On the next 
day, half of the medium was replaced with iPSC proliferation medium supplemented with 
5ng/ml FGF2 and 1mM valporic acid. From this time point on medium was changed daily 
to fresh iPSC proliferation medium containing 5ng/ml FGF2 and 1mM valporic acid. The 
valporic acid was omitted once first colonies emerged. After two weeks, the media was 
aspirated and the cells were treated with collagensase IV for 5 min. The collagenase was 
discarded and fresh iPSC medium was applied. The colonies were morphologically 
selected, picked into 12well and cultivated until good looking colonies were visible. This 
was continued until stable and morphologically bona fide lines emerged. Once a stable 
line was generated, iPSC were propagated on 6 well plates and characterized via alkaline 
phosphatase-staining, silencing analysis by PCR, pluripotency staining as well as three 
germ layer formation by immunocytochemistry and karyotyping. 
1.9. iPSC culture 
After successful reprogramming and characterization of iPSC the stable lines were 
propagated and repeatedly subjected to cryopreservation and thawing. Normal expansion 
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procedure included daily media change with iPSC medium supplemented with 5ng/ml 
FGF2 and passaging using either a picking or a cleaning approach. Once the cells were in 
culture for one week, the MEF feeder started to detach and the media was changed to a 
mixture of conditioned iPSC medium and fresh iPSC medium. The day prior to passaging, 
MEF feeders were seeded at a density of 250000 cells per 6 well. Two hours before the 
start of the passaging procedure, the medium of these feeders was changed to iPSC 
medium supplemented with FGF2 and the Rhok inhibitor Y-27632. Cleaning was used 
when the lines had only a minor contamination with differentiated or morphological 
aberrant colonies. These were mechanically detached and discarded using a stereo 
microscope and pipette tips that where located under a clean bench. The remaining bona 
fide iPSC colonies were treated for 5min at 37°C with 1mg/ml collagenase IV solution. The 
enzyme containing medium was then aspirated and the cells were treated with iPSC 
medium without growth factors. Then the colonies were detached using cell scrapers, 
pooled, centrifuged at 100g for 1min and plated at a ratio of 1:4 on freshly prepared 6 
wells containing MMC treated MEF feeders. The picking technique was used when there 
were only few bona fide iPSC colonies present in the well. Supernatant was aspirated and 
1mg/ml Collagenase IV added and incubated for 5min at 37°C. Enzyme solution was then 
aspirated and iPSC media w/o growth factors was applied to the cells. Using the stereo 
microscope single colonies were detached as a whole and transferred to the 6 well 
containing MEF feeder using a 10μl pipette. Wells were rested for at least 20h to ensure 
proper attachment. Media was changed the next day to iPSC media supplemented with 
FGF2 and Y-27632. 
For cryopreservation, cells were grown until large, undifferentiated colonies emerged. 
Wells were then subjected to the cleaning method of passaging. After centrifugation the 
cell pellet was resuspended with iPSC freezing media: 40% KO-DMEM, 50% KO-Serum, 
10% DMSO and 10μl Y-27632. One well of iPSC was resuspended in 2ml freezing media 
and divided in two cryo tubes. These tubes were then placed in freezing containers and 
transferred to a -80°C freezer. One day after this, cryo tubes were transferred to liquid 
nitrogen tank for long term storage.  
One day before thawing of iPSC lines, MMC treated MEF feeder were seeded on 6 well 
plates at a density of 250000 cells per well. 2h before thawing the medium of the feeder 
was replaced by iPSC medium supplemented with FGF2 and Y-27632. Cryo tubes were 
taken from liquid nitrogen storage and warmed in the water bath until there was only a 
small fraction of ice left. Cell solution was then mixed with 2ml of cold iPSC media to dilute 
the DMSO and centrifuged at 100g for 1 min. Supernatant was discarded and cells were 
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resuspended in prewarmed feeder conditioned iPSC media and then plated on one 6 well. 
For two days after thawing media was replaced daily with iPSC media supplemented with 
FGF2 and Y-27632. From day three on Y-27632 was omitted and cells were normally 
cultured. 
1.10. Culture of small molecule neuronal precursor cells (smNPC) 
SmNPCs were kindly provided by Jared Sterneckert and received at early passage 
numbers. The cells were grown on matrigel coated plates, which were prepared one day 
prior to thawing or passaging. N2B27 media was supplemented with 3μM CHIR99021, 
150μM ascorbic acid (AA) and 0.5μM purmorphamine (PMA) and changed every other 
day during proliferation phase. Cells were initially seeded at a density of 150000 cell/cm². 
Confluency was reached roughly one week past seeding. For passaging or initiation of 
differentiation, cells were washed twice with warm PBS and treated 10min at 37°C with 
accutase. The enzymatic reaction was stopped by adding double the volume of warm 
DMEM/F12. The cell suspension was collected and centrifuged at 250g for 5 minutes. The 
supernatant was then discarded and the cells were resuspended in 1ml warm N2B27 
media supplemented with growth factors. The suspension was diluted 1:100 and counted 
using a Neugebauer counting chamber. 
1.11. MSN differentiation 
Medium spiny neurons were obtained by applying a multistep protocol starting from iPSCs. 
The iPSCs were cultured in 6 wells under normal proliferation conditions until the colonies 
reached a considerable size and had a low level of spontaneous differentiation. Partly 
differentiated or morphological aberrant colonies were scraped off under the stereo 
microscope. These bad colonies were discarded with the supernatant and 2mg/ml 
collagenase IV solution was applied for 1h. After this incubation the colonies were 
detached as a whole by gentle pipetting. Colonies were collected and allowed to settle by 
gravity for 5 min. Collagenase containing supernatant was discarded and the cells 
resuspended in 10ml iPSC media supplemented with 5µM Y-27632, 1µM IWP2, 1µM 
dorsomorphin and 10µM SB-431542 and transferred to 3cm non adherent petri dishes. 
This first step let to the formation of embryoid bodies (EBs). Media was replaced every 
other day (See Figure 5). From day 6 to day 10 dorsomorphin and SB-431542 were 
omitted from the media but 0.2µM PMA was added. On day 12, the EBs were plated on 
two matrigel coated 6well plates. Media was thereafter changed to patterning/maturation 
condition consisting of N2B27 media supplemented with 20ng/ml BDNF, 10ng/ml GDNF 
and 0.5µM dbcAMP. After one week cells were passaged by washing twice with PBS and 
incubating with accutase for 10min. The reaction was stopped with 1.5 fold volume of 
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DMEM/F12 and cells were collected and centrifuged at 250g for 5 min. Cells were 
resuspended in maturation media and plated on freshly prepared matrigel plates. This 
expansion step accumulated progenitor cells and generate a homogenous culture. After 
another week of expansion, cells were passaged a second time using the same strategy 
as before. Prior to seeding the cells were counted and plated at the following densities: 
800000 cells/6well, 200000 cells/4 well, 50000 cells/96 well and 300000 cells/MFC. 
Developing neurons were left in maturation media for at least 2 weeks before experiments 
were conducted. 
 
Figure 5: MSN differentiation scheme 
1.12. mDAN differentiation 
Midbrain dopaminergic neurons were differentiated using a multistep protocol. Initially 
400000 smNPCs per line were seeded in a well of a 6 well plate and media was changed 
every other day. For the first 2 days cells were cultivated under normal proliferation 
conditions suing N2B27 supplemented with 3μM CHIR99021, 150μM AA and 0.5μM PMA. 
On day 2 media was changed to induction conditions which used N2B27 supplemented 
with 200μM AA, 10ng/ml FGF8 and 1μM PMA. On day 10 cells were splitted and 
reseeded into their final format. For ICC, cells were placed in 4 well plates with coated 
cover slips at a density of 200000 cells/well. For survival analysis and live cell imaging of 
total network, cells were seeded on 96 well plates at a density of 50000 cells/well. For 
further RNA and protein isolations, cells were seeded in 6 wells at a density of 800000 
cells/well (See Figure 6). For compartmentalized analysis of live cell imaging, MFC were 
used and 300000 cells were injected per macro channel. Maturation media consisted of 
N2B27 supplemented with 20ng/ml BDNF, 10ng/ml GNDF, 1ng/ml TGFβ3, 0.5mM 
dbcAMP and 200µM AA. After the reseed the media was changed every other day. Cells 
were cultured under maturation conditions until they were treated or harvested for further 
analysis. 
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Figure 6: mDAN differentiation scheme 
2. Nucleic acid biochemistry 
2.1. mRNA isolation 
mRNA isolation was achieved by using a kit. All procedures were done according to the 
manufacture’s recommendations. In the final step DNAse and RNAse free PCR grade 
water was used to elute RNA. RNA was measured using an eppendorf photometer and 
calculating RNA concentration using the 260nm readout and assessing the quality using 
the 260nm/280nm and 260nm/230nm ratio. Isolated RNA was stored in -80°C freezer 
before cDNA was generated. 
2.2. cDNA generation 
cDNA was generated using a Reverse Transcriptase Kit and conducted according to 
manufacture’s instructions. cDNA was generated using 1000ng of RNA as assessed with 
the Eppendorf photometer. In case total RNA amount was lower than 1000ng, as much 
RNA as possible was used. Samples with a total RNA amount of less than 200ng were 
not used. Generated cDNA was stored in -20°C freezer before PCR analysis. 
2.3. Polymerase chain reaction (PCR) 
Polymerase chain reaction was conducted using the commercially available kit Brilliant II 
SYBR Green QRT PCR. PCR setup and primer design was done in compliance to the 
MIQE guidelines (Bustin, et al., 2009). The kit contained a premixed reaction solution with 
the necessary dNTPs, H2O, MgCl2 and the reference dye ROX. Master mixes were 
prepared as follow: 
X+1x12.5μl  Sybr mix 
X+1x1μl  cDNA 
X+1x7.5μl  dH2O 
  X: number of reactions 
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21μl of the mix was then pipetted into a white 96 well PCR plate. 4μl of a 10μM primer mix 
was pipetted into the wells to yield a final reaction volume of 25μl. The plates were 
centrifuged for 1min at 200g and then transferred into the preconditioned MX Pro 3000 
PCR devices. For quality control, no-template-controls (NTC), positive and negative 
controls were used. The software was configured as follows: 
Table 13: Setup of PCR experiments 
Segment Temperature Time Function 
Segment one - 
activation 
1 Cycle   
 95°C 15 min activation of polymerase 
Segment two - 
amplification 
40 Cycles   
 94°C 15 sec melting of DNA 
 57°C 30 sec annealing of primers 
 72°C 30 sec elongation of DNA fragment 
fluorescent measurement for 
amplification plot 
Segment three - 
dissociation 
1 Cycle   
 94°C 60 sec melting of DNA 
 55°C 30 sec annealing of all products 
 ramp to 95°C with at least 
0.5°C difference per step 
 fluorescent measurement for 
dissociation plot 
 95°C 30 sec melting of DNA 
 
After the PCR was conducted, fluorescent thresholds were calculated using the adaptive 
baseline approach of the MxPro software. For further quality control amplification and 
dissociation plots were interrogated and PCR products were analyzed using agarose gel 
electrophoresis to determine fragment size. qPCR results were evaluated using the ΔΔct 
method. 
2.4. Agarose gel electrophoresis 
Fragment size of the product of a newly established primer combination was investigated 
as a part of quality control after qPCR experiments. This was achieved by agarose gel 
electrophoresis. A 2% agarose gel was cast using TAE buffer containing 40mM Tris, 
 
 
- 49 - 
 
20mM acetic acid, and 1mM EDTA and a 1:20000 dilution of the nucleic acid stain 
RedSafe. PCR reactions were mixed with 5μl loading buffer and 8μl of the mixture were 
pipetted into each well of the cast agarose gel. Electrophoresis was conducted with 140V 
and 80mA for 1h before a picture was taken at the gel documentation using the 
transilluminator and saved as tiff. 
3. Cell survival analysis 
Cell survival experiments were done on mature neurons of MSN and mDAN differentiated 
cultures. Stressors were applied one week after the last reseed. Cells were incubated with 
stressors and mock controls over the course of 6 days. The stressors used were 
tunicamycin, an inhibitor of N-linked glycosylation that cause ER related unfolded protein 
response (UPR) or L-canavanine, an arginine analogue that is incorporated during protein 
biosynthesis by the cell and causes protein misfolding (Chan and Egan, 2005; Mytilineou, 
et al., 2004). Supernatants were collected and pooled for lactate dehydrogenase (LDH) 
release assay on day 3 and day 6. PrestoBlue assay was conducted on day 6. Cell 
composition was calculated for day 6. To achieve this, the following model was used. The 
initial assumption is that on day 6 a certain amount of cells is dead and released its LDH 
in the supernatant while another fraction is still metabolic active. Since PrestoBlue and the 
LDH positive control, where all attached cells are lysed, are done in the same well, 
normalization was set to 100%. 
 
Figure 7: Scheme for the assessment of cell composition at time point of measurement 
 
3.1. PrestoBlue cell viability assay 
PrestoBlue assay was carried out according to manufacturer’s recommendations. The 
working solution was prepared by diluting the stock solution with phenol red free N2B27 at 
a ratio of 1:10. The cells were incubated 4h with 55µl of the working solution in the 37°C 
incubator. The same volume was incubated under cell free conditions and used as a 
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negative control. 50µl of the incubated supernatant were analyzed with a Tecan Sunrise 
absorbance plate reader using the following settings: 
 Measurement wavelength:  570nm 
 Reference wavelength:  600nm 
 Shake duration (inside low):  2sec 
 Shake settle time:   2sec 
 Number of kinetic cycles:  3 
Reference corrected OD values were normalized to mock control conditions. 
3.2. Cytotoxicity detection kit: 
The cytotoxicity detection kit was based on the lactate dehydrogenase (LDH) assay. LDH 
is released by a cell upon its death into the supernatant and can be measured 
subsequently. The amount of LDH is direct proportional to the amount of cell death (Burd 
and Usategui-Gomez, 1973). The assay used contains a tetrazolium salt that is turned 
over to its formazan form when exposed to electron donors like NADH. NADH is produced 
by LDH that is released by the dead cells and sodium lactate, which is provided by the 
assay. The amount of formazan can be assessed by absorption measurements in a plate 
reader. One of the limiting factors of this assay is that the half-life of free LDH in 
supernatant is only nine hours. Since the whole treatment was conducted over six days, 
the LDH released in the very beginning has already been degraded on day 6. In order to 
overcome this problem supernatant was pooled on day 3 and day 6. Keeping the decay of 
LDH in mind, it is, however, possible to estimate whether the cell death occurred earlier or 
later in the treatment. To eradicate minute differences in the ratio between stem cells and 
motor neurons in patient lines vs. wild type lines, as well as the different absolute cell 
amounts in between experiments, mock controls were carried out for each line and 
experiment. 
Cytotoxicity detection kit was used according to manufacturer’s instructions. Working 
solution was prepared freshly by diluting the catalyst with the dye solution at a ratio of 
1:46. 50µl of the pooled supernatant was mixed with 50µl of the working solution. Working 
solution mixed with phenol red free N2B27 was used as a negative control. Mock treated 
control wells were incubated with 0.5% triton X-100 for 30 min and the lysate was mixed 
with working solution and served as positive control. The reaction volume was then 
incubated for 25min at RT. Then the plate was centrifuged 5min at 200g to eliminate 
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bubbles. Samples were measured in the Tecan Sunrise absorbance plate reader using 
the following settings: 
 Measurement wavelength:  492nm 
 Reference wavelength:  620nm 
 Shake duration (inside low):  2s 
 Shake settle time:   2s 
 Number of kinetic cycles:  3 
Reference corrected OD values were normalized to triton X-100 lysed controls. 
3.3. DNA damage analysis 
DNA damage was assessed by staining of γH2A.X. This method investigates the 
phosphorylation of serine 139 of the histone H2A.X. This modification is initiated by the 
cell very quickly after detection of DNA double strand breaks (DSB) and is a marker for 
DNA damage (Kinner, et al., 2008). Treatment with 10µM Etoposide for 1h was done as 
positive control, since Etoposide is known as an inducer of DSB in cells (Long, et al., 
1985). To identify and quantify the DSB, Apotome microscopy was conducted using a 63x 
oil objective. Analysis of the spots was done in Fiji using a semi-automated macro. 
4. Metabolic characterization 
Analysis of mitochondrial activity was carried out using the Seahorse XFe96 analyzer. 
This device is capable of measuring changes in the pH value and the oxygen 
concentration simultaneously in real time. The layout of the probe and the well plate is 
designed to create a cavity with a small volume of approximately 2μl. Cells that are 
captured in this region cause a shift in pH and oxygen, which can be measured. The utility 
plate of the measurement stack provides four ports that can be used to inject substances 
that modulate the metabolic activity of the investigated cells. The default assay medium is 
a pH of 7.4 unbuffered, glucose-free solution. The cells are measured in five sets of three 
measurements. After an initial calibration the substances in the ports are injected one by 
one. Before each individual measurement the plates are mixed and the cells are allowed 
to settle. The setup up of the whole experiment is depicted in Table 14. 
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Table 14: Experimental setup of Seahorse XFe96 device 
Section Substance Measurement 
Calibration 
Baseline activity 
- 3 cycles:  3 min shaking 
                1 min resting 
                5min measurement 
Port A 
Glycolytic increase 
10mM glucose 
1mM pyruvate 
3 cycles:  3min shaking 
                1min resting 
                5min measurement 
Port B 
Coupling efficiency 
Glycolytic Reserve 
1µM oligomycin A 3 cycles:  3min shaking 
                1min resting 
                5min measurement 
Port C 
Spare respiratory 
capacity 
0.7µM FCCP 3 cycles:  3min shaking 
                1min resting 
                5min measurement 
Port D 
non-respiratory oxygen    
consumption 
non-glycolytic 
extracellular acidification 
50mM 2-DG 
1.5µM rotenone 
2.5µM antimycin A 
3 cycles:  3min shaking 
                1min resting 
                5min measurement 
 
The first port was used to inject glucose and pyruvate to start the glycolysis and oxidative 
phosphorylation. The increase in the extracellular acidification rate (ECAR) compared to 
the basal level is the glycolytic increase. The second injection was used to add oligomycin 
A, an inhibitor of complex V. This causes a drop in oxygen consumption due to the 
inability of the mitochondrium to convert the proton gradient into chemical energy. The 
only remaining oxygen consumption results from the activity of endogenous uncoupling 
protein like UCP1 (Nicholls, et al., 1978). Therefore coupling efficiency can be calculated. 
Furthermore the cell has to rely solely on glycolysis to meet its energy demand. This 
increase in extracellular acidification rate is reflecting the glycolytic reserve. The third port 
harbors FCCP, an uncoupling agent that diminishes the proton gradient and thereby 
increases the oxygen consumption. This happens because the mitochondrium tries to 
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reestablish the proton gradient and a major component of this machinery is the oxygen 
dependent complex IV of the electron transport chain. The spare respiratory capacity can 
be obtained from this data. The last port is used to inhibit glycolysis with 2-deoxy-D-
glucose (2-DG), a competitive inhibitor of the phosphoglucoisomerase, and to inhibit the 
oxidative phosphorylation by inhibition of complex I with rotenone and complex III with 
antimycin A. The remaining oxygen consumption and extracellular acidification is 
contributed by non-respiratory and non-glycolytic processes. 
5. Protein biochemistry 
5.1. Alkaline phosphatase staining 
Staining of alkaline phosphatase (AP) was conducted according to manufacturer’s 
instruction. 
5.2. Preparation of immunocytochemistry samples 
All cells were washed two times with warm PBS and then fixed with 4% warm PFA pH 7.4 
solution for 12min. After fixation cells were washed three times with PBS. If the desired 
antigen was a surface protein no permeabilization step was conducted. Otherwise a 
treatment of 0.2% triton X-100 in PBS was used to permeabilize the cells. Blocking 
solution was made by using PBS and adding the following ingredients: 
 1%   bovine serum albumin 
 5%   donkey serum 
 0.3M  glycine 
 0.025% triton X-100 
Fixated cells were incubated with blocking solution for one hour. Primary antibody 
combinations were used according to Table 15 and solved in blocking solution. Incubation 
was done overnight at 4°C. 
Table 15: Primary antibody combinations used for ICC grouped by their application 
Pluripotency 
ms Sox2 488 rb Nanog 594 -  
rb Oct4 488 ms Lin28A 594 -  
ms SSEA4 488 -  rat SSEA3 647 
-  ms Tra 1_60 594 -  
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Three germ layer formation: ectoderm 
rb Nestin 488 ms Tuj1 594 -  
ms MAP2 488 rb S100β 594 -  
rb Olig2  488 ms Vimentin 594 -  
ms Galc  488 -  -  
Three germ layer formation: endoderm 
ms α-Fetoprotein  488 gt Gata4 594 -  
rb Gata6 488 ms β-Catenin 594 -  
Three germ layer formation: mesoderm 
ms Pecam-1 488 rb Flk-1 594 -  
ms SMA 488 rb Fibronektin 594 -  
mDAN differentiation 
ms Sox2 488 rb Nestin 594 ch Tuj1 647 
rb TH 488 ms MAP2 594 -  
ms Galc 488 rb S100β 594 -  
ms CytochromeC 488 ch MAP2 594 -  
MSN differentiation 
ms Sox2 488 rb Nestin 594 ch Tuj1 647 
rb Darpp32 488 ms MAP2 594 -  
ms Galc 488 rb S100β 594 -  
ms MAP2 488 rb GABA 594 -  
rb Chat 488 ms MAP2 594 -  
ms Cytochrome C 488 ch MAP2 594 -  
 
The samples were washed three times for 5-10min. Secondary antibodies were solved in 
blocking solution and incubated for one hour. Antibody solution was then aspirated and 
the samples washed three times with PBS. Cell nucleus staining was achieved by 
application of a solution containing 0.75µl Hoechst33342/ml PBS was prepared and 
applied to the cells for 5 min. Samples were washed again three times and then mounted 
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on object slides using fluoromount as mounting media. Samples were stored overnight at 
4°C and for further preservation, coverslips were enclosed with nail polish to prevent 
movement. Samples were stored in 4°C fridges for microscope analysis. 
5.3. Isolation of globular and filamentous actin 
In order to assess the ratio of globular (G) and filamentous (F) actin a protocol from 
Papakonstanti was modified (Papakonstanti and Stournaras, 2007). Two 6 wells of 
matured neurons were first washed with ice cold phosphatase inhibitor. The solution was 
then discarded and the cells incubated 5min with 200μl cold G-actin extraction buffer. The 
soluble fraction was then collected and stored at -80°C. 200μl of cold RIPA buffer was put 
in the well. Then the cells were scraped off, collected in a 1.5ml reaction tube and 
incubated on ice for 15min. To separate the insoluble fraction the tube was centrifuged 
+10000g for 2min at 4°C and the supernatant was transferred into a new tube while the 
pellet was discarded. The F-actin containing fraction that was obtained was stored 
at -80°C before analyzed with western blot. Importantly, this protocol does not use any 
internal protein control or prior protein quantification but the ratio of G vs F actin is 
assessed solely by applying the same volume of G and F actin containing lysates. 
RIPA Buffer:      Extraction Buffer: 
1% TritonX-100     0.3% Triton X-100 
50mM Tris-HCl     5mM Tris-HCl 
0.15M NaCl      300mM Sucrose 
1% Sodiumdeoxycholate    2µM Phalloidin 
0.1% SDS      2mM EGTA 
1mM EDTA      pH 7.4 
1mM DTT      1% Protease Inhibitor Cocktail 
pH 7.4 
1% Protease Inhibitor Cocktail 
5.4. Whole cell protein Isolation 
Whole cell protein was isolated from one 6 well of matured neurons. Remaining media in 
the wells was first discarded and then the wells were washed with ice cold phosphatase 
inhibitor. Cells were then scraped off, collected in 1.5ml reaction tubes and centrifuged for 
4min at 250g. The inhibitor solution was then aspirated and the pellet resuspended in 60μl 
cold RIPA buffer. Lysis buffer was incubated for 15min on ice. The samples were then 
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centrifuged for 2min at +10000g to precipitate the insoluble fraction. Supernatant was 
collected and stored in a -80°C freezer. 
5.5. Cytosolic protein isolation 
Cytosolic protein extraction was done to increase the yield of CHOREIN in the sample and 
solely conducted for CHOREIN western blot experiments. The nuclear extraction kit of 
Active motif was used and protocol was stopped at the step of separation of cytosolic and 
nuclear fraction. Until this point the protocol was followed according to the manufacturer’s 
recommendations. 
5.6. Protein concentration measurement 
Protein concentration was assessed using a modified Bradford assay in conjunction with 
an absorbance plate reader. The used assay was modified from the commercial available 
kit Rothi Nanoquant. For each experiment, a complete standard curve consisting of 
premade solutions containing 0, 5, 10, 25, 50 and 75ng/µl BSA was measured and the 
content of the samples was calculated using a linear regression method. First the working 
solution was prepared by diluting the concentrate stock 1:5 with RNAse/DNAse free water. 
40µl of the standard solutions were mixed with 160μl working solution in a well of a 96 
well plate. 1µl of each sample were mixed with 39μl RNAse/DNAse free water and 160ul 
working solution. The complete plate was then analyzed using the following measurement 
parameters: 
Measurement wavelength:  450nm 
 Reference wavelength:  590nm 
 Shake duration (inside low):  2sec 
 Shake settle time:   2sec 
 Number of kinetic cycles:  3 
Data was exported to Excel and the 450nm/590nm ratio was plotted over the 
concentration and a linear regression was calculated for the standard curve. Protein 
content of the unknown samples was calculated using the standard curve parameters and 
a dilution coefficient of 40. 
5.7. Western blot 
Protein samples were thawed up on ice. For each lane 3μl of NuPage loading buffer were 
added to 18μg protein and filled up with ddH2O to yield a final volume of 12μl. All samples 
were heated to 95°C for 5min before cooling down on ice and centrifugation. Pre-cast gels 
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were prepared and set up in the gel electrophoresis container. The box was then filled 
with the running buffer according to the gel type used. Markers for the determination of the 
electrophoresis process included SeaBlue and Magic marker. A volume of 10µl containing 
15µg of protein was loaded into the wells of the prepared gel. Voltage, ampere and time 
course were selected individually for the corresponding application (See Table 16). 
Table 16: Settings for SDS PAGE electrophoresis for different applications 
Application Voltage Ampere time 
CHOREIN western 
blot 
90V for the first cm then: 140V 60mA 2h 
Cytoskeleton analysis 140V 60mA 1-1,5h 
 
Successful electrophoresis was determined by the separation of bands within the 
reference marker lanes. Then the protein containing gels were transferred to nitrocellulose 
membranes using the iBlot dry blotting system. The gels were first incubated in transfer 
buffer solution for 9min. The blotting stack was assembled according to the manual. 
Blotting conditions were optimized for the corresponding application. Blotting of CHOREIN 
was done using program 3 (20V) for 12min and analysis of cytoskeleton proteins used the 
same program for 9min. After the blotting process was finished, the membrane was 
cropped for application of desired antibodies and blocked for 1 hour using 5% milk powder 
solved in PBS with 0.05% Tween-20 (PBS-T). Primary antibodies were solved in a PBS-T 
containing 1% milk powder. The membrane was incubated in the primary antibody 
solution overnight at 4°C and then washed three times with PBS-T. Secondary antibodies 
were solved in PBS-T containing 1% milk powder and applied to the membrane for 1h at 
RT. Membranes were washed afterwards four times with PBS-T. Membranes were 
developed using Amersham ECL kit according to the manufacturer’s instructions and 
developed using the LAS3000 imaging system with settings according to Table 17. 
Table 17: Settings for Western Blot development 
 Mode Sensitivity Exposure Aperture Light 
Overview Precision Standard 1/100 sec 2.8 White Epi 
ECL development Increment Standard/ High 10sec 0.8 Off 
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Representative pictures were converted to tiff and analyzed using the TotalLab Quant 
software. The pictures with the highest dynamic range and no overexposed pixels were 
chosen for evaluation. 
6. Live cell imaging 
Live cell imaging was conducted on mature neurons obtained from both differentiation 
protocols in either 96well plates or MFC. These cells were treated 2 days prior to imaging 
with 10mM glycolate and 10mM D-lactate, 10µM phallacidin, 0.1% DMSO or 10µM PP2. 
Either the combination of MitoTracker Deepred with LysoTracker Red or the mitochondrial 
potential marker JC-1 was imaged. The utilized concentration can be seen in Table 18. 
Table 18: Tracker and concentrations used for live cell imaging 
Tracker Final concentration 
MitoTracker Deepred 50nM 
LysoTraker Red 50nM 
JC-1 200nM 
 
All videos were taken with a 100x 1.4 objective. The time interval between two images 
was fixed to 0.3 seconds and was controlled by a hardware sequencer. Each video was 
imaged for 2minutes resulting in a set of 400 images. Gain was set to 300 and the 
exposure times to 115ms. These settings were not changed between videos. Brightness 
of the obtained images was regulated by adjustment of the laser power. 
The dye JC-1 was used to visualize the mitochondrial potential. This dye has a free form 
that exhibits green fluorescence (Smiley, et al., 1991). In the presence of a proton 
gradient induced potential, the dye forms J-aggregates that have a shift in fluorescence 
towards red. When a mitochondrium is excited by 488nm, the ratio of the resulting green 
and red fluorescence is an indicator for its membrane potential. Intensity in the channels 
of the JC-1 images was assessed by a semi-automated macro. Analysis of morphological 
features of lysosomes and mitochondria was achieved using a semi-automated macro on 
single images. Trafficking analysis is carried out with the whole video using the TrackMate 
plugin provided with the Fiji suite. KNIME was used for data mining the resulting files. 
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The filter criteria and settings for TrackMate were as follows: 
 Detector:  DoG detector 
 Estimated radius: 0.8 
 Quality:  100 
 Tracker:  Linear motion LAP tracker 
 Kalman radius: 1.25 
 Initial distance: 2 
 Max linking distance: 2 
Gap Closing:  2 
 Track duration: 3 
There was no further filter added in the subsequent analysis. In the first step of the work 
flow of the data analysis, all individual tracks of every video of each individual line within 
one experiment were pooled. A histogram with 100 segments ranging from 0 to 100µm 
with an equidistant binning allowed brief investigation of the distribution of the tracks. In 
the next step the probability of an object moving further than a particular displacement 
was calculated. Then the complementary cumulative distribution function of this probability 
was blotted. The resulting graph resembled an exponential decay (See Figure 8).  
 
Figure 8: Scheme of processing work of tracking analysis. CCDF = complementary cumulative 
distribution function. 
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Regression analysis was used to obtain parameters of a two phase exponential decay 
with the following equation: 𝑌 = 𝑁𝑓𝑖𝑟𝑠𝑡𝑒−𝑘𝑓𝑖𝑟𝑠𝑡𝑋 +𝑁𝑠𝑒𝑐𝑜𝑛𝑑𝑒−𝑘𝑠𝑒𝑐𝑜𝑛𝑑𝑋. The fist decay, which 
occurs at short distances, describes the distribution of stationary tracks while the second 
decay can be interpreted as the influence of the actual moving tracks on the data. In the 
next step the crossing point of the first derivatives of both functions was calculated using 
following equation: 
𝑋𝑐𝑟𝑜𝑠𝑠 =
ln⁡(
𝑘𝑓𝑖𝑟𝑠𝑡𝑁𝑓𝑖𝑟𝑠𝑡
𝑘𝑠𝑒𝑐𝑜𝑛𝑑𝑁𝑠𝑒𝑐𝑜𝑛𝑑
)
𝑘𝑠𝑒𝑐𝑜𝑛𝑑 − 𝑘𝑓𝑖𝑟𝑠𝑡
 
This distance represents the point where the fraction of moving tracks starts to have 
bigger influence on the overall data than the stationary fraction. In the last step, all tracks 
that moved less than this distance were considered stationary and all tracks the displaced 
further were considered as moving. 
7. Statistics 
All statistics shown in this work were calculated using GraphPad Prism. When 
experiments with one independent variable and only two groups were analyzed, a t-test 
was conducted. When the variances were different in between the two groups, Welch’s 
correction was applied. Experimental setups with one independent variable but more than 
two groups were analyzed using a one-way ANOVA. Multiple comparisons were corrected 
using Tukey’s procedure. In case the experiment was comprised of two independent 
variables, a two-way ANOVA was calculated. Tukey’s procedure was used for the 
correction of multiple comparisons. Furthermore for each statistical analysis the effect size 
ω2 was calculated.  
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Results 
1. Generation of induced pluripotent stem cells 
Patient and control fibroblast lines were expanded and prepared for the reprogramming 
procedure. Successful infection was confirmed by analyzing the expression of the 
dtTomato reporter (see Figure 9). The yielded iPSC were then morphologically selected 
and clonally picked. The first experiments were aimed to identify bona fide clones for 
characterization. 
 
Figure 9: Successful infection: Representative pictures of freshly infected human fibroblast lines from 
wild type controls or ChAc lines. DtTomato expression is a sign of successful infection and virus 
integration. Not all cells were infected. Scale bar = 50µm. 
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1.1. Silencing of exogenous transcription factors 
All clones that had a stable and good looking morphology were checked for the silencing 
of the exogenous transcription factors. Silencing is important for differentiation capacity, 
reproducibility and reliability of the further obtained results. Silencing is also mandatory for 
good practice of iPSC culture as published by Maherali and Hochedlinger (Maherali and 
Hochedlinger, 2008). Silencing was investigated by qPCR. The expression of lentiviral 
mRNA was calculated relative to GAPDH and relative to the total expression of the 
transcription factor, including viral and endogenous expression. Thereby the contribution 
of the residual expression of the integrated virus was estimated. A clone was considered 
as silenced, when the expression relative to GAPDH was below 0.2% and the mean 
residual contribution relative to the total expression of the transgene was less than 5%. In 
total 14 clones were analyzed at low passage numbers (≤ P10). One clone had to be 
cultivated significantly longer than the others before yielding a stable morphology. 10 
clones displayed bona fide silencing of transgenes, while four clones maintained 
substantial expression above the threshold. One of the clones however did meet the 
necessary requirement when analyzed again at higher passage number (see Table 19). 
Table 19: Silencing of generated iPSC lines 
Cell line Passage Silencing relative 
to GAPDH 
Mean residual contribution 
(transgenes above 5%) 
Continued 
ChAc 1.1 P5 0.27% 17.6% (OCT4, KLF4, cMYC) - 
ChAc 1.1 P16 0.03% 16.45% (OCT4, KLF4, cMYC) - 
ChAc 1.1 P39 0.04% 23.12% (OCT4, KLF4, cMYC) Yes 
ChAc 1.2 P7 0.04% 1.9% Yes 
ChAc 1.3 P7 0.05% 2.4% (KLF4) Yes 
ChAc 1.4 P5 0.01% 0.6% Yes 
ChAc 1.5 P5 <0.01% 0.5% Yes 
ChAc 2.1 P21 0.05% 1.4% Yes 
ChAc 2.2 P10 0.79% 25.6% (OCT4, KLF4, cMYC) No 
wt 1.1 P6 <0.01% 2.01% (KLF4) No 
wt 1.2 P10 <0.01% 0.2% Yes 
wt 1.3 P7 0.05% 3.2% (KLF4) Yes 
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Cell line Passage Silencing relative 
to GAPDH 
Mean residual contribution 
(transgenes above 5%) 
Continued 
wt 2.1 P5 0.12% 3.5% (KLF4) - 
wt 2.1 P11 0.04% 2.4% (KLF4) Yes 
wt 2.2 P5 <0.01% 0.1% Yes 
wt 2.2 P11 <0.01% 0.1% Yes 
wt 2.3 P11 0.01% 0.8% Yes 
wt 4.1 P6 0.06% 3.4% (KLF4) No 
wt 4.2 P5 0.02% 2.7% (KLF4) Yes 
 
The silencing was successfully demonstrated for at least two clones from the lines ChAc 1, 
wt 1 and wt 2. The reprogramming procedure of ChAc 2 and wt 4 did yield two 
morphologically stable clones per line. When further investigated, however, only one clone 
from each line was considered silenced. Furthermore, silencing improved in a clone that 
was investigated two times at P5 and P11 (wt 2.1), while another clone maintained its 
silencing during the same time (wt 2.2). All silenced clones were further characterized. 
Hierarchical clustering was performed on the data gathered from the silencing and 
characterization PCR of reprogrammed clones (See Figure 10). Three clusters, which 
were separated by a large distance, were identified. The grey box marks the cluster that 
was identified as the freshly infected fibroblast lines, which had a high expression of 
exogenous transcription factors and no activation of endogenous transcription factors or 
genes downstream of these factors. The red box highlights a cluster that was entirely 
comprised of partially reprogrammed cell lines, which harbored some residual exogenous 
expression as well partial activation of the endogenous transcription factors. Only ChAc 
lines were found in this group. The green box identifies the last and biggest cluster, 
populated only by silenced and bona fide reprogrammed iPSC. The distance between 
these cell lines was very small, showing that they all reached a similar level of quality in 
regards to the PCR markers tested. Even though there were two subpopulations observed 
within this group, they were not enriched in either wild type or ChAc cell lines and their 
overall distance was very low. 
 
 
- 64 - 
 
 
Figure 10: Hierarchical clustering of iPSC after silencing/characterization PCR. The grey box shows 
the cluster defined by freshly infected fibroblasts. The red box is comprised of partially reprogrammed 
and unsilenced iPSC. The green box depicts the cluster of bona fide reprogrammed, hence silenced 
iPSC lines. No additional subpopulations of wild type or ChAc lines were observed within this cluster. 
1.2. Karyotyping of iPSC clones 
The karyotype of all iPSC clones has to be analyzed. Since the reprogramming process 
affects chromatin state and DNA-methylation, genomic alterations like deletions, 
multiplications, loss of heterozygosity (LOH) or gene duplications can occur and impair the 
quality of the clone. The iPSC samples were sent to conduct single nucleotide 
polymorphism karyotyping. The clones wt 1.2, wt 1.3, wt 2.1, wt 2.3, ChAc 1.1 and ChAc 
1.2 were investigated. All clones showed minor deletions or multiplications most frequent 
on chromosome 20 and 12. Minor alterations spanning only few kb were detected in 
almost all clones distributed evenly across all chromosomes. Most of the LOHs detected 
were regions that overlapped with the used reference map of the database of genomic 
variants. These overlaps are prone for these events. Wt 1.2 showed severe chromosomal 
aberrations of about 12000 kB. Notably multiple gains of chromosome 1 and major losses 
of chromosomes 8 and 22 were detected. Wt 1.2 was omitted from further experiments. 
1.3. Evaluation of pluripotency 
After the silencing and the correct karyotype were confirmed, the pluripotent properties of 
the generated lines were assessed.  
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1.4. Alkaline phosphatase staining 
Alkaline phosphatase (AP) is an enzyme, which has an elevated expression in iPSC 
compared to dermal fibroblast. The AP assay gives a quick and robust readout for the 
early stages of reprogramming since it is one of the earliest markers of iPSC conversion. 
Representative examples of AP positive iPSC from each line are shown in Figure 11. The 
MEF feeder, on which the iPSC cells were grown, acted as a negative control since these 
cells genuinely do not express AP. All of the clones investigated were AP positive and 
thus none was excluded. 
 
Figure 11: Alkaline phosphatase staining. Colonies stained in red, displaying a round and regular 
shape, represent morphological bona fide iPSC clones. MEF feeder cells surrounding these colonies 
have no expression of alkaline phosphatase and act as intrinsic negative control. 
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1.5. Staining of pluripotency markers 
In order to further validate a genuine pluripotent behavior the next step was to stain for 
stringent markers of pluripotent stem cell in vitro. Markers included the transcription 
factors OCT4 and SOX2 that have been transduced as well. Since the silencing of these 
factors has been proved previously, their proper endogenous expression and localization 
has to be addressed as well. Other markers investigated were the transcription factor 
Nanog, which acts downstream of the OCT4 driven pluripotency complex and LIN28A a 
translational activator of OCT4 translation. The cell surface markers SSEA3 and Tra1-60 
are important markers of pluripotent stem cells and their presence serves as a good 
indicator for successful reprogramming. All of the clones investigated showed proper 
morphology and were positive for the major markers of a genuine pluripotent ESC-like 
stage (see Figure 12).  
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Figure 12: Pluripotency staining. OCT4 and SOX2 staining show endogenous expression, since their 
silencing was confirmed by PCR experiments before. Nanog and LIN28A are markers that are 
important for stemcell maintance are activated during reprogramming. SSEA3 and Tra 1-60 are 
embryonic stem cell specific cell surface markers that are considered hallmarks of in vtro cultures of 
pluripotent stem cells. Scale bar = 200 μm 
1.6. Three germ layer formation 
The three germ layer formation is a very stringent assay which shows that one batch of 
pluripotent stem cells can give rise to cells from all three different germ layers including 
ectoderm, mesoderm and endoderm. For ectoderm the markers NESTIN, TUJ1, MAP2, 
GALC, and S100β/GFAP were chosen. They provide a broad view over the neuro-
ectoderm and label neural stem cells, neurons, astrocytes and oligodendrocytes (See 
Figure 13). 
Demonstration of capability to differentiate into endoderm was achieved by labeling the 
markers AFP and GATA4. All silenced lines showed bona fide expression of the 
investigated markers (See Figure 14A). Successful mesoderm differentiation was 
observed by staining of FLK-1, PECAM-1 and α-SMA, important markers of mesodermal 
lineage (See Figure 14B). 
All lines were capable of giving rise to cells contributing to each germ layer, thus further 
proving the pluripotent nature of the cell lines generated on a functional level. 
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Figure 13: Three germ layer formation I. Representative pictures of neuro-ectodermal marker staining 
of three germ layer formation. All lines gave rise to NPCs, neurons, oligodendrocytes and astrocytes. 
Scale bar = 50μm.  
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Figure 14: Three germ layer formation II. Representative pictures of A) endodermal differentiation and 
B) mesodermal differentiation. All lines were positive for the investigated markers, indicating steady 
pluripotent capability to give rise to these two germ layers. Scale bar = 50 μm. 
1.7. Confirmation of ChAc phenotype by CHOREIN western blot 
The last step of characterization of the generated iPSC lines was the confirmation of the 
disease specific phenotype. This was investigated by western blot analysis of CHOREIN 
 
 
- 70 - 
 
protein. Absence of CHOREIN is a clear diagnostic indication of ChAc. To verify this, the 
already thoroughly characterized lines, obtained from another lab, were used as either 
positive or negative controls. Therefore antibody specific patterns were obtained for 
CHOREIN positive and negative cell lines (see Figure 15) (Walker, 2015). 
 
Figure 15: CHOREIN western blot of generated lines. Wild type CHOREIN has a size of 360 kDA. wt 1 
and wt 2 show expression of CHOREIN while in ChAc 1 CHOREIN is absent. ChAc1 was used a 
negative control and wt 3 was used as a positive control. Both lines were reprogrammed, 
characterized and contributed from the group of Jared Sterneckert, of the MPI Münster. 
All control lines were positive for CHOREIN and all generated ChAc lines featured its 
absence. 
In summary, all lines obtained were bona fide pluripotent iPSCs and the patient specific 
lines retained the ChAc phenotype on the CHOREIN protein level. The following lines 
were used for the disease modeling experiments using MSN differentiation protocol: wt 
1.2, wt 1.3, wt 2.1, wt 2.2, wt 2.3, ChAc 1.1, ChAc 1.3, ChAc 1.4 and ChAc 2.1. For mDAN 
differentiation, smNPC lines were contributed from the group of Jared Sterneckert: wild 
type: 393.1, 393.2, T12.2 and T12.9; ChAc: D1.17, D2.9 and D2.14. The lines T12.9 and 
D2.9 were obtained as iPSC lines as well and used for the MSN experiments accordingly. 
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2. Characterization of differentiation potential 
All experiments that were conducted to model the disease used mature neurons for which 
two differentiation protocols were established. The first started from iPSC stage and 
yielded a mixed striatal culture containing MSN as well cholinergic interneurons. This 
protocol recapitulates the developmental processes of neurons that are primarily affected 
by ChAc. The second protocol started from the more committed stage of NPCs and 
allowed rapid generation of dopaminergic neurons. The first task, however, was to 
compare the differentiation capacity of wild type and ChAc cell lines. Interpretation of 
experiments that characterizes the disease is highly influenced by the quality of 
differentiation protocols. 
2.1. Differentiation efficiency 
Differentiation efficiency was assessed by ICC. The markers SOX2 and NESTIN were 
used to identify undifferentiated stem cell state, TUJ1 as an early marker showed 
neuronal cell fate, MAP2 was stained to detect mature neurons and GABA, CHAT, CTIP2 
and DARPP32 were used to identify the subtype of neurons. 
There was no significant difference observed in the expression of markers SOX2, MAP2 
and the sub-classification of these neurons after the striatal differentiation protocol was 
successfully performed. A large amount of cells were negative for SOX2, TUJ1 or MAP2 
and showed no typical neuronal morphology (See Figure 16, Figure 18 & Figure 17). 
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Figure 16: MSN protocol characterization I. A) Staining of SOX2 and NESTIN reveal the fraction of 
NPCs. Wild type and ChAc cell lines can both give rise to healthy neuronal cultures. Box: TUJ1-
positive immature neurons are SOX2 negative. B) Wild type lines and ChAc lines are both able to give 
rise to GALC-positive oligodendrocytes as well S100β-positive astrocytes. Scale bar = 100μm 
 
Figure 17: Quantification of MSN differentiation capacity. There were no differences detected between 
wild type and ChAc lines. Markers left of the dashed line represent NPCs and immature cells and to 
the right are markers for mature neurons. Bars represent mean + SEM, n≥4 
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Figure 18: MSN protocol characterization II. A) Both wild type and ChAc lines are capable of 
differentiating into MAP2/DARPP32/CTIP2 triple positive mature medium spiny neurons. 
B) Furthermore these cells are able to give rise to MAP2/GABA/CTIP2 triple positive neurons. Scale 
bar = 100 μm 
The differentiation following the mDAN protocol successfully yielded mature dopaminergic 
neurons as shown by co-labelling of MAP2 and TH. Some cells retained their NPC 
characteristics as shown by staining of SOX2 and NESTIN. The cells were able to give 
rise to GALC and GFAP-positive oligodendrocytes and astrocytes, respectively. The yield 
was, however, not quantified because only very few positive cells were observed. This 
further indicates the neuronal character of the used progenitor cell lines. Overall, there 
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was no difference observed in differentiation capacity when comparing wild type and 
ChAc cell lines (See Figure 19 & Figure 21). 
 
Figure 19: mDAN protocol characterization I. Staining of SOX2 and NESTIN label NPCs and immature 
neurons. Wild type and ChAc lines give rise to homogenous healthy neuronal cultures and yield both 
GALC-positive oligodendrocytes as well as GFAP-positive astrocytes. Scale bar 100μm 
Some of the TH-negative neurons are of hindbrain origin and a by-product of the mDAN 
differentiation as shown with the motor neuron marker SMI32. When perinuclear co-
localization was investigated, only few neurons were positive, even though the culture 
appears to contain more motor neurons (See Figure 20 & Figure 21).  
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Figure 20: mDAN protocol characterization II. Wild type and ChAc cells both give rise to MAP2 and TH 
double positive neurons. SMI32 positive motor neurons are an undesired by-product of mDAN 
differentiation due to the posterior nature of the NPCs used. Box: MAP2 and TH double positive 
neurons are negative for the motor neuron marker SMI32. Scale bar = 100μm 
 
Figure 21: Quantification mDAN differentiation capacity. There were no differences detected between 
wild type and ChAc lines. Markers left of the dashed line represent NPC and immature cells, to the 
right are markers for mature neurons. Bars represent mean + SEM, n≥5 
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Taken together, there was no difference observed in the SMI32 and MAP2 double positive 
cells, but ChAc lines gave rise to more MAP2+ TH+ double positive cells. 
2.2. Characterization by qPCR 
To further investigate differences in the differentiation behavior, qPCR was conducted with 
a total of 20 genes (See Table 20). 
Table 20: Genes investigated to characterize MSN differentiation 
Gene name Marker for 
KLF4 Proliferation - pluripotent stem cells 
LIN28 Proliferation - pluripotent stem cells 
NANOG Proliferation - pluripotent stem cells 
OCT4 Proliferation - pluripotent stem cells 
REX1 Proliferation - pluripotent stem cells 
SOX2 Proliferation - pluripotent & neural stem cells 
EMX2 Patterning - cortical transcription factor 
PAX6 Patterning - cortical transcription factor 
FOXG1 Patterning - rostral transcription factor 
LHX6 Patterning - ventral transcription factor - medial ganglionic eminence 
LHX8 Patterning - ventral transcription factor - medial ganglionic eminence 
NKX2.1 Patterning - ventral transcription factor - medial ganglionic eminence  
ASCL1 Patterning - ventral transcription factor - lateral ganglionic eminence 
DLX2 Patterning - ventral transcription factor - lateral ganglionic eminence 
GSX2 Patterning - ventral transcription factor - lateral ganglionic eminence 
KROX20 Patterning - caudal transcription factor 
MAP2 Maturation - pan neuronal 
GAD67 Maturation - MSN 
CTIP2 Maturation - MSN 
DARPP32 Maturation - MSN 
CHAT Maturation - Cholinergic interneurons 
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These genes were chosen because they reflect the entire differentiation process covering 
iPSC transcriptions factor, neuronal pattering factors and markers for mature neurons. 
Hierarchical clustering of the qPCR data was calculated and probed for clusters. The 
originating iPSC lines clustered close together and were distant from the differentiated 
mature neurons. Within the neuronal fraction there was no obvious clustering observed 
(See Figure 22). 
 
Figure 22: Hierarchical clustering of PCR data for the characterization of MSN differentiation. Blue 
indicates wild type lines and red are ChAc lines. The left most cluster represents the proliferation 
stage of iPSC lines. Overall, no obvious clustering of wild type or ChAc lines was observed. Some 
clusters are formed from individual experiments indicating that the inter-experimental variances are 
bigger then intra-experimental. 
The target genes that were selected for the characterization of the mDAN protocol were 
based on a microarray analysis conducted with one ChAc cell line in a collaborating lab. 
The 13 most prominent hits were selected for in depth PCR expression analysis. 
Furthermore, some genes were added in the analysis because they were previously 
linked to ChAc in other modelling systems, they were putatively linked to play a role in 
ChAc as suggested in the literature or they are important in other diseases that share 
similar clinical symptoms like Huntington (See Table 21). 
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Table 21: Genes investigated to characterize mDAN differentiation 
Gene name Investigated because 
VPS13A - vacuolar protein sorting 13 homolog A Linked to Chorea Acanthocytosis 
TH - tyrosine hydroxylase Differentiation capacity 
TUBB3 -  tubulin beta 3 class III Differentiation capacity 
ACT1 - actin Actin Phenotype in erythrocytes 
CFL1 - cofilin 1 Actin Phenotype in erythrocytes 
CTTN - cortactin Actin Phenotype in erythrocytes 
PFN1 - profilin 1 Actin Phenotype in erythrocytes 
BLCAP - bladder cancer associated protein Prominent hit in microarray analysis 
CFLAR - CASP8 and FADD like apoptosis regulator Prominent hit in microarray analysis 
IL13RA2 - interleukin 13 receptor subunit alpha 2 Prominent hit in microarray analysis 
LHX3 - LIM/homeo box 3 Prominent hit in microarray analysis 
NEUROD1 – neuronal differentiation 1 Prominent hit in microarray analysis 
NKAIN2 - Na/K transporting ATPase interacting 1  Prominent hit in microarray analysis 
NNAT - neuronatin Prominent hit in microarray analysis 
PCDH - protocadherin Prominent hit in microarray analysis 
PLXNA2 - plexin A2 Prominent hit in microarray analysis 
RPL39L - ribosomal protein L39 like Prominent hit in microarray analysis 
SMOC1 - SPARC related modular calcium binding 1 Prominent hit in microarray analysis 
SPON1 - spondin 1 Prominent hit in microarray analysis 
SST - somatostatin Prominent hit in microarray analysis 
ADD2 - adducin 2 Linked to Huntington 
RRS1 - ribosome biogenesis regulator homolog 1 Linked to Huntington 
TRK1 - tropomyosin receptor kinase A Linked to Huntington 
TRK2 - tropomyosin receptor kinase B Linked to Huntington 
TRK3 - tropomyosin receptor kinase C Linked to Huntington 
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When hierarchical clustering was performed, one of the genes, NNAT, was highly 
overexpressed in ChAc lines. When NNAT expression was omitted from the hierarchical 
cluster analysis, there was no clustering between wild type and ChAc lines. However, 
when NNAT expression was considered there were two clusters observed. The first 
cluster was comprised of wild type lines and the second cluster contained all the ChAc 
lines and notably one wild type line. 
 
Figure 23: Hierarchical clustering of the PCR data of mDAN differentiation. A) Analysis conducted with 
the result of NNAT expression shows a clear clustering of wild type and ChAc lines, with the exception 
of wt 2.2. B) Exclusion of the NNAT expression shows that no specific cluster can be observed. 
In summary, all lines were able to give rise to mature neurons following MSN as well as 
mDAN differentiation protocol. ICC and qPCR analysis of maturated cultures revealed that 
there was no difference between wild type and ChAc. When mDAN cultures were 
investigated an increased amount of MAP2/ TH double positive cells was detected. 
Hierarchical clustering of qPCR results of 25 investigated genes revealed a separate 
clustering of ChAc lines and wild type lines with the notable exception of Wt 2.2. When the 
expression of NNAT was omitted, there was no clustering observed (See Table 22). 
Table 22:  Characterization of the applied differentiation protocols 
 MSN differentiation mDAN differentiation 
ICC ChAc and wild type lines are capable 
of differentiating into mature MSN 
there was no difference in the 
differentiation capacity observed 
ChAc and wild type lines are capable 
of differentiating into mature mDAN 
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 MSN differentiation mDAN differentiation 
PCR cluster of mature differentiated 
cultures is distant of iPSC cluster 
no cluster within mature MSN cultures 
is observed 
clustering of ChAc and wild type lines 
is observed when expression of NNAT 
is considered 
no clustering is observed when 
expression of NNAT is omitted 
 
2.3. Ratio of polymerized and unpolymerized cytoskeleton proteins   
One of the well-known impairments in ChAc disease is the alteration of the ratio between 
G and F actin in erythrocytes. To evaluate whether this is also aberrant in neurons, the 
ratio was analyzed by western blot. As microtubules play an important role in transport 
and are an essential part of the cytoskeleton, the ratio of polymerized and unpolymerized 
tubulin was investigated as well. Modifications of tubulins are important for their function. 
Acetylation of tubulin is important for protein interaction of microtubules (Howes, et al., 
2014).  
In mature MSN cultures the G/F actin ratio was significantly increased, while in mature 
mDAN there was no difference observed (See Figure 24). Differences in the distribution of 
tubulin were neither detected in mDAN nor MSN cultures. In the western blot, there was 
also no difference detected in the amount of acetylated tubulin relative to total α-Tubulin. 
 
Figure 24: Evaluation of western blots of cytoskeleton proteins and acetylated tubulin ratio of both 
differentiation protocols. A) There was a significant increase observed in the G/F actin ration when 
ChAc lines were compared to wild type. B) No differences in the investigated cytoskeleton 
components were observed in mDAN differentiation. Bars represent mean +SEM. n ≥ 12, */**/*** 
represent p=0.05/0.01/0.001 
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2.4. Cell survival upon stress induction 
Since there were no obvious differences in neuronal differentiation and cell survival by 
VPS13A mutations, the vulnerability for different stressors in ChAc neurons was 
intestigated. Because one of the first putative roles of CHOREIN was vesicle sorting and 
several indications suggested that it might be important in autophagy and lysosomal 
pathway, cell survival under proteasomal stress was evaluated. Proteotoxic stress was 
induced using L-canavanine, an arginine analogue that causes misfolding of protein and 
thereby challenges the protein biosynthesis as well as recycling. Tunicamycin, an inhibitor 
of N-linked glycosylation, causes cell cycle arrest as well as endoplasmatic reticulum-
related unfolded protein response. Matured neurons were treated for six days with three 
different concentrations of the two toxins. Cell viability was then assessed using the 
resazurin-based PrestoBlue and lactate dehydrogenase (LDH) release assay.  
When MSN differentiated neurons were treated with L-canavanine, there was no 
significant interaction and no significant influence of the genotype. The treatment however 
showed a significant influence (p<0.0001, F(3, 87)=148.5, ω²=0.839, two-way ANOVA) 
(See Figure 25 A). When treated with tunicamycin, there was a significant interaction 
between the treatment and the genotype (p=0.0269, F(1, 49)=3.331, ω²=0.111). The 
influence of the treatment was significant (p<0.0001, F(3, 49)=39.82, ω²=0.610) and the 
influence of the genotype was significant as well (p<0.0001, F(3, 49)=21.26, ω²=0.065) 
(See Figure 25 D). 
LDH is released into the supernatant upon disruption of cell membrane and is therefore a 
direct marker of cell death. L-canavanine addition yielded no interaction between 
treatment and genotype and no influence of the treatment. The genotype was significantly 
influencing the LDH release (p=0.0038, F(1, 80)=8.914, ω²=0.106) (See Figure 25 B). 
Tunicamycin resulted in a significant influence of the genotype (p=0.0065, F(1, 80)=7.81, 
ω²=0.098) (See Figure 25 E). 
The cell composition on the day of investigation gives insight into the kinetics of the 
poison by highlighting the ratio between dead and living cells. L-canavanine treatment 
yielded a significant effect of the genotype (p=0.0009, F(1, 80)=11.85, ω²=0.093) as well 
as the treatment (p<0.0001, F(3, 80)=13.3, ω²=0.31) (See Figure 25 C). Treatment with 
tunicamycin resulted in a significant treatment effect (p=0.02, F(3, 80)=3.466; ω²=0.179)  
but not of the genotype nor the interaction (See Figure 25 F). Taken together, these 
results indicate that mature MSN derived from ChAc cell lines are less metabolic active 
after 6 days of tunicamycin treatment and that the majority of the cell death occurred in 
both ChAc and wild type lines earlier during the treatment. L-canavanine did not affect 
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ChAc cell lines’ metabolic activity differently. However, the cell death in ChAc cell lines 
seems to peak at a different time point than in wild type lines. 
 
Figure 25: Survival of mature MSN cultures. A-C) Treatment with L-canavanine resulted in reduced 
metabolic activity and increased LDH release. Cell composition indicated an early cell death in ChAc 
lines. D-F) Treatment with tunicamycin showed a decreased metabolic activity and increased LDH 
release. Analysis of cell composition revealed no differential temporal response to the poison. Bars 
represent mean + SEM. n ≥ 9. * indicate significant differences within a treatment. # indicate significant 
differences to control condition. */**/***; #/##/### represent p=0.05/0.01/0.001 
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Mature mDAN cultures were treated the same way. Application of L-canavanine over the 
course of the experiment showed a significant interaction between treatment conditions 
and genotype (p=0.0476, F(3, 52)=2.826 ω²=0.033) as well as significant influence of both 
genotype (p=0.0007, F(1, 52)=13.07, ω²=0.04) and treatment (p<0.0001, F(3, 52)=92.13, 
ω²=0.796) (See Figure 26 A). For tunicamycin, no significant interaction between 
genotype and treatment were observed. Both genotype (p=0.0134, F(1, 52)=6.556 
ω²=0.019) and treatment (p<0.0001, F(3, 52)=113 ω²=0.844) influence were significant 
however (See Figure 26 D). 
LDH release was measured for the treatments as well. L-canavanine addition yielded no 
interaction between treatment and genotype. The genotype was significantly influencing 
the LDH release (p<0.0001, F(1, 68)=22.06, ω²=0.171) as well as the treatment (p<0.0001, 
F(3, 68)=13.6, ω²=0.324) (See Figure 26 B). Tunicamycin resulted in no observable 
interaction between treatment and genotype. The genotype however was significant 
(p=0.003, F(1, 68)=14.46, ω²=0.132) as well as the treatment (p<0.0001, F(3, 68)= 10.63, 
ω²=0.297) (See Figure 26 E). 
The cell composition on the day of investigation was probed for mDAN differentiation as 
well. L-canavanine treatment yielded a significant interaction (p<0.0001, F(3, 68)=20 
ω²=0.142). The genotype was rated significant (p<0.0001, F(1, 64)=53.45, ω²=0.123) as 
well as the treatment (p<0.0001, (F3, 64)=88.54, ω²=0.605) (See Figure 26 C). Treatment 
with tunicamycin resulted in a significant interaction (p=0.0082, F(1, 64)=4.27, ω²=0.08), 
genotype (p<0.0001, F(1, 64)=22.01, ω²=0.116) and treatment (p<0.0001, F(1, 64)=32.98, 
ω²=0.513) (See Figure 26 F). Midbrain dopaminergic neurons showed an increased 
susceptibility to both drugs, including a differential temporal pattern. 
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Figure 26: Survival of mature mDAN cultures. A-C) Treatment with L-canavanine resulted in reduced 
metabolic activity and increased LDH release. Cell composition indicated an acute late-phase cell 
death in ChAc lines. D-F) Treatment with tunicamycin showed a decreased metabolic activity and 
increased LDH release. Analysis of cell composition revealed a later cell death. Bars represent mean + 
SEM. n ≥  8. * indicate significant differences within a treatment. # indicate significant differences to 
control condition. */**/***; #/##/### represent p=0.05/0.01/0.001 
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2.5. DNA damage in mature neurons 
To identify whether increased DNA damage or susceptibility to it is present in ChAc 
patient derived mature neurons, DSB were analyzed under control conditions and after 
treatment with the DNA damage inducer etoposide. Phosphorylation of histone H2A.X at 
serine 139 is a well-established marker for DSB in cells and can be investigated using 
conventional ICC protocols. When subjected to MSN differentiation, ChAc neurons 
showed significantly less DSB than wild type under control conditions. When treated with 
etoposide however there was significant interaction between the influence of the treatment 
and the genotype (p=0.048, F(1, 867)=3.937, ω²=0.004, two-way ANOVA). There was no 
influence of the genotype observed, but the treatment had a significant influence 
(p<0.0001, F(1, 867)=230.211, ω²=0.210) (See Figure 27 A). 
The size of the spots was investigated as well. There was a significant interaction 
between the genotype and etoposide treatment observed (p=0.0062, F(1, 2413)=7.517, 
ω²=0.004). The genotype (p=0.0132, F(1, 2413)=6.153, ω²=0.003) and the treatment was 
significant as well (p=0.0411, F(1, 2413)=4.178, ω²=0.002) (See Figure 27 B). 
 
Figure 27: DNA damage in MSN differentiation. A) Analysis of γH2A.X showed increased DSB upon 
acute treatment for 1h with 10 µM etoposide that resulted in increase of γH2A.X spots per nucleus in 
ChAc lines. B) Analysis of the size of γH2A.X spots showed a decrease in size under control as well as 
treatment conditions. Boxes represent 25-75 percentiles, line represents median, whiskers represent 
10-90%, + represents mean. n = at least 168 nuclei from 8 independent experiments. * indicate 
significant differences within a treatment. # indicate significant differences to control condition. 
*/**/***; #/##/### represent p=0.05/0.01/0.001, respectively. 
Neurons that were differentiated according to mDAN protocol were subjected to etoposide 
treatment as well. There was a significant interaction observed between genotype and 
treatment (p<0.0001, F(1, 2626)=22.32, ω²=0.007). The influence of the treatment 
(p<0.0001, F(1, 2626)=465.1, ω²=0.149) and of the genotype (p=0.035; F(1, 2626)=8.525, 
ω²=0.003) were both significant (See Figure 28 A). The size of the γH2A.X spots showed 
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that there is no interaction and no influence of genotype. The treatment however had a 
significant influence (p<0.0001, F(1, 7784)=33.78, ω²=0.004) (See Figure 28 B). 
 
Figure 28: DNA damage in mDAN differentiation. A) Analysis of γH2A.X showed increased DSB upon 
acute treatment for 1h with 10μM etoposide that resulted in increase of γH2A.X spots per nucleus in 
ChAc lines. B) Size of γH2A.X spots is unaffected by genotype and treatment. Boxes represent 25-75 
percentiles, line represents median, whiskers represent 10-90%, + represents mean. n = at least 433 
nuclei from 8 independent experiments. * indicate significant differences within a treatment. # indicate 
significant differences to control condition. */**/***; #/##/### represent p=0.05/0.01/0.001, respectively. 
The experiments showed that in both differentiation protocols ChAc patient derived 
neurons gain more DNA damage than healthy controls when treated with etoposide. 
In summary, no increased cell death or DNA damage under control conditions was 
detected. However, both protocols showed an increased vulnerability to disruptions to 
proteostasis as well as DNA damage induction by etoposide. A major difference between 
mDAN and MSN differentiated neurons was the differential reaction to the stressors used. 
While mixed striatal cultures showed an increased vulnerability to tunicamycin, midbrain 
dopaminergic neurons were more susceptible to L-canavanine poisoning. Analysis of the 
cell composition highlighted a difference in the time point of cell death (See Table 23). 
Table 23: Summary of stressing experiments 
L-canavanine MSN differentiation mDAN differentiation 
PrestoBlue 1mM had no effect on wild type 
and ChAc 
2mM and 5mM decreased cell 
survival, however, wild type and 
ChAc were similar 
1mM had no effect on wild type 
and ChAc 
2mM and 5mM decreased cell 
survival and ChAc was more 
severely affected 
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L-canavanine MSN differentiation mDAN differentiation 
LDH ChAc lines had an reduced LDH 
release 
ChAc lines had an increased 
LDH release 
composition ChAc lines showed a more 
pronounced early cell death 
ChAc lines showed a more 
pronounced acute late cell death 
tunicamycin MSN differentiation mDAN differentiation 
PrestoBlue 10µM had no effect on wild type 
and ChAc 
50µM and 100µM decreased cell 
survival and ChAc was more 
severely affected 
10µM had no effect on wild type 
and ChAc 
50µM and 100µM decreased cell 
survival and ChAc was more 
severely affected 
LDH 
 
ChAc lines had an reduced LDH 
release 
ChAc lines had an increased 
LDH release 
composition wild type and ChAc behaved 
similar 
ChAc lines showed an more 
pronounced acute late cell death  
γH2A.X MSN differentiation mDAN differentiation 
Count of spots strong effect of etoposide treatment 
no effect of the genotype 
strong effect of etoposide 
treatment 
weak effect of the genotype 
Size of the 
spots 
weak effect of the genotype no effect of the genotype 
 
2.6. Characterization of metabolism 
Glycolysis and oxidative phosphorylation are important pathways for the cell to meet 
energy requirements of various processes. It is known that these metabolic pathways are 
tightly regulated and dependent on each other. To elucidate whether their balance is 
shifted, complex multi-step analysis of mature neurons was conducted. The seahorse 
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device allows simultaneous measurement of changes in pH and oxygen concentration 
and provides the possibility to inject multiple substances to investigate their influence. 
Alterations in oxygen consumption and extracellular acidification rate can be used to 
characterize the energy metabolism of the cells and for an in depth analysis of metabolic 
parameters, since the interactions of the injected substances with different complexes of 
the electron transport chain are known. For characterization of metabolism the increase in 
glycolysis, the glycolytic reserve, the non-glycolytic acidification rate, the coupling 
efficiency, the spare respiratory capacity and the non-respiratory oxygen consumption 
were calculated. 
 
Figure 29: Metabolic characterization of mature neurons after MSN differentiation. A-C) No differences 
were observed during the characterization of glycolysis. D-F) Mature MSN neurons have a low 
coupling efficiency and comparable low spare respiratory capacity. The non-respiratory oxygen 
consumption was significantly increased in ChAc lines. Bars represent mean + SEM. n ≥ 4. * indicate 
significant differences. */**/*** represent p=0.05/0.01/0.001, respectively. 
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When mature MSN were investigated, there was no difference observed in glycolytic 
increase, glycolytic reserve, non-glycolytic acidification rate, the spare respiratory capacity 
and coupling efficiency of mitochondria. There was, however, a significant increase in 
non-respiratory oxygen consumption (See Figure 29 A-F). 
Following the mDAN differentiation protocol there was no difference observed in glycolytic 
increase, glycolytic reserve and non-glycolytic acidification rate. Characteristics of 
oxidative phosphorylation were altered. Coupling efficiency and spare respiratory capacity 
were higher in patient derived neurons than in wild type controls. The non-respiratory 
oxygen consumption was decreased in mDAN derived from ChAc compared to wild type 
(See Figure 30 A-F). 
 
Figure 30: Metabolic characterization of mature neurons after mDAN differentiation. A-C) No 
differences were observed during the characterization of glycolysis. D-F) Mature mDAN from ChAc 
lines have significantly higher coupling efficiency as well as higher spare respiratory capacity. The 
non-respiratory oxygen consumption was significantly decreased in ChAc lines. Bars represent mean 
+ SEM. n ≥ 5. * indicate significant differences. */**/*** represent p=0.05/0.01/0.001, respectively. 
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In summary in neither differentiation protocol there was a disturbance in glycolytic 
parameters observed. Analysis of mitochondrial characteristics revealed differential 
results between MSN and mDAN derived neurons. While mixed striatal cultures harbored 
a reduction in coupling efficiency, mDAN differentiations exhibited an increase. 
Furthermore, the spare respiratory capacity was unaltered in MSN differentiations but 
increased in mDAN cultures. The non-respiratory oxygen consumption was lowered in 
both protocols, suggesting a putative pan neuronal phenotype. 
Table 24: Summary of the results of the metabolic analysis 
 MSN differentiation mDAN differentiation 
Glycolytic parameters No alterations in glycolytic 
parameters 
no alterations in glycolytic 
parameters 
Mitochondrial parameters low coupling efficiency 
ChAc lines showed a 
reduced non-respiratory 
oxygen consumption 
ChAc lines showed an 
increased coupling 
efficiency, spare 
respiratory capacity and 
non-respiratory oxygen 
consumption 
 
3. Live cell imaging 
In neurons the energy demand along a neurite is not constant. There are local energy 
sinks that require a larger supply with ATP. Therefore it is crucial that there is a proper 
distribution of mitochondria. This distribution is achieved by axonal transport along the 
microtubule. Furthermore dynamics of fusion, fission and recycling of damaged 
mitochondria have to be maintained over a long distance. Live cell trafficking analysis of 
mitochondria was used to investigate the morphology and functions of mitochondria. 
The trafficking of lysosomes was investigated to elucidate whether the autophagic 
recycling and endosomal signaling pathways are disturbed. Likewise, the morphology and 
trafficking parameters of lysosomal compartments were analyzed. 
3.1. Mitochondrial dynamics 
To investigate if the shape and transport of mitochondria is impaired in patient neurons, 
live cell imaging of mitochondrial marker MitoTracker DeepRed was utilized. Videos were 
taken for 2 min and consisted of 400 frames resulting in a frame time interval of 0.3 
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seconds. For the morphological analysis of mitochondria, the first frame of each video was 
analyzed. Trafficking parameters were obtained from the whole video.  
3.1.1. Morphological analysis 
The investigated morphological parameters included the amount of organelles per 
arbitrary neurite length, the shape and the size. 
3.1.1.1. Undirected neurons (96 well plate format) 
Mature neurons that were differentiated according to MSN protocol were analyzed and the 
amount of mitochondria per arbitrary neurite length was evaluated. Counting of organelles, 
assessment of their morphological features as well as measurement of network size was 
done using semi-automated macros in FIJI to avoid bias. The shape of the mitochondria 
was described using the estimated aspect ratio. The object recognition tries to fit ellipses 
to the mitochondria and then the aspect ratio can be calculated by dividing the major 
radius with the minor. Round objects will therefore have a ratio close to one. When a 
mitochondrium in a neurite is estimated as a rode like object, the area it occupies in an 
image is linearly correlated to its volume and therefore its biomass. Since the biomass of 
a mitochondrium is a crucial readout for its capability to generate ATP, the size of a 
mitochondrium can be used to estimate this ability (Agnello, et al., 2008). Size of 
mitochondria was measured in pixel and compared using two-way ANOVA. 
There were significantly less mitochondria in neurons from ChAc patients than in wild type. 
In an attempt to rescue this phenotype, three different substances were investigated. 
Conditions included untreated control, DMSO mock, the Lyn kinase inhibitor PP2, which 
was used in previous studies to treat the abnormally shaped membranes of erythrocytes 
and a mixture of glycolate and D-lactate (GADL), that was shown to activate and rescue 
the mitochondria of Parkinson’s disease patients cells (De Franceschi, et al., 2011; 
Toyoda, et al., 2014). The phenotype of the disease was investigated by comparing wild 
type and ChAc lines under control conditions using a t-test, when needed with Welch’s 
correction, and estimating the effect size using Cohen’s d. Results of the treatment 
conditions were analyzed using two-way ANOVA with the genotype (wild type and ChAc) 
and different treatment conditions as the independent variables. 
The number of mitochondria was significantly reduced in ChAc lines and the effect was 
large (p<0.0001, t(40.89)=4.556, d=1.12). For GADL treatment, the genotype had a 
significant influence (p=0.0003, F(1, 85)=14.26, ω²=0.15). There was, however, no effect 
of the treatment observed and no interaction between genotype and treatment. The 
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evaluation of the treatment with PP2 and the DMSO vehicle control showed no effects of 
genotype, treatment and interaction between genotype and treatment (See Figure 31 A). 
Mixed striatal cultures had normally shaped mitochondria and there was no differential 
behavior when GADL or PP2 were applied. Statistical analysis did not reveal any 
interactions between treatment conditions and genotype (See Figure 31 B). 
There was a very large effect observed on the size of ChAc mitochondria, resulting in a 
smaller size (p<0.0001, t(36.29)=6.54, d=1.47). MSN differentiated mature neurons from 
ChAc patients showed a decreased size of the mitochondria. The genotype itself was 
considered significant (p=0.0003, F(1, 82)=14.55, ω²=0.152) but there was no influence of 
the treatment. An interaction between GADL treatment and the genotype was observed 
(p=0.0345, F(1, 82)=4.621, ω²=0.055). The treatment with PP2 revealed an influence of 
the genotype (p=0.0082, F(1, 84)=7.329, ω²=0.089) but no significant effect of the 
treatment and no interactions between PP2 treatment and genotype (See Figure 31 D). 
 
Figure 31: Morphological analysis of mitochondria of MSN differentiation. A) The number of 
mitochondria per neurite length is reduced in ChAc lines. B) The aspect ratio of mitochondria was not 
different. C) Representative picture of wild type and ChAc neuronal net with the latter showing a 
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decreased count. D) The size of the observed mitochondria is reduced in neurons from ChAc patients. 
Boxes represent 25-75 percentiles, line represents median, whiskers represent 10-90%, + represents 
mean. n = at least 26 images from 4 independent experiments. * indicate significant differences within 
a treatment. # indicate significant differences to control condition. */**/***; #/##/### represent 
p=0.05/0.01/0.001, respectively. Scale bar = 10μm 
Neurons yielded by mDAN differentiation showed a small but significant reduction of 
mitochondria per neurite length (p=0.0003, t(320.2)=3.668, d=0.40). GADL, Phallacidin 
and PP2 were applied to cells and their effect was investigated. There was a significant 
influence of the genotype (p=0.0031, F(1, 442)=8.833, ω²=0.021) as well as an influence 
of the GADL treatment (p<0.0001, F(1, 442)=15.45, ω²=0.035). Interaction between 
treatment and genotype was not observed. Upon application of phallacidin, the influence 
of the genotype remained (p=0.004, F(1, 392)=8.4, ω²=0.023). The treatment, however, 
had no effect and there was no interaction between the genotype and the treatment. 
Investigation of PP2 showed the effect of the genotype (p=0.0332, F(1, 271)=4.582, 
ω²=0.020) but treatment had no effect and there was no significant interaction (See Figure 
32 A). 
Analysis of of the aspect ratio of mitochondria in dopaminergic cultures revealed a 
medium effect resulting in shortened mitochondria (p<0.0001, t(294.3)=5.538, d=0.60). 
Aspect ratio was reduced under control conditions. The influence of the genotype was 
considered significant (p=0.0123, F(1, 449)=6.315, ω²=0.015) as well as the influence of 
the treatment with GADL (p<0.0001, F(1, 449)=32.59, ω²=0.068). ChAc patient’s cell 
reacted differently to GADL treatment as statistics revealed an interaction between 
genotype and treatment (p=0.0101, F(1, 449)=6.669, ω²=0.015). During phallacidin 
treatment, the influence of the genotype was also observed (p=0.001, F(1, 400)=50.8, 
ω²=0.113), but not of the treatment itself. Moreover, interaction between treatment and 
genotype was rated signidicant (p=0.0110, F(1, 400)=6.533, ω²=0.016) (See Figure 32 B). 
When the size of mDAN mitochondria was measured, they showed a reduced size. This 
effect was rated small ((p=0.0042, t(310)=2.883, d=0.33). Treatment with GADL showed 
that the influence of the genotype (p<0.0001, F(1, 409)=45.33, ω²=0.086) and of the 
GADL treatment (p<0.0001, F(1, 409)=60.9, ω²=0.115) were significant. There was an 
interaction between the treatment and genotype (p<0.0001, F(1, 409)=20.9, ω²=0.041) 
that was significant as well. Phallacidin application on midbrain dopaminergic neurons 
revealed a significant influence of the genotype (p<0.0001, F(1, 377)=20.42, ω²=0.051) 
and the treatment (p=0.0001, F(1, 377)=14.55, ω²=0.038). However, no interaction 
between the treatment and the genotype was found. When treated with PP2, no influence 
of genotype, treatment or interactions were observed (See Figure 32 D). 
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Figure 32: Morphological analysis of mitochondria of mDAN differentiation. A) The number of 
mitochondria per neurite length is reduced in ChAc lines under control conditions. GADL treatment 
increased the count in wild type and ChAc lines. B) The aspect ratio of investigated mitochondria was 
reduced for ChAc lines under control conditions but was rescued with GADL treatment. C) 
Representative picture of wild type and ChAc neuronal, with the latter showing a decreased count and 
aspect ratio. D) The size of the observed mitochondria is different under control conditions. GADL 
treatment increases the size. Phallacidin treatment reduces the size. Boxes represent 25-75 
percentiles, line represents median, whiskers represent 10-90%, + represents mean. n = at least 26 
images from 5 independent experiments. * indicate significant differences within a treatment. # 
indicates significant differences to control condition. */**/***; #/##/### represent p=0.05/0.01/0.001, 
respectively. Scale bar = 10μm 
3.1.1.2. Microfluidic chambers 
Microfluidic chambers (MFCs) were used to differentiate whether observed defects were 
present in both proximal and distal neurite positions. Furthermore, in later analyses the 
direction of a moving track can be evaluated and the estimated parameters of motility, 
speed and the like can be further differentiate into an anterograde and retrograde fraction.  
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When the identity of the neurons that grew through the channels of an MFC was 
investigated, only a minority of the neurons was TH positive. Most of the neurons that 
were observed were motor neurons (See Figure 33). 
 
Figure 33: Characterization of the channel-exits of MFC. A) MSN are growing inefficiently through the 
channels. Only cholinergic interneurons were detected. TUJ1 is a pan neuronal marker. SMI-32 labels 
a neurofilament. CHAT is a marker for cholinergic interneurons. B) Few dopaminergic neurons grow 
through the channels. TH is a marker for dopamindergic neruons. SMI-32 labels motor neurons in the 
mDAN protocol. Scale bar = 100 μm 
As a first parameter, the amount of mitochondria per arbitrary neurite length was 
investigated. The parameters for the two-way ANOVA were the genotype and the 
positions (distal vs. proximal). Striatal cultures of patient cell lines showed a reduced 
amount of mitochondria (See Figure 34 A). Influence of the genotype was considered 
significant (p=0.0067, F(1, 122)=7.602, ω²=0.064), however, the influences of the position 
and interaction, however, were not significant. The shape of the mitochondria was 
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investigated using the aspect ratio of both radii of the fitted ellipses. Neurons derived by 
MSN differentiation showed no alteration in the aspect ratio and there was no influence of 
the genotype, position and no interaction (See Figure 34 B). 
When the amount of mitochondria in MFCs of mDAN cultures was investigated, there was 
no significant influence of the genotype, position or interaction observed (See Figure 
34 C). Analysis of the aspect ratio revealed a significant influence of the genotype 
(p=0.0002, F(1, 445)=14.17, ω²=0.033), but no influence of the position. Furthermore, no 
interaction between position and genotype was observed (See Figure 34 D). 
 
Figure 34: Morphological analysis of MFC cultures. A) MSN differentiated cultures showed a reduction 
in number of mitochondria per neurite length that was most pronounce in the proximal region of 
patient lines. B) MSN differentiated cultures had no difference in aspect ratio. n(A/B) = at least 26 
images from 6 independent experiments. C) mDAN differentiated cultures showed no reduction in the 
count of mitochondria per neurite length. D) Mitochondria of mDAN differentiated neurons had a 
reduced aspect ratio that was most pronounced in distal position. n(C/D) = at least 94 images from 18 
independent experiments. Boxes represent 25-75 percentiles, line represents median, whiskers 
represent 10-90%, + represents mean. * indicate significant differences within a treatment. */**/***; 
represent p=0.05/0.01/0.001, respectively. 
In summary, ChAc lines hab less mitochondria in undirected 96-wells in both 
differentiation protocols. These mitochondria were smaller and mDAN cultures even 
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showed a shortening, while the aspect ratio in MSN differentiations was not different. 
When MFC were investigated, the reduction in the amount was only observed in mixed 
striatal but not midbrain dopaminergic cultures. The change in the aspect ratio was 
reproduced in the distal parts of the channels. GADL treatment had no effect on the 
phenotypes in MSN cultures but increased the count, aspect ratio and size in mDAN 
cultures. The treatment, however, was not specific for ChAc lines but also in wild type 
lines. PP2 treatment had no effect (See Table 25). 
Table 25: Summary of morphological features of mitochondria in ChAc 
 MSN differentiation mDAN differentiation 
96 well ChAc lines had fewer mitochondria 
There was no difference in the aspect 
ratio 
ChAc lines had smaller mitochondria 
GADL and PP2 treatment had no 
effect 
ChAc lines had fewer mitochondria 
ChAc lines had shorter mitochondria 
GADL treatment increased count, 
aspect ratio and size 
MFC ChAc lines had fewer mitochondria in 
proximal position 
no difference in distal parts 
no difference in the aspect ratio 
No difference in the count 
ChAc lines had shorter mitochondria 
 
3.1.2. Trafficking analysis 
Using the tracking algorithms from the FIJI suite all objects in each frame of one video 
were first detected and then the nearest spots between each picture of a stack were 
linked. The linear motion tracker minimizes linking costs and favors linear movement. The 
translocation of the spots in between pictures is interpreted as movement and parameters 
like speed, distance travelled and angle of movement were calculated. In the end, 
databases with characteristics for individual tracks were generated. These databases 
were processed as explained in the Materials and Methods section. 
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Figure 35: Examples of plots obtained from trafficking analysis of mitochondria. Stripes indicate the 
standard deviation of the amount of displaced tracks of the original data set. Lines indicate the fitted 
curves of the calculated two-phase decay model regression. 
3.1.2.1. 96 well 
The motility of mitochondria in cell culture was described by two parameters. The first is 
the estimation of the amount of moving mitochondria and the second describes the 
motility of this moving fraction. The fraction of moving objects was estimated using two-
way ANOVA as described in the Materials and Methods section. 
Neither the amount of moving mitochondria, nor the mean speed of the motile fraction was 
different under control conditions. When the addition of GADL was compared to control 
condition, the moving fraction of mitochondria of mixed striatal cultures harbored no 
influence from the genotype. The influence of the treatment, however, was significant 
(p<0.0001, F(1, 18)=53.93, ω²=0.748). There was no interaction between genotype and 
treatment. The motility was not significantly influenced by the genotype, treatment or any 
interaction. In the comparison of DMSO mock control with PP2, there was no significant 
influence of the genotype or the treatment observed. There was, however, a significant 
interaction between genotype and treatment (p=0.0015, F(1, 16)=14.63, ω²=0.476) that 
influenced the amount of the moving fraction. The motility of the mitochondria was not 
influenced by either genotype, treatment nor interaction when the cells were investigated 
under these conditions (See Figure 36 A & B). 
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Figure 36: Trafficking analysis of mitochondria of MSN differentiated cultures. A) MSN differentiated 
cultures showed no difference between wild type and ChAc lines. GADL treatment reduced the moving 
fraction. B) There was no difference observed in the mean speed of moving mitochondria. Bars 
represent mean + SEM. n ≥ 4. * indicate significant differences within a treatment. # indicate significant 
differences to control condition. */**/***; #/##/### represent p=0.05/0.01/0.001, respectively.  
The fraction of moving mitochondria of mid brain dopaminergic neurons from ChAc lines 
was moderately increased in ChAc lines (p=0.0017, t(56)=3.3, d=0.88). The mean speed 
under control conditions, however, was largely reduced (p<0.0001, t(56)=4.504, d=1.19). 
GADL treatment of mDAN cultures showed significant influence of the genotype (p=0.008, 
F(1, 81)=7.399, ω²=0.055), the treatment (p<0.001, F(1, 81)=62.2, ω²=0.414 ), but no 
interaction in regards to the moving fraction. The motility was also influenced by genotype 
(p=0.007, F(1, 81)=7.667, ω²=0.069) treatment (p=0.0017, F(1, 81)=10.51, ω²=0.108 ) 
and the interaction of both (p=0.0137, F(1, 81)=6.346, ω²=0.069). The treatment with the 
actin stabilizer phallacidin showed no significant influence of genotype, treatment or any 
interaction. The motility, however, was influenced by the genotype (p<0.0001, F(1, 
65)=32.62, ω²=0.326), but not the treatment. A significant interaction was observed as 
well (p=0.0497, F(1, 65)=4, ω²=0.048). When PP2 was added a significant influence of the 
genotype (p=0.0102 F(1, 59)=7.042 ω²=0.099), significant influence of the treatment 
(p=0.0039, F(1, 59)=9.031, ω²=0.123) and the interaction (p=0.0254, F(1, 59)=5.259, 
ω²=0.077) on the amount of moving mitochondria was observed. The motility of the 
mitochondria was not influenced by the addition of PP2 when compared to DMSO control 
condition (Figure 37 A & B). 
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Figure 37: Trafficking analysis of mitochondria of mDAN differentiated cultures. A) mDAN 
differentiated ChAc cultures showed an increased moving fraction. GADL treatment further increased 
the moving fraction. PP2 treatment selectively increased the moving fraction of mitochondria of ChAc 
lines. B) Wild type lines had an increased average movement speed under control conditions that 
dropped to ChAc levels after GADL treatment. Bars represent mean + SEM. n ≥ 5 * indicate significant 
differences within a treatment. # indicate significant differences to control condition. */**/***; #/##/### 
represent p=0.05/0.01/0.001, respectively. 
Another characteristic of organelle trafficking in cells is that it is not random but rather 
direct movement. For example, mitochondria travel directly to parts of the cell that exhibit 
an increased energy demand (Safiulina and Kaasik, 2013). To estimate whether there 
was a difference in the directedness of the movement, the total displacement of a track 
was divided by the total track length. An object that moved from its start A to its end B in 
direct manner will have a directedness close to 1, while an object just moving around its 
stationary position will have a directedness close to 0. To quantify this parameter, the 
amount of tracks that moved with directedness above 0.75 was compared between wild 
type and ChAc patients under different treatment conditions. 
The fraction of directly moving mitochondria was not different in mixed striatal cultures 
when wild type and ChAc lines were compared under control conditions. The analysis of 
the directedness of mitochondrial movement during treatment, showed that there was no 
significant effect of the genotype, treatment of GADL, and no interaction. Treatment of the 
lines with PP2 had no effect on directedness compared to DMSO mock control (See 
Figure 38 A). 
There was no difference in the amount of directly moving mitochondria under control 
conditions between wild type and ChAc lines in mDAN differentiation protocol. When the 
cell lines were treated with GADL, there was no influence of the genotype. However, a 
significant effect of the treatment (p<0.0001, F(1, 432)=52.64, ω²=0.11) was observed. 
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The influence of the interaction between genotype and treatment, however, was not 
significant. Treatment with phallacidin revealed a significant influence of the genotype 
(p=0.0003, F(1, 348)=13.43 ω²=0.034). The influence of the treatment was not considered 
significant. Furthermore, a significant interaction (p=0.0004, F(1, 348)=12.92, ω²=0.035) 
was observed. When PP2 was applied, genotype, treatment and interaction were all 
considered not significant (See Figure 38 B). 
 
Figure 38: Analysis of direct movement in both differentiations protocols. A) MSN differentiation had 
no observable difference in the fraction of direct movement. n ≥ 4. B) Fraction of direct movement was 
influenced by the treatment but not the genotype in mDAN differentiation. Application of phallacidin 
caused differential response in wild type and ChAc lines. n ≥  5. Bars represent mean + SEM. * indicate 
significant differences within a treatment. # indicate significant differences to control condition. 
*/**/***; #/##/### represent p=0.05/0.01/0.001, respectively. 
Since the mean speed of all moving tracks corresponds to overall fitness of the cell and is 
governed by global effects, the analysis of sub fractions might be useful to determine the 
status of individual mitochondria themselves, and local events like energy demanding hot 
spots. Therefore the speed of the 10% fasted tracks was investigated. 
MSN protocol derived neurons showed no significant difference under control conditions, 
GADL or PP2 treatment as well as no dependency on the genotype. There was no 
interaction between the treatment and the genotype (See Figure 39 A). 
There was a medium sized effect on the maximum speed observed, when mitochondria of 
wild type and ChAc lines were compared under control conditions (p=0.0405, t(56)=2.097, 
d=0.56). However, no response to GADL or PP2 was evident. The treatment with 10μM 
phallacidin, however, showed a significant influence of the genotype (p=0.0004, F(1, 
65)=13.98, ω²=0,175) as well as an interaction (p=0.0488, F(1, 65)=4.031, ω²=0.059) 
(See Figure 39 B). 
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Figure 39: Speed of the top decile of the fastest mitochondria of both differentiation protocols. A) 
There was no difference observed in MSN differentiated neurons. n ≥ 4. B) mDAN differentiated 
neurons showed no difference in the max speed that was accounted to influence of the genotype. 
Differential response to phallacidin treatment was observed. n ≥ 5. Bars represent mean + SEM. * 
indicate significant differences within a treatment.  * represents p=0.05, respectively. 
3.1.2.2. Microfluidic chambers 
Trafficking analysis in MFCs allows differentiation between anterograde and retrograde 
transport and its dependency on proximal or distal position in a neurite. 
The moving fraction of mitochondria of mature neurons, which were yielded by the MSN 
differentiation protocol, was not influenced by the proximal/distal position or the genotype. 
There was no interaction observed (See Figure 40 A). The motility of the mitochondria 
was not influenced by genotype or position as well. The trend of a possible interaction 
between genotype and position was not rated significant (See Figure 40 B). 
 
Figure 40: Trafficking analysis of mitochondria of MSN differentiated MFC cultures. A) MSN 
differentiated cultures showed no differences but a trend of increased movement was observed B) The 
genotype as well as the position had no significant influence on the MSN differentiation cultures. A 
trend of increased mean speed of mitochondria of ChAc lines in proximal parts was observed. Bars 
represent mean + SEM. n ≥ 6. 
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Analysis of mature neurons derived from mDAN differentiation showed that the genotype 
and the position had no influence on the amount of moving organelles. The interaction 
between both was not significant (See Figure 41 A). When the motility of the moving 
fraction was evaluated, a significant influence of the genotype (p<0.0001, F(1, 85)=20.2, 
ω²=1.62), the position (p=0.0001, F(1, 85)=16.23, ω²=0.132) and an interaction (p=0.0054, 
F(1, 75)=8.135, ω²=0.070) was discovered (See Figure 41 B). 
 
Figure 41: Trafficking analysis of mitochondria of mDAN differentiated MFC cultures. A) mDAN 
differentiated cultures showed no differences in the moving fraction. B) mDAN differentiated cultures 
showed an increased speed in ChAc lines that was more pronounced in proximal position. Bars 
represent mean + SEM. n ≥ 18. * indicate significant differences within a treatment. # indicate 
significant differences to control condition. ***; ### represent p=0.001, respectively. 
In order to further characterize trafficking of mitochondria, the fraction of anterograde 
movement was analyzed and the average speed of the anterograde and retrograde 
fraction was investigated. Only tracks with a directedness above 0.75 were included in the 
analysis to make sure that the investigated mitochondria were moving in the according 
direction and not just randomly drifting due to focus or stage shift or minute pseudo 
stationary movement. 
When the iPSCs were differentiated according to MSN differentiation protocol, the fraction 
of anterograde transport of mitochondria was not influenced by the genotype or the 
position. Furthermore, there was no interaction between the two (See Figure 42 A). Upon 
investigating the speed of the anterograde fraction of moving mitochondria, a significant 
influence by position (p=0.0104; F(1, 69)=6.949; ω²=0.103) but not of genotype or 
interaction between the two was observed. The speed of retrograde transport of 
mitochondria was not influenced of genotype, position or interaction (See Figure 42 B). 
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Figure 42: Detailed characterization of mitochondria trafficking in MFC. A) No difference in the 
anterograde fraction of moving mitochondria in MSN differentiation detected. B) Genotype had no 
influence on the mean speed of anterograde moving mitochondria but position had. There was a trend 
observed for retrograde movement in the proximal position indicating the increased mean speed for 
ChAc lines. C) No difference in direct movement was detected in MSN differentiations. n(A-C) ≥ 6 D) 
There was a difference in anterograde moving fraction detected between proximal and distal position 
in mDAN differentiations. Decrease in anterograde movement in proximal parts was observed in ChAc 
lines. E) No influence of the position was observed in wild type lines in regards to retrograde transport. 
ChAc lines showed an increased mean speed in proximal positions that reduced to wild type level in 
distal parts. F) No difference in direct movement was detected in mDAN differentiations. n(D-F) ≥ 18. 
Bars represent mean + SEM. Boxes represent 25-75 percentiles, line represents median, whiskers 
represent 10-90%, + represents mean. * indicate significant differences within a treatment. # indicate 
significant differences to control condition. */**/***; #/##/### represent p=0.05/0.01/0.001, respectively 
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Neurons derived from mDAN differentiation showed significant influence of the genotype 
(p<0.0001, F(1, 436)=16.33, ω²=0.031) and the position (p<0.0001, F(1, 436)=89.39 
ω²=0.161). Furthermore, the interaction between both was significant (p<0.0001, F(1, 
436)=18.45 ω²=0.035) (See Figure 42D). The speed of the anterograde fraction was not 
significantly influenced the genotype, but by the position (p=0.0059, F(1, 411)=7.66 
ω²=0.02). There was no interaction observed (See Figure 42 E). The speed of the 
retrograde fraction was significantly influenced by the genotype (p=0.0003, F(1, 
401)=13.24, ω²=0.034), the position (p=0.0297, F(1, 401)=4.76, ω²=0.014) but not the 
interaction (See Figure 42 E). 
The directedness of the trafficking in regards to the position in the investigated neurite can 
also give crucial information. In both differentiation protocols there was no influence of the 
genotype and no influence of the position when the directedness of movement of 
mitochondria was investigated (See Figure 42  C & F). 
The mean speed of the mitochondria above the ninth decile was investigated for MFC 
cultures as well. There was no significant influence of position, genotype or interaction 
observed in mixed striatal cultures when cultured in MFC (See Figure 43 A). Mature 
cultures yielded from mDAN differentiation protocol showed a significant influence of the 
genotype (p=0.0137, F(1, 85)=6.335, ω²=0.075). The influence of the position and the 
interaction was not considered significant (See Figure 43 B). 
 
Figure 43: Mean speed of the top decile fastest mitochondria in MFC of both differentiation protocols. 
A) MSN differentiated neurons indicate no difference in the top speed. A trend was observed in the 
proximal position. n ≥ 6. B) mDAN differentiation revealed an increased average speed of fast moving 
mitochondria in proximal position that dropped to wild type levels in distal parts. n ≥ 18. Bars 
represent mean + SEM. * indicate significant differences within a treatment. * represent p=0.05. 
In summary, when undirected 96-wells were investigated MSN derived cultures showed 
no difference in the amount of moving mitochondria or their mean speed. mDAN cultures 
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harbored a reduction in the moving fraction, but an increase in the mean speed. 
Directedness and the top speed was unaffected by the ChAc genotype. Investigation of 
MFC revealed no difference in the moving fraction in mixed striatal as well as midbrain 
dopaminergic cultures. The mean speed of ChAc patients’ mitochondria was elevated in 
proximal positions for both differentiation protocols. Furthermore midbrain dopaminergic 
cultures showed an increase in the retrograde transport of mitochondria at the proximal 
site. Treatment with GADL reduced the moving fraction in MSN but increased it in mDAN 
cultures. The mean speed was unaffected in both differentiation protocols. PP2 had 
exhibited a differential result in MSN cultures, where the moving fraction was increased for 
wild type but decreased for ChAc lines. mDAN differentiations showed a selective 
increase in the moving fraction for ChAc lines when treated with PP2. The mean speed 
was unaffected in both differentiation protocols (See Table 26). 
Table 26: Summary of analysis of the dynamic parameters of mitochondria 
96-well MSN differentiation mDAN differentiation 
Movement 
 
Mean speed 
 
Directedness 
 
Max speed 
no difference between wild type 
and ChAc 
no difference between wild type 
and ChAc 
no differences between wild type 
and ChAc 
no differences between wild type 
and ChAc 
ChAc lines have increased 
movement under control condition 
ChAc lines had a reduced mean 
speed 
no differences between wild type 
and ChAc 
no differences between wild type 
and ChAc 
MFC MSN differentiation mDAN differentiation 
Movement 
 
 
 
 
 
 
Mean speed 
 
 
 
no differences between wild type 
and ChAc 
no difference between proximal 
and distal 
no differences between wild type 
and ChAc in the anterograde 
fraction 
no differences between wild type 
and ChAc 
no difference between proximal 
and distal 
no differences between wild type 
and ChAc 
no difference between proximal 
and distal 
ChAc lines had an increase in 
retrograde transport in proximal 
parts 
ChAc lines had an increased 
speed in proximal position 
No difference between wild type 
and ChAc in distal part 
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MFC MSN differentiation mDAN differentiation 
Mean speed 
 
 
 
 
 
 
 
 
 
Directedness 
 
 
 
 
 
 
 
Max Speed 
anterograde and retrograde moving 
mitochondria in proximal parts are 
faster than the ones in distal parts 
 
 
 
 
no differences between wild type 
and ChAc 
no difference between proximal 
and distal 
no differences between wild type 
and ChAc 
no difference between proximal 
and distal 
anterograde and retrograde 
moving mitochondria in proximal 
parts are faster than the ones in 
distal parts 
ChAc lines had an increased 
speed of retrograde moving 
mitochondria 
no differences between wild type 
and ChAc 
no difference between proximal 
and distal 
ChAc lines had an increased 
speed in proximal position 
No difference between wild type 
and ChAc in distal part 
Treatments MSN differentiation mDAN differentiation 
Moving 
 
 
 
 
Mean speed 
 
Directedness 
 
Max speed 
GADL treatment decreased the 
moving fraction 
ChAc lines reacted differently to 
PP2 treatment 
 
no response to any treatment 
 
no response to any treatment 
 
no response to any treatment 
GADL treatment increases the 
moving fraction 
Only ChAc lines reacted to PP2 
treatment by increase in moving 
fraction 
ChAc lines responded to no 
treatment 
GADL reduced the direct moving 
fraction 
no response to any treatment 
3.1.3. JC-1 
The JC-1 dye is used to characterize the mitochondria on a functional level. JC-1 is 
sensitive to the intermembrane potential of mitochondria. In high potential mitochondria 
the dye dimerizes and emits light at around 590nm while in depolarized mitochondria the 
dye has a monomeric form and emits at 529nm. To assess the polarization of a 
mitochondrium, the emission of both channels was measured and the ratio between red 
and green channels calculated. A high ratio indicates a strong polarization. 
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3.1.3.1. 96 well 
The JC-1 ratio of mitochondria in mixed striatal cultures was increased by a huge amount 
in ChAc lines compared to wild type, when investigated under control conditions. Upon 
treatment with GADL, the genotype had a significant influence (p<0.0001, F(1, 105)=63.11, 
ω²=0.367), but there was no influence of the treatment. The interaction between the 
treatment and genotype was significant as well (p=0.0187, F(1, 105)=5.704, ω²=0.038). 
The treatment with PP2 resulted in an influence of the genotype (p<0.0001, F(1, 
87)=86.43, ω²=0.49) but no influence of the treatment or interaction was observed (See 
Figure 44 A). 
ChAc patients’ neurons derived from mDAN protocol had a large reduction of JC-1 ratio 
(p<0.0001, t(63.98)=4.289, d=0.92). Treatment with GADL results in no influence of the 
genotype but a significant influence of the treatment (p<0.0001, F(1, 123)=17.71, 
ω²=0.118) and a significant interaction (p=0.0002, F(1, 123)=15.21, ω²=0.102). When 
treated with PP2, there was no influence of the genotype, treatment or interaction 
observed (See Figure 44 B). 
 
Figure 44: Analysis of membrane potential marker JC-1. A) MSN differentiated neurons showed a 
significantly increased ratio of JC-1 in ChAc lines. GADL treatment lowered the ratio in ChAc but not 
wild type lines. n at least 6 images from 5 independent experiments. B) mDAN differentiated neurons 
harbored a decreased mitochondrial potential. Treatment with GADL reduced wild type lines to ChAc 
levels but had no influence on ChAc lines. n = at least 8 images from 6 independent experiments. 
Boxes represent 25-75 percentiles, line represents median, whiskers represent 10-90%, + represents 
mean. * indicate significant differences within a treatment. # indicate significant differences to control 
condition. ***; ### represent p=0.001, respectively. 
3.1.3.2. Microfluidic chambers 
Polarization of mitochondria was measured in MFC as well and analyzed dependent on a 
proximal and distal position in the neurite under control conditions. When cells were 
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differentiated according the mDAN protocol, there was a significant influence of the 
genotype (p<0.0001, F(1, 2917)=233, ω²=0.064) as well as the position (p<0.0001, F(1, 
2917)=306.9, ω²=0.084). Furthermore there was a significant interaction between position 
and genotype (p<0.0001, F(1, 2917)=219.9, ω²=0.060) (See Figure 45). 
 
Figure 45: Analysis of membrane potential marker JC-1 in MFC with mDAN differentiated neurons. 
While potential of wild type was the same when proximal and distal positions were compared, ChAc 
lines had a significantly increased ratio in the distal position. Boxes represent 25-75 percentiles, line 
represents median, whiskers represent 10-90%, + represents mean. n = at least 604 mitochondria from 
two independent experiments. * indicate significant differences within a treatment. # indicate 
significant differences to control condition. ***; ### represent p=0.001, respectively. 
3.2. Lysosomal dynamics 
Lysosomes are organelles that are important for several vital processes in a cell including 
autophagy and the endocytic pathway. They contain various hydrolytic enzymes and have 
an acidic lumen. This acidity is utilized by the pH sensitive LysoTracker to visualize 
lysosomes in living cells which allows their observation in life-cell microscopy. To 
characterize the lysosomal compartment read-outs like the morphological and trafficking 
analyses similar to the mitochondrial study were conducted. 
3.2.1. Morphological analysis 
3.2.1.1. 96 well 
The number of lysosomes per arbitrary neurite length was analyzed for mixed striatal 
cultures. Within the control condition there was a large effect that resulted in significantly 
fewer lysosomes (p=0.003, t(39.95)=3.156, d=0.83). There was no difference observed in 
control, GADL-treated and PP2-treated conditions. No influence of the genotype or 
interaction between the treatments and genotype was discovered (See Figure 46 A). 
Since the shape of a lysosome is almost spherical, the aspect ratio is expected to be 
close to 1. However, depending on the cargo that is digested the shape can diver a lot. 
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Lysosomes of mixed striatal cultures showed no differences between ChAc patients and 
healthy controls across control conditions as well as treatment with GADL or PP2 (Figure 
46 B). 
Under Control conditions the size of the lysosomes was significantly reduced. The effect 
was moderate (p=0.0238, t(36.87)=2.359, d=0.61). When control conditions were 
compared with GADL treatment, no influence of the genotype, treatment or any interaction 
was observed. When the neurons were treated with PP2 and compared to DMSO mock 
control, however, the genotype showed significant influence (p=0.0278, F(1, 81)=5.016, 
ω²=0.065) as well as the treatment (p=0.0317, F(1, 81)=4.779, ω²=0.063). No interaction 
was observed in this set (See Figure 46 D). 
 
Figure 46: Morphological analysis of lysosomes of MSN differentiation. A) MSN differentiation showed 
no significant differences in the number of lysosomes per neurite length. B) The aspect ratio of was 
not altered in MSN differentiated neurons. C) Representative picture of wild type and ChAc neuronal 
network showing similar morphological features. B) The size of the observed lysosomes is not 
different. Boxes represent 25-75 percentiles, line represents median, whiskers represent 10-90%, + 
represents mean. n = at least 13 images from 4 independent experiments. Scale bar = 10μm 
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There was a small but significant effect on the amount of lysosomes in dopaminergic 
neurons observed, resulting in an increase of their amount (p=0.0175, t(281)=2.39, 
d=0.28). The treatment of mDAN cultures with GADL unraveled no influence of genotype 
or the treatment, but a significant interaction was observed (p=0.0311, F(1, 395)=4.682, 
ω²=0.014). When treated with phallacidin, there was no influence of genotype, treatment 
or interaction observed. When the PP2 treatment was compared to mock control, there 
was no influence of genotype, treatment or interaction observed as well (See Figure 47 A). 
 
Figure 47: Morphological analysis of lysosomes of mDAN differentiation. A) mDAN differentiation 
showed no significant difference in the number of lysosomes per neurite length. B) The aspect ratio 
was not altered in mDAN differentiated neurons under control conditions but in GADL, phallacidin and 
PP2 treatments. C) Representative picture of wild type and ChAc neuronal net showing similar 
morphological features under control conditions. D) The the observed lysosomes is not different 
under control conditions. GADL treatment increased size of lysosomes. Boxes represent 25-75 
percentiles, line represents median, whiskers represent 10-90%, + represents mean. n = at least 22 
images from 5 independent experiments. * indicate significant differences within a treatment. # 
indicate significant differences to control condition. */**/***; #/##/### represent p=0.05/0.01/0.001, 
respectively. Scale bar = 10μm 
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Even though there was no difference observed under control conditions, investigated 
neurons derived from mDAN differentiations showed significant influence of genotype 
(p<0.0001, F(1, 364)=15.75, ω²=0.041), influence of treatment (p<0.0001, F(1, 
364)=18.35, ω²=0.048) and an interaction (p=0.0281, F(1, 364)=4.862, ω²=0.015) when 
treated with GADL compared to control. When phallacidin was used, the genotype 
showed no influence. The treatment, however, was significantly influencing the aspect 
ratio (p<0.0001, F(1, 312)=27.8, ω²=0.083). A significant interaction between genotype 
and treatment was observed as well (p=0.0295, F(1, 312)=4.784, ω²=0.017). Addition of 
PP2 revealed a significant effect of the genotype (p=0.0012, F(1, 247)=10.69, ω²=0.043) 
and a significant interaction between the genotype and the treatment (p=0.0025, F(1, 
247)=9.358, ω²=0.038). The influence of the treatment was not considered significant 
(See Figure 47 B). 
The size of lysosomes of mature neurons generated by mDAN protocol was not different 
under control conditions but influenced by treatment with GADL (p<0.0001, F(1, 
375)=30.99, ω²=0.076) and an interaction between the treatment and the genotype 
(p=0.0026, F(1, 375)=9.224, ω²=0.024) was observed. The genotype itself was not rated 
significant in control, GADL, phallacidin as well as PP2 treatment conditions. Treatment 
with PP2 or phallacidin had no effect on the size of lysosomes (See Figure 47 D). 
3.2.1.2. Microfluidic chambers 
The amount of lysosomes per arbitrary neurite length was assessed in MFCs in respect to 
proximal and distal position. Mature neurons, which were generated by MSN 
differentiation protocol, showed a significant influence of the genotype (p=0.0391, F(1, 
90)=4.384, ω²=0.054) but no influence of the position or any interaction. Aspect ratio of 
the observed lysosomes of mixed striatal cultures was influenced by the genotype 
(p=0.0096, F(1, 90)=6.994, ω²=0.077) and the position (p=0.0267, F(1, 90)=5.075, 
ω²=0.058). There was no interaction observed (See Figure 48 B).  
The amount of lysosomes of mature neurons that were obtained from mDAN protocol 
exhibited no influence of the genotype but the influence of the position was considered 
significant (p<0.0001, F(1, 432)=17.86, ω²=0.042) (See Figure 48 C). Aspect ratio of 
lysosomes of mDAN cultures showed no influence of the genotype. The position, however, 
had a significant influence (p<0.0001, F(1, 432)=23.96, ω²=0.054) and there was a 
significant interaction observed (p=0.0439, F(1, 432)=4.086, ω²=0.011) (See Figure 48 D). 
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Figure 48: Morphological analysis of MFC cultures. A) MSN differentiated cultures showed a reduction 
in number of lysosomes per neurite length in ChAc lines at proximal region. While wild type lines 
experienced a reduction in lysosome count, ChAc lines exhibited a similar amount in distal as 
observed in proximal part. B) MSN differentiated cultures showed a significant reduction of the aspect 
ratio in proximal parts not present in distal parts. N(A/B) ≥ 6. C) mDAN differentiated cultures showed 
no reduction in the count of lysosomes mitochondria per neurite length that was attributed to the 
genotype. There was a reduction observed in the distal parts of the neurite. D) Lysosomes of mDAN 
differentiated neurons had a reduced aspect ratio when proximal position was compared to distal. 
n(C/D) ≥ 18. Boxes represent 25-75 percentiles, line represents median, whiskers represent 10-90%, + 
represents mean. * indicate significant differences within a treatment. * represents p=0.05, 
respectively. 
In summary, when the phenotype was investigated in undirected 96-well under control 
conditions, there were less lysosomes observed in both differentiation protocols in ChAc 
lines. In addition, the size of ChAc patient’s lysosomes was reduced in mixed striatal 
cultures. When the cell lines were cultivated and analyzed in MFC, there was general 
reduction in the amount of lysosomes and their aspect ratio observed when proximal and 
distal position was investigated. Phenotype related differences were observed in proximal 
parts of MSN and resulted in a reduced amount and reduced aspect ratio. Midbrain 
dopaminergic cultures showed no differences in MFC. When the cells were treated with 
GADL the size and the aspect ratio increased in all investigated cell lines, hence no 
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disease specific effect was observed. PP2 treatment had didn’t affect mDAN cultures but 
increased the size of lysosomes in both wild type and ChAc lines (See Table 27). 
Table 27: Summary of morphological features of lysosomes in ChAc 
 MSN differentiation mDAN differentiation 
96well no difference in the amount of 
lysosomes 
no difference in the aspect ratio of  
no difference in the size of lysososmes 
no response to treatments 
no difference in the amount of 
lysosomes 
Lysosomes of ChAc lines have an 
reduced aspect ratio under GADL 
treatment conditions 
Lysosomes of ChAc lines have an 
increased size under GADL 
treatment conditions 
PP2 had no influence on count, 
aspect ratio or size  
MFC ChAc lines had fewer lysosomes in 
proximal parts when compared to wild 
type 
Distal parts had fewer lysosomes than 
proximal parts 
ChAc lines had a reduced aspect ratio 
in proximal parts when compared to 
wild type 
No difference of count or aspect ratio 
between wild type and ChAc in distal 
parts 
No differences between wild type 
and ChAc 
Distal parts had fewer lysosomes 
than proximal parts 
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3.2.2. Trafficking 
3.2.2.1. 96 well 
The trafficking of lysosomes was characterized by assessing the moving objects and the 
motility of that fraction. The same regression analysis that was conducted on the 
mitochondria was used on the lysosomal fraction. Examples of fitted curves are shown in 
Figure 49. The obtained parameters of the regression are shown in the supplement. 
 
Figure 49: Examples of plots obtained from trafficking analysis of lysosomes. Stripes indicate the 
standard deviation of the amount of displaced tracks of the original data set. Lines indicate the fitted 
curves of the calculated two-phase decay model regression. 
When the control condition of MSN differentiations was analyzed, the moving fraction was 
significantly increased by a very large amount (p=0.048, t(9)=2.287, d=1.43). The mean 
speed of this fraction increased as well and the effect rated very large (p=0.0143, 
t(9)=3.027, d=1.89). The next experiment conducted focused on GADL treatment. The 
amount of moving lysosomes was influenced by the genotype (p=0.0086, F(1, 18)=8.678, 
ω²=0.326) but not the treatment or the interaction between the treatment and the 
genotype. The motility was not influenced by the genotype or the treatment. The 
interaction, however, was considered significant (p=0.0028, F(1, 18)=11.98, ω²=0.384). 
Treatment with PP2 resulted in a significant influence of the genotype (p=0.0252, F(1, 
16)=6.096, ω²=0.294) on the stationary fraction. But neither the treatment nor the 
interaction had an influence. The motility of the lysosomes upon PP2 intervention was not 
influenced by genotype, treatment or any interaction (See Figure 50 A & B). 
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Figure 50: Trafficking analysis of lysosomes of MSN differentiated cultures. A) MSN differentiated 
cultures showed an increased movement of lysosomes that was present in ChAc lines. GADL 
treatment further increased that movement. B) There was a significant increase of the mean speed of 
moving lysosomes in ChAc lines under control conditions. GADL had a differential effect on the 
average speed. Bars represent mean + SEM. n ≥ 4. * indicate significant differences within a treatment. 
* represent p=0.05 
Initial investigation of the control condition of mature neurons that have been derived by 
mDAN differentiation protocol showed no significant difference in the fraction size of 
moving lysosomes. However, there was a huge effect on the mean speed observed 
(p<0.0001, t(20)=6.758, d=3.23). When treated with GADL no significant influence of the 
genotype and no interaction between genotype and treatment was found, but the 
treatment itself had a significant influence (p<0.001, F(1, 81)=7659, ω²=0.093) on the 
moving lysosomal fraction. The motility under GADL treatment conditions was not 
significantly influenced by the genotype but the treatment itself did influence the motility 
significantly (p=0.0219, F(1, 81)=5.461, ω²=0.069). An interaction between genotype and 
treatment was not observed. Treatment with phallacidin resulted in changes in the moving 
fraction that was significantly influenced by the genotype (p=0.0024, F(1, 65)=9.945, 
ω²=0.131) but not the treatment. The interaction between both was rated significant 
(p=0.0435, F(1, 65)=4.239, ω²=0.063). The motility of the observed lysosomes was 
influenced by the genotype (p<0.0001, F(1, 65)=28.86, ω²=0.283) but not the treatment. 
The observed interaction between genotype and treatment was significant as well 
(p=0.0034, F(1, 65)=9.245, ω²=0.097). The moving fraction that was observed upon PP2 
treatment was not significantly influenced by the genotype, treatment or any interaction. 
The motility of the trafficking lysosomes in PP2 treated conditions was not influenced by 
the genotype. The influence of the treatment was significant (p<0.0001, F(1, 59)=33.32, 
ω²=0.359), but the interaction was not significant (See Figure 51 A & B). 
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Figure 51: Trafficking analysis of lysosomes of mDAN differentiated cultures. A) mDAN differentiated 
cultures showed an decreased movement of lysosomes in ChAc lines. GADL treatment further 
decreased that movement. Phallacidin increased the movement of lysosomes in wild type lines but not 
ChAc lines. B) There was a significant decrease of the mean speed of moving lysosomes in ChAc 
lines under control conditions. GADL treatment only affected wild type lines and caused a drop of the 
means speed to ChAc levels. Phallacidin had a differential effect depending on the genotype. PP2 
treatment similarly reduced the mean speed of moving lysosomes. Bars represent mean + SEM. n ≥ 5. 
* indicate significant differences within a treatment. # indicate significant differences to control 
condition. */**/***; #/##/### represent p=0.05/0.01/0.001, respectively.  
The directedness of lysosome trafficking was investigated similar to the mitochondrial 
studies. Mature neurons derived from MSN differentiation protocol were analyzed under 
control condition and when treated with GADL. There was no influence of the genotype or 
the treatment on the directedness. Furthermore, no interaction was observed. When PP2 
was added and compared to DMSO the directedness was influenced significantly by the 
genotype (p=0.0016, F(1, 95)=10.61, ω²=0.109) but not the treatment or any interaction 
(See Figure 52 A). 
The directedness of trafficking of lysosomes of mDAN was analyzed as well. Without any 
treatment there was an small reduction of directly moving lysosomes observed (p=0.0001, 
t(288.8)=3.86, d=0.42). Treatment with GADL revealed an influence of the genotype 
(p=0.0001, F(1, 435)=14.9, ω²=0.033) as well as an influence of the treatment (p<0.0001, 
F(1, 435)=28.59, ω²=0.062). But there was no interaction. Phallacidin treatment showed 
that there was a significant influence of the genotype (p<0.0001, F(1, 386)=29.04, 
ω²=0.070) and of the treatment (p=0.0093, F(1, 386)=6.835, ω²=0.018). The interaction 
between phallacidin treatment and genotype was rated significant (p=0.017, 
F(1, 386)=5.743, ω²=0.016). Analysis of the DMSO/ PP2 treatments showed no influence 
of the genotype and no interaction between treatment and genotype. The treatment itself 
was rated significant (p=0.0007, F(1, 271)=11.65, ω²=0.044) (See Figure 52 B). 
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Figure 52: Analysis of direct movement in both differentiation protocols. A) MSN differentiation had no 
significant difference in the fraction of direct movement but there was a trend observed where ChAc 
lines exhibited an increased amount of direct movement. B) Fraction of direct movement was 
influenced by the genotype as well as the treatment in mDAN differentiation. Application of GADL 
decreased the directedness while phallacidin caused differential response in wild type and ChAc lines. 
Bars represent mean + SEM. n ≥ 4. * indicate significant differences within a treatment. # indicate 
significant differences to control condition. */**/***; #/##/### represent p=0.05/0.01/0.001, respectively. 
The top decile of the fastest tracks was analyzed for lysosomes as well. Even though 
there was very large effect on the top speed in MSN differentiated mature neurons, 
resulting an increase of the velocity (p=0.0377, t(9)=2.434, d=1.53), no difference for the 
treatments with GADL or PP2 and no influence of the genotype were observed when the 
cells were treated. There was no interaction observed as well (See Figure 53 A). 
In mDAN differentiated neurons there was a moderate effect observed that resulted in the 
reduction of the velocity of the fasted tracks (p=0.0058, t(56)=2.871, d=0.76). When 
treated with GADL the analysis revealed a significant influence of the genotype (p=0.0179, 
F(1, 81)=5.841, ω²=0.074), however, no treatment effect or interaction was observed. The 
addition of phallacidin revealed a significant influence of the genotype as well (p<0.0001, 
F(1, 65)=30.39, ω²=0.295) and, furthermore, an interaction that was considered significant 
(p=0.0025, F(1, 65)=9.873, ω²=0.102). The treatment itself was not considered significant. 
Upon investigation of PP2, there was an influence of the treatment observed (p<0.0001, 
F(1, 59)=18.43, ω²=0.245) but not of the genotype or any interaction (See Figure 53 B). 
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Figure 53: Speed of the top decile of the fastest lysosomes of both differentiation protocols. A) There 
was no difference observed in MSN differentiated neurons. B) mDAN differentiated neurons had no 
difference in the max speed that was accounted to influence of the genotype. Differential response to 
phallacidin treatment was observed. PP2 treatment decreased the directness as well. Bars represent 
mean + SEM. n ≥ 5. * indicate significant differences within a treatment. # indicate significant 
differences to control condition. */**/***; #/##/### represent p=0.05/0.01/0.001, respectively. 
3.2.2.2. Microfluidic chambers 
Motility of lysosomes in MFCs was analyzed similar to mitochondria by first investigating 
the fraction of moving organelles and comparing the motility of this moving fraction. The 
amount of moving lysosomes of mixed striatal cultures was not influenced by the 
genotype, the position or any interaction. The motility was not influenced by any of these 
factors as well (See Figure 54 A & B). 
 
Figure 54: Trafficking analysis of lysosomes of MSN differentiated MFC cultures. A) No significant 
differences were observed although a trend on increased movement was noticed in distal position 
was. B) MSN differentiated cultures had no difference that was significantly influenced by position or 
genotype. Bars represent mean + SEM. n ≥ 6. 
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The fraction of moving lysosomes of neurons derived from mDAN differentiation was not 
influenced by the genotype but by the position (p<0.0458, F(1, 85)=4.11, ω²=0.057). 
Furthermore there was no significant interaction observed. The motility of the moving 
fraction was influenced by the genotype (p= 0.0093, F(1, 85)=7.082, ω²=0.085) but not the 
position or the interaction between the both (See Figure 55 A & B). 
 
Figure 55: Trafficking analysis of lysosomes of mDAN differentiated MFC cultures. A) mDAN 
differentiated cultures showed no differences in regards to the genotype but a trend of increased 
amount of moving organelles was observed in a distal position in ChAc lines. B) Mean speed of 
lysosomes of mDAN differentiated cultures was increased for ChAc lines. Bars represent mean + SEM. 
n ≥ 18.  * indicate significant differences within a treatment. 
The antero- and retrograde transport of lysosomes in MFCs was assessed as well. The 
same requirement of a directness above 0.75 for each track was used. When mixed 
striatal cultures were investigated, no difference was observed in respect to genotype or 
proximal vs. distal position (See Figure 56 A). Anterograde or retrograde speed of 
lysosomes was not influenced by the genotype or the position. No interactions were 
observed as well (See Figure 56 B). 
The fraction of anterograde transport in mature neurons obtained from mDAN 
differentiation protocol was not influenced by genotype but by the position within the 
neurite (p=0.011, F(1, 443)=6.524, ω²=0.017) (See Figure 56 D). 
The speed of the anterograde fraction was not significantly influenced by the genotype or 
position (See Figure 56 E). The speed of the retrograde moving fraction, however, was 
influenced by the genotype (p<0.0001, F(1, 443)=16.53, ω²=0.036) as well as the position 
within the neurite (p<0.0001, F(1, 443)=23.46, ω²=0.05) (See Figure 56 E). 
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Figure 56: Detailed characterization of lysosomes trafficking in MFC. A) There is no difference in the 
anterograde fraction of moving lysosomes. B) Genotype and position had no influence on the mean 
speed of anterograde moving lysosomes. ChAc lines had a slightly, but not significantly, increased 
speed. For retrograde movement, there was no significant difference found as well. But a trend in the 
proximal position indicated decreased mean speed for ChAc lines. C) Increased direct movement was 
detected in distal positions of MSN differentiations. n(A-C) ≥ 6. D) Difference in anterograde moving 
fraction detected between proximal and distal position in mDAN differentiations was observed. 
Genotype showed no influence. E) Mean speed of anterograde moving lysosomes was lower in distal 
parts. ChAc lines showed an increased mean speed in proximal positions that reduced to wild type 
level in distal parts. n(D-F) ≥ 18. F) Direct movement of lysosomes was increased in distal parts. Bars 
represent mean + SEM. Boxes represent 25-75 percentiles, line represents median, whiskers represent 
10-90%, + represents mean. * indicate significant differences within a treatment. # indicate significant 
differences to control condition. */**/***; #/##/### represent p=0.05/0.01/0.001, respectively. 
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The directedness of lysosomal trafficking was investigated dependent on the axonal 
position. Mixed striatal cultures showed a significant influence of the position (p=0.0254, 
F(1, 111)=5.134, ω²=0.051) but no influence of the genotype and no interaction between 
the two (See Figure 56 C). 
Directedness in mature neurons from the mDAN protocol was also not sensitive to 
influence of the genotype. The influence of the position, however, was significant 
(p=0.0006, F(1, 443)=11.81, ω²=0.028) (See Figure 56 F). 
The analysis of the ten percent fastest tracks revealed no significant influence of the 
genotype, treatment or interaction in mixed striatal cultures (See Figure 57 A). 
Differentiated mDAN cultures that were subjected to the same conditions showed a 
significant influence of the genotype (p=0.0152, F(1, 85)=6.138, ω²=0.077) but no 
influence of the position and no interaction (See Figure 57 B). 
 
Figure 57: Mean speed of the top decile fastest lysosomes in MFC of both differentiation protocols. A) 
MSN differentiated neurons indicate no difference in the top speed. n ≥ 6. B) mDAN differentiation 
revealed an increased average speed of fast moving lysosomes. n ≥ 18. There was no influence of the 
position discovered. Bars represent mean + SEM. 
In summary, when undirected 96-well cultures were investigated ChAc lines in mixed 
striatal cultures showed an increase in the moving fraction and an increase in the mean 
and top speed, while mDAN cultures harbored a reduced moving fraction and decreased 
in mean and top speed. The directedness as unaffected in MSN cultures but upon mDAN 
differentiation ChAc patients’ lysosomes moved less direct than wild type ones. 
Investigation of MFC showed that, in general, distal parts had more moving lysosomes 
that also travelled more direct. The majority of these lysosomes moved in an retrograde 
fashion. Treatment with GADL increased the moving fraction of MSN cultures further and 
decreased it when applied to mDAN cutures. The mean speed of lysosomes was not 
affected in either differentiation protocol. The directedness was not influenced in mixed 
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striatal but in midbrain dopaminergic cultures. Application of PP2 had no effect on MSN 
differentiated neurons but lowered the mean and top speed of wild type and ChAc lines in 
mDAN cultures (See Table 28). 
Table 28: Summary of analysis of dynamic parameters of lysosomes 
96 well MSN differentiation mDAN differentiation 
Movement 
 
 
Mean Speed 
 
Directedness 
 
Max Speed 
ChAc lines had more moving 
lysosomes 
 
ChAc lysosomes moved faster under 
control conditions 
ChAc lysosomes had increased 
directedness in DMSO/PP2 set 
no difference between wild type and 
ChAc 
no difference between wild type 
and ChAc under GADL and PP2 
treatment conditions 
ChAc lines had slower 
lysosomes in control conditions 
ChAc lysosomes moved less 
direct in control conditions 
ChAc lines had slower 
lysosomes in control conditions 
MFC MSN differentiation mDAN differentiation 
Movement 
 
 
 
 
 
 
 
Mean Speed 
 
 
 
 
 
 
Directedness 
no difference between wild type and 
ChAc 
no difference between proximal and 
distal parts 
no difference between wild type and 
ChAc 
no difference between proximal and 
distal 
 
Retrograde moving lysosomes in 
proximal parts are faster than the 
ones in distal regions 
Directedness is increased in distal 
position 
no difference between wild type and 
ChAc 
no difference between proximal and 
distal 
no difference between wild type 
and ChAc 
distal parts had more moving 
lysosomes than proximal parts 
ChAc lysosomes were faster 
Anterograde and retrograde 
moving lysosomes in proximal 
parts are faster than the ones in 
distal regions 
Retrograde moving lysosomes in 
ChAc lines were moving faster 
than wild type ones in proximal 
parts 
Directedness is increased in 
distal position  
ChAc lysosomes had a higher 
max speed 
no difference between proximal 
and distal 
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Treatment MSN differentiation mDAN differentiation 
Movement 
 
Mean Speed 
Directedness 
 
Max Speed 
No significant influence of the 
treatment 
no response to any treatment 
No significant influence of the 
treatment 
no response to any treatment 
GADL treatment reduced the 
moving fraction 
PP2 treatment reduced speed 
PP2 treatment reduced 
directedness 
PP2 treatment reduced max 
speed 
4. Comparison with Huntington’s disease 
Neurons that are primarily affected by Huntington’s disease are the MSNs of the basal 
ganglia. To elucidate whether the discovered ChAc phenotypes are specific, some 
experiments were conducted on a Huntington line. Since investigation was limited to one 
Huntington line and not all experiments were repeated, this section focuses on differences 
between ChAc and Huntington rather than an in depth analysis of Huntington’s disease. 
4.1. DNA damage 
There was no difference between ChAc and Huntington lines during assessment of 
γH2A.X. Treatment with etoposide was significant (p<0.0001, F(1, 663)=140.3, ω²=0.175). 
The area of the spot sizes was analyzed as well and showed an significant influence of 
the treatment (p=0.0015, F(1, 1842)=10.17, ω²=0.006) and a significant interaction 
(p<0.0001, F(1, 1842)=15.34, ω²=0.009) (See Figure 58 A & B). 
 
Figure 58: DNA damage in mature MSN of Htt lines. A) More DSB upon acute treatment for 1h with 
10μM etoposide. B) Size of spots is unaffected by genotype and treatment. Boxes represent 25-75 
percentiles, line represents median, whiskers represent 10-90%, + represents mean. n = at least 139 
nucelei from 3 independent experiments * indicate significant differences within a treatment. # indicate 
significant differences to control condition. *; #/##/### represent p=0.05/0.01/0.001, respectively. 
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4.2. Characterization of metabolism 
When the parameters of energy metabolism were investigated, the Huntington line 
behaved similar to ChAc lines. There was no difference observed in glycolytic increase, 
glycolytic reserve, non-respiratory acidification, coupling efficiency and spare respiratory 
capacity. The non-respiratory oxygen consumption, however, was significantly lower in 
Huntington (p=0.0037) and resembled the data obtained from wild type. A trend of 
increased spare respiratory capacity was observed. The result was, however, not rated 
significant (See Figure 59). 
 
Figure 59: Metabolic characterization of mature MSN of Htt lines. A-F) No differences were observed 
during the characterization of glycolysis and oxidative phosphorylation. n ≥3 
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4.3. Live cell imaging 
Live cell imaging was performed, using the same workflow as was established previously. 
4.3.1. Mitochondria 
4.3.1.1. Morphological analysis 
The morphology of Huntington patients’ mitochondria was assessed in 96 well plates. 
When the count per arbitrary neurite length was calculated, there was a significant 
interaction between genotype and treatment with GADL (p=0.0462, F(1, 45)=4.202, 
ω²=0.101). The absence of any significant influence of the genotype showed that there 
was no difference between ChAc and Huntington. Mitochondrial count of the investigated 
Huntington line was in between the values of ChAc and wild type. Importantly, the reaction 
to the treatment was similar to that of the wild type. Treatment with PP2 showed no 
influence of genotype, treatment or interaction (See Figure 60 A). 
 
Figure 60: Morphological analysis of mitochondria of Htt lines in MSN differentiation. A) MSN 
differentiation showed that Htt lines had a reduced amount of mitochondria per arbitrary neurite 
length. B) The aspect ratio was reduced in Htt lines when compared to wild type. C) The size of 
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mitochondria was reduced in Htt lines. Boxes represent 25-75 percentiles, line represents median, 
whiskers represent 10-90%, + represents mean. n = at least 7 images from 3 independent experiments. 
* indicate significant differences within a treatment. **/***; represent p=0.01/0.001, respectively. 
The aspect ratio of investigated mitochondria was not different between ChAc and 
Huntington under GADL and PP2 treatment conditions. There was, however, a trend 
observed that Huntington patients’ mitochondria have a slightly decreased aspect ratio. 
When compared to wild type lines within the ctrl/GADL set, there was a significant 
phenotype observed (p=0.0016, F(1, 83)=10.62, ω²=0.119) (See Figure 60 B). 
The size of mitochondria was not significantly influence by genotype, any treatment or any 
interaction. The obtained values were in between ChAc and wild type. Treatment effects 
were comparable to wild type (See Figure 60 C). 
4.3.1.2. Trafficking 
The trafficking of mitochondria was investigated using MitoTracker Deepred staining in 
96 well plates. The amount of moving mitochondria was significantly reduced in 
Huntington during GADL treatment. All parameters of the two-way ANOVA were 
significant. The genotype (p=<0.0001, F(1, 10)=64.6, ω²=0.409), the treatment (p<0.0001, 
F(1, 10)= 67.77, ω²=0.429) as well as the interaction (p=0.0026, F(1, 10)=15.9, ω²=0.101) 
were rated significant. When DMSO and PP2 sets were analyzed, the significant influence 
of the genotype remained (p<0.0001, F(1, 10)=55.9, ω²=0.821) (See Figure 61 A). 
 
Figure 61: Trafficking analysis of mitochondria of Htt lines in MSN differentiated cultures. A) MSN 
differentiated cultures showed an decreased movement of mitochondria that was present in Htt lines. 
GADL treatment further decreased that movement. The moving fraction of Htt lines was increased 
under DMSO mock conditions. B) There was a significant increase of the mean speed of moving 
mitochondria in Htt lines under control conditions. Bars represent mean + SEM. n ≥ 3.* indicate 
significant differences within a treatment. */** represent p=0.05/0.01 
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Analysis of mitochondria motility under GADL treatment conditions showed a significant 
influence of the genotype (p=0.0027, F(1, 10)=15.68, ω²=0.555) when ChAc was 
compared to Huntington. When DMSO and PP2 sets were investigated, however, the 
influence of the genotype, the treatment and the interaction were not rated significant (See 
Figure 61 B). 
The directedness of movement was reduced in Huntington compared to ChAc. This was 
observed under GADL and PP2 treatment conditions. During addition of GADL, the 
influence of genotype was significant (p=0.0098, F(1, 51)=7.204, ω²=0.133). When PP2 
was used, this finding could be observed as well (p=0.0327, F(1, 52)=4.814, ω²=0.094) 
(See Figure 62 B). 
The speed of the top decile of the fastest tracks was investigated as well. In GADL 
treatment conditions, there was no difference observed. Influence of the genotype, 
treatment and interaction were not significant. When PP2 treatment was applied, there 
was a significant influence of the genotype observed (p=0.0341, F(1, 10)=6.012, 
ω²=0.409) (See Figure 62 A). 
 
Figure 62: Analysis of top speed and direct movement of Htt lines. A) There was no difference 
observed in the fastest moving mitochondria of Htt lines. B) Direct movement was impaired for Htt 
lines. Bars represent mean + SEM. n ≥ 3. * indicate significant differences within a treatment. ** 
represents p=0.01, respectively. 
4.3.1.3. JC-1 
Mitochondria potential was investigated under GADL and PP2 treatment conditions. When 
treated with GADL, there was no significant influence of the genotype, treatment or 
interaction. Huntington lines had an increased ratio of the red and green channel when 
compared to wild type, highly similar to ChAc. Treatment response was similar to wild type, 
but the influence of the treatment was not significant. When DMSO and PP2 sets were 
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investigated, there was a significant influence of the genotype observed (p=0.0025, 
F(1, 85)=9.722, ω²=0,111). The ratio of the Huntington line was in between the values of 
wild type and ChAc. The treatment response resembled wild type rather than ChAc. The 
treatment itself, however, failed to be considered significant even when wild type and 
Huntington lines were directly compared (See Figure 63). 
 
Figure 63: Analysis of membrane potential marker JC-1. Htt lines showed a significantly increased 
ratio of JC-1 in MSN differentiation conditions. GADL treatment increased the ratio in wildtype but not 
Htt lines. Boxes represent 25-75 percentiles, line represents median, whiskers represent 10-90%, + 
represents mean. n = at least 18 images from 3 independent experiments. * indicate significant 
differences within a treatment. *** represent p=0.001, respectively. 
4.3.2. Lysosomes 
4.3.2.1. Morphological analysis 
The morphology of Huntington patients’ lysosomes was assessed in 96 well plates. When 
the count per arbitrary neurite length was calculated, there was no significant influence of 
genotype, any treatment or any interaction observed. The absence of any significant 
influence showed that there was no difference between ChAc and Huntington. Lysosomal 
count of the investigated Huntington line was in between the values of ChAc and wild type. 
Importantly, the reaction to the treatment was again similar to that of the wild type. 
Analysis of the aspect ratio of lysosomal compartments revealed no differences between 
ChAc and Huntington (See Figure 64 A & B). 
Investigation of the size of LysoTracker-positive objects under GADL treatment conditions 
showed decrease in the Huntington line in comparison to ChAc. This was calculated by a 
significant influence of the genotype (p=0.0068, F(1, 44)=8.073, ω²=0.164). A similar 
behavior was observed in the DSMO and PP2 sets. The influence of the genotype was 
rated significant as well (p=0.0016, F(1, 45)=11.26, ω²=0.205) (See Figure 64 C). 
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Figure 64: Morphological analysis of lysosomes of Htt lines in MSN differentiation. A) MSN 
differentiation showed no significant difference in the number of lysosomes per neurite length. B) The 
aspect ratio was not altered in MSN differentiated neurons under control conditions but in GADL and 
PP2 treatments. C) The size of the observed lysosomes is reduced in Htt lines. Boxes represent 25-75 
percentiles, line represents median, whiskers represent 10-90%, + represents mean. n ≥ 3. * indicate 
significant differences within a treatment.  ***; represent p=0.001, respectively. 
4.3.2.2. Trafficking 
The trafficking of lysosomal compartments was investigated using 96 well plates. The 
amount of moving lysosomes was significantly reduced in Huntington when compared to 
ChAc. This was highlighted when the influence of the genotype was calculated under 
Ctrl/GADL conditions (p=0.0075, F(1, 10)=11.14, ω²=0.465). During DMSO and PP2 
conditions, the influence of the genotype was significant as well (p=0.0117, F(1, 
10)=9.481, ω²=0.502). There was no difference observed when Huntington was compared 
to wild type (See Figure 65 A). 
When the motility of the lysosomes was investigated, there was no difference of between 
ChAc and Huntington, regardless of the treatment conditions. When compared to wild 
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type lines, GADL treatment revealed an increased motility of lysosomes in Huntington. 
The influence of the genotype was rated significant (p=0.0063, F(1, 16)=9.887,  ω²=0.304). 
There was an interaction observed as well (p=0.009, F(1, 16)=8.82, ω²=0.275). This 
interaction is specific for the wild type vs. Huntington comparison and not the ChAc vs. 
Huntington analysis. The treatment response to GADL on lysosomal motility was the 
same in Huntington and ChAc and was considered significant (p=0.0170, F(1, 10)=8.171 
ω²=0.44) (See Figure 65 B). 
 
Figure 65: Trafficking analysis of lysosomes of Htt lines in MSN differentiated cultures. A) Htt lines 
have a similar moving fraction when compared to wild type. B) There was a significant increase of the 
mean speed of moving lysosomes in Htt lines under control conditions. GADL had a differential effect 
on the average speed. Bars represent mean + SEM. n ≥ 3. * indicate significant differences within a 
treatment. */** represent p=0.05/0.01 
The directedness of lysosomal trafficking was significantly reduced in Huntington lines. 
This was calculated for ctrl and GADL conditions with the influence of the genotype 
(p<0.0001, F(1, 50)=21.58, ω²=0.307) as well as under DMSO and PP2 conditions 
(p<0.0001, F(1, 51)=38.57, ω²=0.437). When compared to wild type lines, it was 
significantly reduced for GADL treatment conditions (p=0.0142, F(1, 82)=6.281, ω²=0.081) 
as well as when treated with PP2 (p=0.0119, F(1, 84)=6.614, ω²=0.083) (See Figure 66 B). 
When the top speed of the fastest decile of moving objects was analyzed, there was no 
difference observed between ChAc and Huntington (See Figure 66 A). 
 
 
- 132 - 
 
 
Figure 66: Analysis of top speed and direct movement of Htt lines. A) There was no difference 
observed in the fastest moving mitochondria of Htt lines. B) Direct movement was similar in Htt lines 
and wild type lines. Bars represent mean + SEM. n ≥ 3. 
To summarize the findings of the investigation regarding the behavior of Huntington lines, 
their results were mainly compared to ChAc lines. Huntington lines harbored a similar 
amount of DNA damage when treated with Etoposide, when compared to ChAc lines. The 
treatment resulted in an increase in DSB. The metabolic characterization, using Seahorse, 
showed that there are no differences between ChAc and Huntington. The non-respiratory 
oxygen consumption, however, was similar to wild type conditions, thus lower than in 
ChAc lines. When mitochondria were investigated in Huntington lines, their count was 
reduced, they were smaller in size and shorter compared to wild type lines, resembling the 
ChAc phenotype. The results of the treatments, however, resembled the wild type. 
Analysis of the dynamic parameters of the live cell imaging revealed, that fewer 
mitochondria move in Huntington, but these move faster when compared to ChAc or 
wildtype. The directedness was reduced and the max speed showed no difference when 
Huntington lines were compared to ChAc lines. The results of the treatments were similar 
to the ones obtained in wild types. Assessment of mitochondria potential with the JC-1 
dye showed that the potential is, similar to ChAc lines, increased when compared to wild 
type. When lysosomes were investigated, the count and size was reduced compared to 
ChAc. The Aspect ratio remained unchanged. Treatment had the same effects on 
Huntington that it had on wild type and ChAc lines. The amount of moving lysosomes as 
was similar to wild type lines, while the mean speed was comparable to ChAc levels, thus 
larger than wild type. The directedness was reduced but the max speed similar to wild 
type lines. The treatment response of the dynamic parameters of lysosomes was similar 
to ChAc lines. 
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 ChAc vs. Huntington 
DNA damage Etoposide treatment increased the amount of DSB 
No difference between ChAc and Htt 
metabolic characterization No difference in the glycolytic parameters 
Non-respiratory oxygen consumption is reduced to wild 
type levels in Htt when compared to ChAc 
 Morphology Trafficking 
Live cell imaging 
mitochondria 
Mitochondria count was 
similar to ChAc 
Reduced aspect ratio was 
observed 
No difference in size of 
mitochondria 
Treatment responses 
resemble wild type 
Fewer mitochondria are 
moving in Htt 
Moving mitochondria are 
faster in Htt 
Directedness is reduced in 
Htt 
Mitochondria potential was 
increased 
Treatment responses similar 
to wild type 
 Morphology Trafficking 
Live cell imaging 
lysosomes 
Lysosome count was 
similar to ChAc 
Aspect ratio was similar to 
ChAc 
Size was smaller in Htt 
Moving Htt lysosomes similar 
to wild type 
Speed is increased in Htt 
Directedness reduced in Htt 
Treatment response similar 
to ChAc 
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Discussion 
The reprogramming of somatic cells of ChAc patients into iPSCs using a polycistronic lenti 
viral vector system was successfully achieved for the first time (Warlich, et al., 2011). 
Even though this system offers high efficiency, reproducibility and is easy to handle, 
during the course of the work, an even more refined system using Sendai virus became 
available, which, due to its non-integrative approach of delivery of exogenous factors, 
would be the system of choice for further establishment of disease specific iPSC lines. In 
this work the guidelines of Maherali and Hoechedlinger for good scientific practice were 
followed (Maherali and Hochedlinger, 2008). Only iPSC that showed a bona fide 
morphology, featuring densely packed small cells that were growing as a monolayer with 
a distinct boarder, AP positive, silenced for the exogenous transcription factors, were 
positive for pluripotency markers, capable of three germ layer formation and showed no 
aberrant karyotype were used for disease modeling. A notable exception is the clone 
ChAc 1.1, which was further used in experiments albeit the high residual expression of 
about 17%. It displayed bona fide iPSC morphology with activation of endogenous factors. 
Within the culture, there was a subpopulation of fast growing cancer like cells that most 
likely is responsible for the unsilenced transgene expressions. These patches were easily 
identified and scrapped off before every passaging and before the start of a new 
differentiation to prevent overgrowth. As a last step, it has to be shown that the disease 
defining mutations are still in place and have not been altered by the reprogramming 
process. Western blot was conducted to prove the absence CHOREIN protein (Dobson-
Stone, et al., 2002). This procedure is also part of the clinical diagnosis of ChAc and, 
therefore, appropriate to determine the status of generated cell lines (Dobson-Stone, et al., 
2004). Already established and published ChAc lines were used as either negative or 
positive controls. The Antibody used for the blot has been used in other studies as well 
and the observed pattern is similar to the one reported by other groups (Hayashi, et al., 
2012). Each line investigated showed the proper expression of CHOREIN. Some of the 
generated lines were already shared with other labs and contributed to the field. 
1. Characterization of ChAc lines 
1.1. ChAc stem cell lines show no impaired differentiation potential 
 
The differentiation protocols for mixed striatal cultures and dopaminergic neurons that 
have been used in this work were chosen to reflect two distinct populations that are 
affected by the disease. The MSN differentiation protocol was successfully established to 
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investigate the neuronal population, whose degeneration is causing the main choreiform 
symptoms of ChAc. mDAN differentiation protocol was used to investigate the 
degeneration of neurons that are related to Parkinsonism, which is present in roughly 50%  
of the patients (Velayos Baeza A, 2014). Starting from NPC stage the mDAN protocol is 
quicker and yields a more homogenous culture compared to MSN protocol (Reinhardt, et 
al., 2013). One of the questions of this thesis is to evaluate the mDAN protocol as a 
replacement for the MSN protocol and whether the results obtained from both are 
comparable.  
Both protocols were able to generate mature neurons as shown by MAP2 staining. The 
semi-automated macros used for quantification of these pictures increased the throughput 
and allowed an unbiased background controlled detection of positive cells. Even though 
detection of false positive and false negative signals was a problem, the quantifications of 
wild type and ChAc cell were conducted with the same settings, hence, any error caused 
by the macro is systematic and only affects the absolute values but not relative 
quantification. Both differentiation protocols yielded similar efficiencies for wild type and 
ChAc lines. MSN derived neurons were only 45-80% positive for the markers DARPP32 
and GABA. Remaining neurons were CHAT positive and most likely cholinergic 
interneurons. Therefore, these cultures were referred to as mixed striatal cultures. During 
midbrain dopaminergic differentiation, ChAc lines followed were not different from wild 
type ones. This result is reflecting the clinical disease phenotype, since ChAc has no 
known developmental implications. Only a minor fraction of neurons were identified as 
motor neurons in undirected 96-well cultures. However, when the mDAN differentiation 
was conducted in MFC, the yield of TH positive neurons dropped significantly. Addition of 
cues that are known to attract dopaminergic neurons, like Netrin-1, can be tested to 
improve the growth of in MFC. The trend of faster differentiation of ChAc lines, albeit not 
significant, was observed in both protocols. This might be an artifact of the in vitro cell 
culture or a line specific observation, since no isogenic controls were used. Both protocols 
showed a large remaining pool of SOX2-positive stem cells. Other protocols that are 
available to yield MSN and mDAN address this problem by exposing the remaining stem 
cells to supplements that either boost their differentiation, like TGFβ3 and ACTIVIN A, or 
inhibit their growth, like DAPT (Caiazzo, et al., 2011; Crawford and Roelink, 2007; 
Kawasaki, et al., 2000; Lee, et al., 2000; Perrier, et al., 2004). Even though DAPT itself 
has no direct toxic effect on neurons, it can be detrimental because the early maturation 
can facilitate detachment of the generated neurons (Kirkeby, et al., 2012). 
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The hierarchical clustering of the PCR data showed that there was a clustering of the 
iPSCs and the mature MSN cultures, showing that these populations are very distinct from 
each other. The small clusters that were found within the differentiated cells indicate that 
that the biological variance between experiments might be bigger than the variance 
between wild type and ChAc lines, in regards to the investigated markers. The hierarchical 
clustering of mDAN differentiation gave two different results depending on the 
implementation of one of the previous mentioned genes discovered by CHIP analysis. 
When NNAT was not included, there was no clear clustering of the lines. Every line was 
fairly unique and there was no clear clustering. All wild type lines behaved more similar 
than the different ChAc lines. When the gene NNAT was included in the analysis, there 
was a clear separation of wild type and ChAc lines. Expression of NNAT was 10000 fold 
increased in ChAc when compared to controls. Wt 2.2 is a notable exception since it also 
had an increased expression and clustered within the ChAc lines, which shows that the 
grouping in this setting was solely achieved by the parameter of NNAT expression. The 
interpretation of this finding is very difficult. There is very little known about NNAT and its 
product NEURONATIN. It is known that this gene is paternal imprinted and responsible for 
brain development (Joseph, 2014). In the adult brain, NEURONATIN is expressed in 
parvalbumin-positive GABAergic interneurons (Sharma, et al., 2013). Recent research 
shows that NEURONATIN might be stress induced and a common feature in 
neurodegenerative diseases (Joseph, 2014; Shinde, et al., 2016). These data might 
recapitulate the finding of the observed trend of faster differentiation and suggest, that 
there is either a sublime developmental phenotype in mDAN cultures or that the mature 
cultures might be more stressed than their healthy wild type controls. Due to the 
epigenetic changes that cells undergo during reprogramming, it has been shown that 
imprinted genes could randomly be reactivated and subsequently silenced again in a 
randomized pattern, thus rendering the speculations about the effect of these genes in 
reprogrammed cell lines futile (Chang, et al., 2014; Hewitt and Garlick, 2013). The only 
differences between ChAc and wild type lines that were found in the differentiation 
capacity were minor and negligible and therefore don’t impair the further experiments, 
highlighting the phenotype of the disease. 
1.2. Neurons from MSN differentiation have an altered G/F actin ratio 
Investigations of the cytoskeleton included the characterization of the G/F actin ratio, the 
G/F tubulin ratio and the amount of acetylated tubulin relative to total α tubulin. Mixed 
striatal cultures showed a phenotype in the G/F actin ratio similar to the one reported in 
the literature while there was none observed in mDAN cultures. (Foller, et al., 2012). This 
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can be attributed to the huge differences in the differentiation protocols. There is another 
possibility that actin cytoskeleton can be affected in dopaminergic cells beyond the simple 
ratio of globular and filamentous actin. Functional assay like growth cone dynamics, 
outgrowth assays or the proper internalization of receptors need to be done to further 
characterize the actin cytoskeleton. Tubulin filaments play a major role in organelle 
trafficking and cell homeostasis (Maeder, et al., 2014). Acetylation of tubulin, is important 
for enhancing the binding of KINESIN1 and therefore initiating trafficking (Chen, et al., 
2010). This is important for proper guidance and distribution of travelling organelles. In 
neither mature MSN nor mDAN cultures was any difference in the G/F tubulin ratio or the 
acetylated tubulin ratio observed. These data suggest that the homeostasis of the tubulin 
related cytoskeleton remains intact in ChAc derived neurons in regards to overall G/F 
ratios and modifications. 
1.3. Mature neurons from ChAc lines are susceptible to UPR, proteotoxicity and 
DNA damage 
Because over the course of the differentiation there was no major difference in cell 
survival or morphological abnormalities observed, mature cultures were treated with 
substances to investigate whether ChAc lines are more susceptible to certain kind of 
stress. ChAc lines proved to be more vulnerable to the application of tunicamycin, an 
inducer of ER-related UPR, as well as L-canavanine, an inducer of proteotoxic stress, 
when compared to wild type lines. At a concentration of 1mM for L-canavanine and 10μM 
for tunicamycin, there was little to no effect to the neurons over the time course of six days, 
while 2mM and 5mM of L-canavanine and 50μM and 100μM of tunicamycin, respectively, 
showed a strong effect on cell survival. These low concentrations could be used for 
chronic stress conditions or to assess cross talk between different disease pathways that 
could affect other organelles or cell homeostasis. The data obtained by MSN protocol 
suggest different mechanisms for the substances when compared to mDAN differentiated 
cells.  L-canavanine seems to induce cell death quicker in MSN, suggesting that cells can 
cope worse with misfolded protein or higher demand in protein biogenesis in comparison 
to mDAN, which seem to be able to resist the stress for a longer time but then 
decompensate very quickly once a certain threshold is reached. Tunicamycin seems to 
have similar effects on MSN and mDAN differentiated neurons. Both protocols exhibit 
reduced metabolic activity, but, while MSN protocols have similar rates of cell death, 
mDAN neurons seem to suffer from acute cell death. This is in accordance with the finding 
that that silencing of VPS13A in HeLa cells caused disruption of the autophagy pathway 
(Munoz-Braceras, et al., 2015). It is possible that fusion and fission of vesicles, which is 
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pivotal for proper protein recycling, is disturbed in ChAc lines. This is backed up by 
publications that showed that loss of VPS13 in yeast led to major impairments in the 
phosphoinositol pathway, which were also observed in humans, and an important player 
in vesicle fusion and fission (Park, et al., 2015; Park and Neiman, 2012). Taken together 
this data suggests a different penetrance of the susceptibility to UPR and protein 
misfolding depending on the cell type investigated. The exact differences of the involved 
pathways, however, remain elusive and cannot be clarified with experiments conducted 
within this work. 
1.4. ChAc neurons are not susceptible to DNA damage 
It has been shown that in most neurodegenerative diseases DNA damage plays a pivotal 
role (Madabhushi, et al., 2014). Whether this is causative to the disease, a result of the 
degeneration or if these cells have impaired DNA damage repair mechanisms remains 
elusive. Importantly, this was recently reported for Huntington’s disease (Mollica, et al., 
2016). γH2A.X, a histone modification that is important for initiation of DSB repair was 
investigated to assess the susceptibility to DNA damage (Kinner, et al., 2008). Treatment 
with 10μM etoposide, a substance known to induce DSB, was used as a positive control 
as well as inducer of stress. Both differentiation protocols showed a weak susceptibility to 
DNA damage as determined by a very small effect size. The Huntington cell lines showed 
results similar to ChAc, having no intrinsic accumulations of DNA damage under control 
conditions, but increased DSB when treated with etoposide. Even though in mice, DNA 
damage was suggested to play a role in disease progression of Huntington, the 
experimental setup in this study yielded different results (Cardinale, et al., 2015). Since 
DNA damage can accumulated over time and even minute changes to gene expression 
profiles can have a huge impact on cell metabolism it is, however, possible that these 
vulnerabilities are important aspects of the ChAc phenotype. The aspect of recovery after 
DNA damage was not assessed with the experimental setup, but could highlight more 
differential results. 
1.5. Energy dynamics in ChAc and Huntington lines feature a shift to glycolysis 
Neurons are highly specialized cells with a tremendous energy demand needed for 
organelle transport along neurites, biosynthesis of proteins and propagation of action 
potentials (Berndt and Holzhutter, 2013). Many neurodegenerative diseases have been 
linked to deficits to meet this energy demands (Lezi and Swerdlow, 2012). The analysis of 
MSN differentiated cultures revealed that there was no difference in parameters 
characterizing the glycolysis. The OCR related measurements, however, revealed that the 
oxidative phosphorylation of the mitochondria was impaired and the non-respiratory 
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oxygen consumption increased. These data suggest that the cells rely more on glycolysis 
than on oxidative phosphorylation. This might be the case because of an elevated fraction 
of stem cells in the cell culture even after prolonged maturation, which are known to rely 
on glycolysis (Shyh-Chang, et al., 2013). The increase in non-respiratory oxygen 
consumption can be related to microsomal activities or cell surface oxygen consumption, 
which is a regulator of glycolysis (Rosenfeld, et al., 2002). Whether these processes are 
overly activated in ChAc patients remains elusive and has to be addressed by other 
means. The data obtained from the Huntington line recapitulated the findings in ChAc 
cells. There was no overall phenotype in glycolysis or oxidative phosphorylation. The 
major difference that was observed between ChAc and Huntington was the decrease in 
non-respiratory oxygen consumption. This parameter was similar to wild types in the 
Huntington line and can be an indication that this parameter might a crucial hall mark of 
ChAc pathology. Analysis of mature dopaminergic cultures harbored no differences in the 
parameters of glycolysis as well. The coupling efficiency as well as the spare respiratory 
capacity, however, was increased in ChAc lines. These findings would suggest that the 
function of the respiratory chain is maintained. However,  since patient cells don’t seem to 
utilize it as much as wild type and given a normal function of the proton pumps together 
with a non-pathological coupling efficiency could hint to a complex V deficiency (Hroudova, 
et al., 2014). It is, however, not possible to clearly deduct this from the given results and 
further experiments that back up this hypothesis have to be conducted. Since the 
unraveled differences are presented as relative changes compared to wild type cell lines, 
only a selective vulnerability to cell death of the ChAc lines could explain this. Because no 
vulnerability was observed in other experiments without specific cell stressors, the 
obtained data indicates that the observed phenotype is disease relevant. There was an 
article published recently that focused on the interaction of VPS13 with the membrane of 
mitochondria-endosome junctions (Park, et al., 2016). The authors suggested that there 
might be a basal impairment of mitochondria in ChAc patients. Since disturbance of 
energy homeostasis seems to be downstream of different pathways in mDAN and MSN 
cultures, analyzing the ultrastructure of the mitochondria with electron microscopy, 
including their cristae, can be beneficial to exclude structural differences as a cause. 
2. Live cell imaging of ChAc lines 
2.1. Video analysis is reproducible and sensitive 
Because the cultures obtained by the differentiation protocols are a mixture of various cell 
types, the underlying background noise from non-neuronal cells renders observation of 
minute changes impossible. Live cell imaging of labelled cell organelles can give 
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information about morphological aspects as well as functional readout, when their 
trafficking is analyzed. With the proper placement of the field of view, it is possible to keep 
the background signal of non-neuronal cells to a minimum. Furthermore, when MFC are 
used it is possible to distinguish between proximal and distal parts of a neuron as well as 
antero- and retrograde movement. The establishment of MFCs as a novel cell culture 
system for spatiotemporal analysis of neuronal cultures was achieved recently (Folch, et 
al., 1999; Reyes, et al., 2004). Due to the small dimensions of the channels only neurites 
can grow into the device and imaging readout is not influenced by non-neuronal cells or 
perinuclear organelles. The markers used in this study are MitoTracker DeepRed, Lyso 
Red and JC-1. Since none of these dyes requires excitation in UV or blue light, induction 
of phototoxicity and therefore detrimental effects on the illuminated cells are minimized 
(Douthwright and Sluder, 2016). Shape analysis was conducted using semi-automated 
macros and fitting algorithms. Trafficking analysis was based on the assumption of two 
distinct populations, which describe a stationary and a moving fraction, that were modeled 
on the data obtained from the well-established Fiji Plugin TrackMate. Conducting a 
regression analysis by using a two-phase decay model yields two e-functions that 
describe parameters of these populations, which can be used to assess the individual 
trafficking parameters of each video. This approach has the advantage of not relying on a 
possibly biased and arbitrary fixed threshold that is used in some publication (Atkin, et al., 
2011; Brickley and Stephenson, 2011; Cai, et al., 2005). The fraction of moving organelles 
varies between different cell types and their culture conditions. Furthermore, different 
publications utilize different methods of quantifying the amount of moving objects. 
Therefore comparison of the results obtained in the herein presented experimental setup 
cannot directly be compared to other reported values. The spectrum of physiological 
movement ranges from 10% to 40% (Schwarz, 2013). The mean speed of motile 
mitochondria in this experimental setup was 0.4 to 0.6μm/sec. Even though the reported 
values vary in between publications, the expected velocity ranges from 0.3 to 1.0μm/sec 
(MacAskill and Kittler, 2010). The fraction of moving lysosomes is considered to be 
roughly 50% (Cordonnier, et al., 2001; Stagi, et al., 2014). In this work 10-30% of the 
lysosomes were considered moving. The calculated mean speed of the lysosomes was 
about 0.6 to 1.2μm/sec. It is reported that the average speed of lysosomes is about 
0.67 ± 0.79μm/sec, showing that the data obtained by the algorithm is with a physiological 
range (Bandyopadhyay, et al., 2014). 
The discrepancies between different publications as well as when compared to this work 
can be explained by the criteria considered defining a track as moving and the technique 
applied. Kymographs that are generated and evaluated by hand are most often used to 
 
 
- 141 - 
 
investigate organelle trafficking. Some publications consider an object as moving if its 
maximum velocity is above 0.1μm/sec (Lee, et al., 2011). Due to the small time interval in 
between pictures that was used in the setup of the present work, a speed of 0.1μm/sec 
would be obtained when an object displaces only 30nm in between two pictures. However, 
this displacement is below the resolution of the used imaging system and when this 
criterion was used to assess the size of the moving fraction of lysosomes a result of 
99.177% ± 1.654% for moving tracks was obtained. This is clearly overestimating the 
moving fraction and not representing the subjective impression of the videos and therefore 
cannot be applied to the imaging setup used in this study. The investigated time frame 
plays a crucial role for the quantification of moving fraction. A lot of organelles can pause 
during their movement by detaching from microtubules and remain stationary for a 
prolonged time (Ori-McKenney, et al., 2010). Since images are only taken over a course 
of 2min, there is a possibility that stationary tracks would have moved at a given time if the 
imaging period was extended. Considering these drawbacks of the system, a relative 
evaluation in regards to genotype, treatment or position is still possible since the error 
caused has a systematic nature and affects wild type as well as ChAc lines. The quality of 
the algorithm can easily be determined by interrogation of regression parameters like the 
regression coefficient. 
2.2. ChAc lines have altered mitochondria shape and trafficking 
The morphological features of ChAc patients’ mitochondria were similar in mixed striatal 
as well as dopaminergic cultures. The count per neurite length was reduced in both 
protocols leading to an overall smaller population. These mitochondria had a smaller size 
as well. Furthermore, in mDAN cultures they exhibited a reduced aspect ratio, which was 
not significantly reduced in MSN differentiations. Even though the size was reduced in 
mDAN differentiated ChAc lines, this is most likely a resemblance of the shortening and 
not a reduction that goes beyond this morphological change. Shortening of mitochondria 
can be an indication for problems with control of fusion and fission events. These 
alterations suggest that ChAc cells might have an underlying impaired mitochondria 
homeostasis that results in reduced mitochondria biomass and can subsequently cause 
deficits in energy homeostasis. This theory can be backed up by the fact, that CHOREIN 
is involved in signaling of mitochondria and other organelle at specific junctions (Park, et 
al., 2016). Huntington lines behaved very similar to ChAc. The organelle count, was 
diminished in Huntington but not as much as in ChAc. While an observed decrease in size 
was stronger in ChAc, reduction of the aspect ratio was more pronounced in Huntington. 
One possible explanation of the observed phenotype is that striatal neurons from 
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Huntington lines exhibit excessive mitochondrial fission resulting in shortened 
mitochondria (Guedes-Dias, et al., 2015). When MFC were investigated they were similar 
to the results obtained in undirected 96wells. The count was reduced in proximal parts of 
MSN, but not in mDAN cultures. The aspect ratio was reduced in distal parts of mDAN 
cultures suggesting that for midbrain dopaminergic cultures the neurons observed in 
undirected 96wells are of distal nature. A possible explanation for this is the different 
neuronal subtype that grew through the MFC channels. In the case of mixed striatal 
cultures only cholinergic interneurons grew through the channels. This might be a certain 
characteristic of MSN, since these cells don’t grow over large distances in vivo as well 
(Koos, et al., 2004). Other chemical cues might be sufficient however to drive their 
outgrowth. In midbrain dopaminergic cultures, only SMI32 positive motor neurons crossed 
the channels. This significant difference in neuronal subtype can also explain why there 
was no significant reduction in the count of mitochondria observed in mDAN cultures. This 
behavior can be explained by the lack of appropriate chemical cues for growth. Further 
addition of Netrin-1 into the terminal side could be tested to increase the fraction of TH-
positive dopaminergic neurons that grow along the channels (Lin and Isacson, 2006). 
Since some dopaminergic neurons were found to grow through the channels and 
exhibited a healthy morphology, the low amount TH-positive cells is most likely attributed 
to the lack of neurotrophic factors they receive on the soma side. But once they grow 
through the channel, the supplied factors on the terminal side are sufficient for their 
survival. 
The analysis of the dynamic movement of mitochondria revealed that there in mixed 
striatal cultures no difference in the moving fraction and their mean speed was observed. 
In midbrain dopaminergic cultures there were more mitochondria moving, however, there 
mean speed was reduced. It is possible that the reduction of the mean speed is causing 
problems in the cell’s energy homeostasis and therefore more mitochondria are moving to 
reach hot spots of energy demand or return to the perinuclear area for recycling (Sheng, 
2014). To address the fact that mitochondria don’t move randomly but in a coordinated 
fashion, the directedness of wild type and ChAc lines was compared (Berndt and 
Holzhutter, 2013; Zajac, et al., 2013). In both protocols there was no difference observed 
in the directedness, suggesting that signaling and positioning of mitochondria under 
control conditions is not impaired in ChAc line derived MSN and mDAN. Interestingly the 
amount of direct movement was almost doubled in mDAN compared to MSN culutres. 
This data suggests that, due to the decreased moving fraction under control conditions in 
mDAN cultures, the remaining moving fraction had to traffic more coordinated. When the 
fastest 10% of moving mitochondria were analyzed, there were no differences found 
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between wild type and ChAc. When the Huntington line was investigated, there were 
fewer mitochondria moving in Huntington’s patients differentiated mixed striatal cultures, 
and these mitochondria moved faster and less direct. There is evidence in the literature 
that mitochondrial transport in Huntington is impaired and causes more stops and a 
decrease in the distance of progressive movement (Weiss and Littleton, 2016). It is very 
likely that the reduction in moving fraction caused an increase of the average speed in the 
moving fraction, since the local energy demands in the axons pose a stronger chemical 
cue. The decreased directedness observed in the trafficking analysis is likely to reflect the 
increase in pauses. The measured velocities were still below the technical limitation of the 
tracking algorithm, which can theoretically detect up to 6μm/sec. Another important 
fraction is the slowest, non-stationary fraction. This slow but coherent transport of 
mitochondria along axons is very important (Miller and Sheetz, 2006). This fraction was, 
however, not investigated due to the short timeframe of only 2min for each video. 
When trafficking was investigated in MFC, there was no difference observed in the moving 
fraction of wild type and ChAc lines in both protocols. The trend of an increased mean 
speed that was observed in proximal parts of MSN cultures was rated significant in mDAN 
differentiations. In mDAN cultures there was an increase in retrograde transport observed, 
which was absent in MSN differentiations. While there was no difference in the mean 
speed observed for anterograde transport, retrograde transport showed an increased 
mean speed in the proximal conditions. Since the directedness was not affected by 
anterograde/retrograde, proximal/distal or wild type/ChAc conditions in both protocols this 
increased mean speed is not an artifact from the absence of stop events. This elevated 
retrograde transport of mitochondria in MSN and mDAN cultures might be a hint for an 
increase in mitochondria damage since retrograde transport occurs when damaged 
mitochondria have to be recycled (Saxton and Hollenbeck, 2012). 
While there seem to be no alterations in the distal parts of the cultures, proximal parts 
show a clear phenotype. This seems to recapitulate the findings of the morphological 
analysis in MFC, where the distal phenotype was established closer to the soma in ChAc 
lines when compared to wild type lines. Anterograde transport seems to be unaffected, 
indicating that newly generated perinuclear mitochondria are healthy but are either more 
susceptible to damaging in the distal part or that there is an underlying problem with 
proper recycling. Because mitochondrial trafficking is linked to dynein and kinesin function, 
another possible explanation is a selective disturbance of dynein motor protein which is 
responsible for retrograde transport. However, since obtained transport speeds at distal 
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position were similar in wild type and ChAc lines, there seems to be no generalized motor 
protein deficit in ChAc patients. 
2.3. Treatments are not selective on ChAc lines mitochondria 
Application of GADL had the biggest effect when mDAN cultures were treated. Even 
though the aspect ratio of mitochondria in mDAN cultures of ChAc lines was restored to 
normal levels, this increase was also observed in wild type lines. Therefore this treatment 
is unspecific. Since none of the assessed morphological parameters of mitochondria in 
mixed striatal cultures was influenced by GADL, it is likely that the pathogenesis is 
different in mDAN and MSN. 
Furthermore, GADL treatment increased the amount of the moving fraction in mDAN 
cultures even further. Even though mean speed of wild type and ChAc mitochondria was 
not different anymore when the cells were treated with GADL, the speed of ChAc 
mitochondria was not increased to wild type levels, but wild type mitochondria moved 
slower. Therefore, GADL cannot be considered a cure for the ChAc phenotype, since it 
only affected the speed of wild type lines. The directedness of mitochondria movement in 
MSN cultures was not influenced by GALD, however, when mDAN cultures were treated, 
their levels dropped to values similar to MSN cultures. 
In summary GADL treatment had different effects in MSN and mDAN cultures that were, 
however, stronger in mDAN differentiations. This can be seen in accordance with the 
differential results of mitochondria electron transport chain that was already observed in 
the seahorse experiment. To see whether treatment with GADL has a direct impact on 
electron transport chain, metabolic characterization of GADL treated neurons with a 
seahorse device needs to be conducted. 
Treatment with PP2 and phallacidin showed almost no effect on the evaluated parameters 
of morphology and trafficking. This suggests that the phenotype described in this thesis is 
not related to a hyper activation of LYN or an disturbed G/F actin ratio but is acting in 
parallel and can be considered as a novel impairment of ChAc patients. 
Importantly, treatment response of the Huntington line was akin to wild type and not ChAc 
lines. This strongly suggests a different pathological pathway of the disease progression 
that resulted in the same morphological observation. 
2.4. Mitochondrial potential is altered in ChAc lines 
Potential of mitochondria is an important aspect of proper function and was visualized by 
JC-1 staining. MSN and mDAN cultures yielded differential results. While ChAc lines in 
MSN differentiations showed an increase under control conditions, the ratio was reduced 
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in mDAN differentiations. Investigation of the ratio in Huntington lines showed an 
increased mitochondrial potential that was in between the values of wild type and ChAc, 
indicating a similar yet not as severe progression. When mDAN MFC cultures were 
investigated, there was no difference in the proximal position. In the distal position, 
however, there was a significant increase in JC-1 ratio in ChAc lines, while the wild type 
lines were similar to proximal side. This resembles the findings of undirected MSN 
cultures and could be caused by the absence of dopaminergic cells in the channels of 
MFC, or the MFC system itself which might pose a certain stress due to possible lack of 
nutrition and oxygen. After MSN differentiation, GADL treatment increased the potential in 
wild type but decreased it in ChAc lines, while in mDAN cultures the potential was further 
decreased in both genotypes. Huntington lines reacted to GADL similar to wild type rather 
than ChAc, suggesting a different underlying mechanism. 
Even though there is a differential phenotype in MSN compared to mDAN cultures, which 
reflects the findings of the seahorse experiments and the GADL treatment on the 
trafficking, it is clear that VPS13A mutations in ChAc lines cause impairment to their 
mitochondria homeostasis. It has been reported that increased as well as decreased 
mitochondria potential may impair mitochondrial function (Gottlieb, et al., 2000). Some 
articles in the literature link an increased mitochondrium potential to putative neuronal 
degeneration (Green and Reed, 1998; Kroemer, et al., 1998). Hyperpolarization can be 
utilized by the cell to prevent apoptosis (Ward, et al., 2007). A recent published paper 
linked the function of VPS13 directly to mitochondria und suggests a direct interaction at 
the endosomal mitochondria interface (Park, et al., 2016). 
2.5. ChAc lysosomes feature normal morphology but altered trafficking 
The lysosomal system, which is important for protein homeostasis by participating in 
autophagy and the endosomal pathway, and was already shown to be impaired to some 
extent, when cells were treated with tunicamycin and L-canavanine, was visualized and 
analyzed using the readily commercial available probe LysoTracker. Both differentiation 
protocols had less lysosomal organelles and their aspect ratio was not altered. 
Furthermore, mixed striatal cultures showed that ChAc lines had smaller compartments. 
Since LysoTracker stains unselectively for acidic cell compartments, thus labelling 
lysosomes, hybrid lyso-endosomes, autolysosomes and mature autophagosomes, it is 
possible that the composition of these organelles is changed in ChAc. Of the 
aforementioned compartments lysosomes are the smallest and a decrease in overall size 
could be a sign of an accumulation of them. However, because the overall count is 
diminished as well, it is more likely that progression within the lysosomal pathway is 
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impaired. Findings of disturbance of autophagic flux in HeLa cells as well as disruption of 
organelle-to-organelle signaling in CHOREIN knock-out lines is supporting this theory 
(Munoz-Braceras, et al., 2015; Park, et al., 2016). Huntington lines had morphological 
features that were similar to ChAc. However, the size of the lysosomes was reduced. 
Since a possible shift in the composition of the lysosomal compartments cannot be 
excluded, different markers that allow the identification of different vesicles, like early or 
late endosomes have to be used to investigate these organelles independently.  There is 
evidence in the literature that defective Huntingtin can cause a shift in the positioning of 
lysosomes that affects their function (Erie, et al., 2015). When MFCs were investigated 
the reduction of the amount of lysosomal organelle was confirmed in MSN but not mDAN 
cultures. The trend, that distal parts harbor fewer organelles was observed in MSN and 
was rated significant in mDAN differentiations. The aspect ratio was found to be smaller in 
distal parts than in proximal parts, which reflects the fact, that lysosomal compartments 
carry more cargo in proximal parts and already underwent several fusion events that 
potentially alter their shape. Compared to undirected cultures, the aspect ratios of 
lysosomes in MFC seem to be elevated in both differentiation protocols. Since it was 
shown that distal parts have a lower aspect ratio, and given the fact the only significant 
differences between wild type lines and ChAc were found in the proximal position, it 
seems that the data of undirected cultures resembles more the distal part. This finding is 
in accordance with the observation achieved with MitoTracker. The aspect ratio was lower 
ChAc line MSN differentiations when compared to wild type. This suggests that MSN 
cultures are heavier impaired in their lysosomal homeostasis, which could be a first link to 
the disease progression. Early clinical symptoms are also caused by cell death of MSN. 
While Parkinsonism, a symptom of the later ChAc stages, is cause by death of 
dopaminergic neurons. 
Differences between MSN and mDAN cultures were also present in the analysis of 
lysosomal trafficking. While MSN differentiated ChAc lines had more moving lysosomes in 
and a significantly increased mean speed in control conditions, mDAN differentiated 
cultures highlighted no difference of the moving fraction between wild type and ChAc. The 
fraction of direct movement was smaller in MSN differentiations when compared to mDAN 
cultures. Furthermore, the trend observered in mixed striatal cultures that show an 
increase in ChAc lines was reversed in dopaminergic neurons, where there was a 
significant reduction. The fact that directness resembles the actual moving fraction 
indicates that almost all moving organelles move in a directed manner. Therefore, the 
organelles can be put in two groups, stationary lysosomes and direct moving lysosomes. 
Stopping events and change of direction, however, would result in a decrease in 
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directedness. This suggests that the movement is unidirectional, meaning once an 
organelle starts moving only a small fraction changes its direction or stops, because these 
events would cause a violation of the inclusion criteria for this analysis. 
The maximum speed of lysosomes was significantly increased in ChAc lines of MSN, but 
decreased in ChAc lines of mDAN cultures. These substantial differences can attributed to 
a different composition of the lysosomal system as well. Therefore it is important to further 
investigate with more precise markers to which extent specific organelles are affected. 
The amount of moving lysosomes of Huntington’s patients was more similar to wild types. 
However, the speed of the lysosomes was increased, similar to ChAc lines. Since different 
lysosomal organelles travel with a different speed according to their cargo and position, it 
is very likely that the observed tracks represent a specific subset of lysosomal 
compartments that is increased in Huntington. The directedness of movement was 
strongly reduced and might be a phenotype that is specifically pronounced in Huntington, 
since these findings were unique to the investigated line. These findings suggest that the 
effect on the lysosomal pathway is very different between ChAc and Huntington. Some 
evidence was found in the literature where expression of mutant Huntingtin was sufficient 
to disrupt axonal transport of lysosomes. The authors hypothesized a potentially inhibition 
of autophagosome/lysosome fusion, which would be in line with our data showing 
especially the fraction of small lysosomes affected (Wong and Holzbaur, 2014). 
Moving fraction and mean speed lysosomes in MFCs of MSN cultures were not significant 
different for wild type/ChAc and proximal/distal comparisons. In MFCs of mDAN cultures 
there were more moving lysosomes in the distal position. Furthermore, ChAc lysosomes 
were faster. In general, the percentage of moving tracks was higher in MFC than in 
undirected cultures. The mean speed was similar. The trend of increased movement in 
ChAc vs wild type was observed in distal parts of the MFC indicating again that the 
undirected cultures yielded results more akin to distal positions. The increase in mean 
speed observed in the ChAc lines and the absence of different movement in proximal and 
distal positions did not recapitulate the findings of undirected cultures. This might be due 
to the fact that mainly motor neurons were observed in MFC. Similar to the diametric 
results of the mitochondrial analysis, this data reflects the differences between ChAc 
phenotypes in motor neurons vs dopaminergic neurons. 
In both protocols the majority of lysosomes move retrograde. This finding is well 
established in the literature (Lee, et al., 2011). In mDAN MFC cultures, a further reduction 
of anterograde transport was observed in distal positions. There was a strong trend 
observed in the speed of retrograde transport in MSN MFCs. In both protocols no 
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difference was observed for the velocity of anterograde movement. The speed of 
retrograde moving ChAc lysosomes in proximal parts was similar to the distal counterpart, 
while wild type lines exhibited an increased speed in the proximal region. In mDAN MFC 
the velocity of retrograde transport was increased for ChAc. Furthermore there the speed 
was reduced in distal parts. The amount of direct movement was similar to the overall 
moving fraction, suggesting that all movement is highly directed. Directedness was not 
different for ChAc lines but an increase in distal parts was observed in both protocols. This 
behavior was observed in 96 wells as well, indicating that undirected cultures are 
represented by the distal parts of MFCs. 
The top speed of lysosomes in MFC cultures of ChAc lines did not yield any significant 
differences, similar to undirected wells. It is very likely that the effect on the speed of 
trafficking vesicles is occurring not only on a separate subpopulation but is an overall 
effect. The mechanism behind this increase remains elusive. 
2.6. Lysosomes of MSN cultures respond poorly to treatments 
When GADL was added to MSN cultures the morphological parameters of the lysosomal 
fraction did not change. In mDAN differentiations an increase in the size and aspect ratio 
was observed that was larger in ChAc lines. Furthermore, the treatment showed a trend to 
increase the moving fraction of lysosomes in MSN, but decreased it in mDAN cultures. 
Since all moving lysosomes move in a direct manner, the same effects were observed for 
directness. The mean speed and top speed were unaffected.  
PP2 treatment caused differential results in the size of lysosomes. While it increased the 
size in MSN, it did not affect mDAN cultures. Aspect ratio and count remained unaffected 
by the treatment. When trafficking was investigated, a trend of decrease in the moving 
fraction of ChAc lysosomes in MSN cultures was observed, while wild type lines 
responded with an increase. This trend of decrease in ChAc lines was observed for 
mDAN differentiations as well. The directedness behaved similar and the decrease was 
rated significant in mDAN cultures of ChAc lines. The treatment response of the 
Huntington line was comparable to effects in ChAc lines. 
Taken this data together, the differential behavior in regards to wild type/ChAc differences 
and response to chemical intervention, suggests that there is a substantial difference in 
the disease phenotype in the investigated neuronal subtypes. The fact that MSN cultures 
failed to significantly respond to any treatment, even though ChAc lines were imparied, 
suggests that the treatments do not interact directly with the lysosomal system. Hence, 
observed effects in mDAN cultures might be attributed to bystander effects. One of these 
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effects was recently highlighted by a group that showed that impairment of mitochondria 
results in lysosomal impairment by the production of ROS (Demers-Lamarche, et al., 
2016). This interaction is very likely because previous experiments already showed an 
influence of the treatments with the mitochondrial system. 
3. MSN and mDAN differentiation highlight different aspects of the disease 
Conclusions that were drawn from the present work feature important aspects for disease 
modelling of Chorea acanthocytosis that can also extend to other diseases. For the first 
time detailed experiments that highlight specific susceptibility of ChAc patient derived 
neurons are presented and show opportunities for putative treatments. Showing the 
complexity of the disease phenotypes being present on a functional level in pivotal 
pathways including endo-lysosomal pathway, energy metabolism and organelle trafficking, 
further emphasizes the importance of CHOREIN protein on cell homeostasis. The 
differential results obtained from midbrain dopaminergic neurons and mixed striatal 
cultures suggest that the disease progression differs between different cell types. 
Therefore, upcoming treatment approaches have to be verified under different culture 
conditions as well. Taking all data into account, it is highly advised to not substitute one 
differentiation protocol with the other because the treatment responses and underlying 
mechanisms have to be considered on an individual level. Therefore, a combination of 
experimental setups with mDAN, MSN or other cultures has to be established. 
Furthermore there were significant differences found when ChAc was compared to 
Huntington, a disease that features similar clinical symptoms but is cause by an entirely 
different genotype. These differential results show clearly that the pathological 
progression follows a different pathway in both diseases and potential medications that 
will be developed for treatment of Huntington or ChAc cannot simply be applied to the 
other respective disease due to different underlying mechanisms. Even though 
morphological phenotypes observed for the mitochondria were very similar in both 
diseases, differences observed in the aspect ratio as well as the differences in the moving 
fraction and motility can be a downstream symptom of both diseases. Reduction in aspect 
ratio was observed in mitochondria of mDAN differentiated ChAc lines as well. 
Homeostasis of mitochondria by selective biogenesis and mitophagy is a complex 
problem in many if not all neurodegenerative disease (Aufschnaiter, et al., 2016; Chen, et 
al., 2016; Giachin, et al., 2016; Hung and Calkins, 2016; Osborne, et al., 2016). With the 
experiments conducted in this work, it cannot be determined whether the disruptions are 
causative or symptomatic. 
 
 
- 150 - 
 
This work combined state of the art approaches using microfluidic cell culture systems 
with high temporal resolution live cell imaging, semi-automated image analysis and a data 
mining workflow that is robust and sensitive enough to detect minute changes in organelle 
morphology and trafficking patterns. The proposed protocols can be easily extended to 
cover an even broader range of trafficking readouts, once they are peer reviewed and 
published. They can be modified for complex screening approaches as well. Due to the 
nature of MFCs selecting purely for neurons and providing defined media composition as 
well as positional control over the readout, it is further advised to conduct upcoming 
experiments in this cell culture system rather than classical undirected well dishes. 
However, their influence on the cells due to local deprivation of oxygen and nutrition as 
well as the steric challenges of the narrow channels needs to be investigated in the future.  
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